2009

The Emergent Logic of Health Law

Maxwell Gregg Bloche
Georgetown University Law Center, bloche@law.georgetown.edu

This paper can be downloaded free of charge from:
https://scholarship.law.georgetown.edu/facpub/363

82 S. Cal. L. Rev. 389-480 (2009)

This open-access article is brought to you by the Georgetown Law Library. Posted with permission of the author.
Follow this and additional works at: https://scholarship.law.georgetown.edu/facpub

Part of the Administrative Law Commons, and the Health Law and Policy Commons
The Emergent Logic of Health Law

82 S. Cal. L. Rev. 389-480 (2009)

Maxwell Gregg Bloche
Professor of Law
Georgetown University Law Center
bloche@law.georgetown.edu

This paper can be downloaded without charge from:
Scholarly Commons:  http://scholarship.law.georgetown.edu/facpub/363/
SSRN:  http://ssrn.com/abstract=1588117

Posted with permission of the author
ARTICLES

THE EMERGENT LOGIC OF HEALTH LAW

M. GREGG BLOCHE

ABSTRACT

The American health care system is on a glide path toward ruin. Health spending has become the fiscal equivalent of global warming, and the number of uninsured Americans is approaching fifty million. Can law help to divert our country from this path? There are reasons for deep skepticism. Law governs the provision and financing of medical care in fragmented and incoherent fashion. Commentators from diverse perspectives bemoan this chaos, casting it as an obstacle to change. I contend in this Article that pessimism about health law’s prospects is unjustified, but that a new understanding of health law’s disarray is urgently needed to guide reform. My core proposition is that the law of health care provision is best understood as an emergent system. Its

* Professor of Law, Georgetown University; Visiting Professor of Law, University of Chicago. E-mail: Bloche@law.georgetown.edu. This work was supported in part by a Guggenheim Fellowship and by the Economic Studies Program at The Brookings Institution. Parts of this paper have been presented at symposia and workshops sponsored by The Brookings Institution, the O’Neill Institute for Health Law at Georgetown University Law Center, the Petrie-Flom Center for Health Law at Harvard Law School, the Harvard University Program on Medical Ethics, the Polish Academy of Sciences, the Tsinghua University School of Public Policy and Management, Wake Forest University School of Law, UCLA School of Law, University of Chicago Law School, University of Illinois College of Law, University of Toronto Law School, and University of Pittsburgh School of Law. Parts of this paper were also presented as the 2009 Deinard Memorial Lecture on Law & Medicine at the University of Minnesota. I thank Henry Aaron, Nicholas Bagley, Martha Blaxall, Rosalind Dixon, Mark Duggan, Richard Epstein, Michael Gottlieb, Robin Hacke, Mark Hall, Russell Korobkin, Anup Malani, Martha Nussbaum, Eric Posner, William Sage, Elyn Saks, Adam Samaha, Ellen Waldman, and Daniel Wikler for their challenges, quibbles, and suggestions. I am grateful to Rachel Beattie and Michael Gottlieb for their research assistance.
contradictions and dysfunctions cannot be repaired by some master design. No one actor has a grand overview—or the power to impose a unifying vision. Countless market players, public planners, and legal and regulatory decisionmakers interact in oft-chaotic ways, clashing with, reinforcing, and adjusting to each other. Out of these interactions, a larger scheme emerges—one that incorporates the health sphere’s competing interests and values. Change in this system, for worse and for better, arises from the interplay between its myriad actors.

By quitting the quest for a single, master design, we can better focus our efforts on possibilities for legal and policy change. We can and should continuously survey the landscape of stakeholders and expectations with an eye toward potential launching points for evolutionary processes—processes that leverage current institutions and incentives. What we cannot do is plan or predict these evolutionary pathways in precise detail; the complexity of interactions among market and government actors precludes fine-grained foresight of this sort. But we can determine the general direction of needed change, identify seemingly intractable obstacles, and envision ways to diminish or finesse them over time. Dysfunctional legal doctrines, interest group expectations, consumers’ anxieties, and embedded institutional and cultural barriers can all be dealt with in this way, in iterative fashion. This Article sets out a strategy for doing so. To illustrate this strategy, I suggest emergent approaches to the most urgent challenges in health care policy and law—the crises of access, value, and cost.

TABLE OF CONTENTS

I. INTRODUCTION ................................................................. 391

II. THREE “TAKES” ON HEALTH CARE LAW ............................... 397
   A. REJECTIONISM: THE CASE AGAINST HEALTH LAW ............ 399
   B. “BIG THEORY”: PURSUIT OF A UNIFYING PARADigm ........... 408
   C. CASE-BY-CASE PRAGMATISM .......................................... 416

III. HEALTH CARE LAW AS AN EMERGENT SYSTEM ................. 421
   A. BEYOND THE MYTH OF THE “DECIDER” .......................... 422
   B. THE EMERGENT LOGIC OF HEALTH CARE LAW ................ 423

IV. TOWARD AN AGENDA FOR HEALTH CARE LAW ............... 428
   A. EXPANDING ACCESS TO CARE ...................................... 430
   1. State Solutions? .......................................................... 431
   2. Personal Responsibility ................................................. 433
   3. Taxes, Subsidies, and Settled Expectations ....................... 434
   4. The Politics of Emergence: The Demise and Rebirth of Health Care Reform ........................................ 437
I. INTRODUCTION

The American health care system is on a glide path toward ruin. Medical spending is rising at an unsustainable rate: it is on track to reach 30 percent of gross domestic product (“GDP”) a quarter century from now and half of GDP within seventy-five years.1 The number of Americans without health insurance is approaching fifty million,2 and surging unemployment could push this figure much higher.3 Most of the care that

1. CONGRESSIONAL BUDGET OFFICE, THE LONG-TERM OUTLOOK FOR HEALTH CARE SPENDING 12 (2007). These CBO projections presume excess cost growth rates (rates by which medical cost increases exceed GDP growth) for Medicare, Medicaid, and other health spending that are well below historical averages. Were medical costs to continue to rise at historical rates, health spending would soar to an unimaginable 100 percent of GDP within seventy-five years. Id. app. D.


3. A rough rule of thumb is that each 1 percent rise in the unemployment rate boosts the number of uninsured adults by 1.1 million (job loss is thought not to substantially increase the number of children without insurance since children who lose coverage are typically eligible for Medicaid or SCHIP). KARYN SCHWARTZ, KAISER COMM’N ON MEDICAID AND THE UNINSURED, HEALTH
patients receive is of unproven value, and up to one hundred thousand Americans die prematurely each year from medical mistakes. So it is for good reason that health reform has returned to the top of the nation’s political agenda. A decade and a half after the collapse of President Clinton’s health reform plan, Americans are again pressing for relief from soaring costs and telling pollsters and politicians that they want medical care for all. The main difference, this time, is that the problems have grown much worse.

Are law and lawyers part of the cure? The prevailing view among health care reformers today is that lawyers have little to offer. Sure, statutes need to be drafted, laws must be enforced, and clients need to be told how to comply, but many reformers see these as technical tasks, requiring little insight or imagination. Lawyers should follow the dots that policymakers draw. Within legal academia as well, there is much skepticism about health law: many do not view it as worthy of separate study. Such skepticism might seem anomalous, since America is awash in health law. Terabytes of legal text address the provision and financing of medical care, mandating and constraining all manner of activities. But does this vast

---

4. COMM. ON QUALITY OF HEALTH CARE IN AM., INST. OF MED., TO ERR IS HUMAN: BUILDING A SAFER HEALTH SYSTEM 26 (Linda T. Kohn et al. eds., 2000) (estimating, based on extrapolations from New York, Colorado, and Utah data, that between forty-four thousand and ninety-eight thousand Americans die prematurely from medical errors each year).

5. Christopher Jennings, President Clinton’s senior health policy advisor from 1994 through 2000 (and chief health policy advisor to Senator Hillary Rodham Clinton’s 2008 presidential campaign) states that health care policy is the province of people with expertise in politics, economics, and medicine and public health, not law. Lawyers, he argues, should limit themselves to advising and advocating for their clients—and to implementing and enforcing policies formulated by others with relevant expertise. Interview with Christopher Jennings, President, Jennings Policy Strategies (Mar. 2007). Lawyers played peripheral roles in developing President Clinton’s health reform plan, numerous participants in that process have told me, and President George W. Bush’s health reform proposals (emphasizing high-deductible health plans and medical savings accounts) were developed by economist Katherine Baicker (a member of the Council of Economic Advisors) and her staff. Interview with Katherine Baicker, Member, Council of Economic Advisors (July 2006). To be sure, lawyers drafted the legislation that Presidents Clinton and Bush submitted to Congress, but they had minimal roles in formulating the concepts behind it. Lawyers have been similarly peripheral, so far, in the development of President Obama’s nascent health care reform plans, though these plans present intricate questions of regulatory governance. Economists (with some input from political scientists and physicians) have thus far led the way: no legal scholar or practitioner participated in the presidential transition’s health policy team, and only a few served on or advised the transition’s Health & Human Services Department review team.
body of law have a distinctive purpose or mission, or is it merely the sum total of diverse doctrines that happen to apply in the health sphere? To borrow from Judge Frank Easterbrook, who chided “cyberlaw” on these grounds, does it make as little sense to study health care law as it does “the law of the horse”?6 Laws govern the sale, theft, and racing of horses, but they do not thereby constitute a field of inquiry,7 let alone reform-minded action. Scholars who devote much of their energy to health law8 are made uncomfortable by this question9—and by the status anxiety it invites.10 The


7. This is not to say that laws pertaining to horses do not matter, but it is to suggest that the law of the horse is not usefully analyzed as a discrete field. “Far better for most students—better, even, for those who plan to go into the horse trade—to take courses in property, torts, commercial transactions, and the like . . . . Only by putting the law of the horse in the context of broader rules about commercial endeavors could one really understand the law about horses.” Id. at 208.

8. The number of these is difficult to estimate, but a fair measure may be the one hundred or so attendees that are typical at the annual Health Law Professors Conference, sponsored by the American Society of Law, Medicine & Ethics. See 2008 Health Law Professors Conference—Description, https://www.aslme.org/aslmesecure/info/description.php?conf_id=70 (last visited Mar. 20, 2009). Most of these attendees hold faculty positions at law schools; others teach in schools of medicine and public health.


10. This anxiety is justified by the peculiarities of legal academia’s pecking order. As Henry Greely has pointed out, publications in elite medical and health policy venues like the New England Journal of Medicine and Health Affairs do not count for much when a candidate is being considered for a law faculty position or for tenure. And elite law reviews—those at schools near the top of the U.S. News & World Report rankings—rarely publish articles on health law topics. Since publication in these venues is the principal metric of scholarly accomplishment when hiring and tenure are at issue, would-be health law scholars face a competitive disadvantage. Greely, supra note 9, at 400–02. A glimpse at legal academia’s skepticism about health law as a field was recently afforded by litigation (and discovery) that followed the University of Michigan Law School’s denial of tenure to Peter Hammer in 2002. Hammer sued the school, alleging discrimination based on sexual orientation, obtained his tenure file, and posted its contents on a website. A law school committee voted to grant him tenure, but at least one panel member, James J. White, dissented. White won a sufficient percentage of “no” votes from the full faculty to turn down the committee’s recommendation (the faculty voted 18-12 to tenure Hammer; he thus fell two votes short of the two thirds majority that Michigan requires). Hammer v. University of Michigan, Peter Hammer’s Lawsuit Against the University of Michigan Law School, http://wayneoutlaws.org/hammer_v_umich/background (last visited Mar. 20, 2009). In a memo explaining his dissent, White acknowledged that Hammer “has been recognized by many in the health law field as one of the most prominent students of antitrust law’s application to the health care
question is, of course, rhetorical; the point meant by those who pose it is that the “best” legal thinking stays within bounds—bounds drawn by established doctrinal category (tort, contract, etc.) or disciplinary method (philosophy, history, or law and economics).

The unspoken corollary is that the best scholars and practitioners, even on health law topics, are those who combine elite credentials of the classic sort with professional commitment to a legal category or analytic method. Thus, for example, medical malpractice law’s conundrums are best explored by scholars with a rich understanding of tort law theory, or by economists using sophisticated mathematical models and statistical methods. And the legal governance of competition between health care providers is best understood by antitrust lawyers with command of relevant market analysis, rule-of-reason doctrine, and the economics of collusion. In this view, a sophisticated grasp of health care systems and medical decisionmaking is of secondary import. Lawyers can do more for the regulatory governance of medicine, and for law’s coherence, by not treating health care as different from other endeavors that law governs.

Health law scholars and practitioners have responded to the law-of-the-horse challenge in two ways. Some have argued that medical care provision and financing is indeed different—so unique and complicated that it calls for an integrated regulatory governance strategy, cutting across doctrinal boundaries. Others, especially practitioners, have more or less accepted the law-of-the-horse problem as an endemic feature of the field. They have eschewed grand theory in favor of practical questions within one

industry.” Plaintiff’s Brief in Opposition to Defendant’s Motion for Summary Disposition at exhibit 7, Hammer v. Bd. of Regents of Univ. of Mich., No. 04-241 (Mich. Ct. Cl. June 20, 2006) [hereinafter Plaintiff’s Brief], available at http://wayneoutlaws.org/hammer_v_umich/plaintiffs-opposition-to-defendants-motion-for-reconsideration. But White said this merited “less weight” than the views of antitrust law scholars. Id. Criticizing Hammer—who is both a lawyer and an economist—for having “little contact with law and economic scholars outside of the health care field,” White concluded, “I do not believe that we can rely on the judgment of those in health care about the tenure standards that an elite law school should use.” Id.

11. See CLARK C. HAVIGHURST, HEALTH CARE CHOICES 22–28 (1995) (calling for reinterpretation of health care law’s diverse doctrines to support market competition among health plans); James F. Blumstein, Health Care Reform and Competing Visions of Medical Care: Antitrust and State Provider Cooperation Legislation, 79 CORNELL L. REV. 1459 (1994) (same). See also M. Gregg Bloche, The Invention of Health Law, 91 CAL. L. REV. 247, 299–300 (2003) (urging that the task of health law be reconceived as mediation among medical care’s competing therapeutic, caring, and other purposes); Elhauge, supra note 9, at 388–90 (urging harmonization of health law doctrines to support a reform strategy that incorporates market competition, universal coverage, the setting of spending limits via political means, and some deference to physician judgment); William M. Sage, Managed Care’s Crime: Medical Necessity, Therapeutic Benefit, and the Goals of Administrative Process in Health Insurance, 53 DUKE L.J. 597, 630 n.131 (2003) (proposing that health care law be formulated based on “therapeutic jurisprudence” principles).
or another policy sphere. Health care law matters greatly (and merits respect as a field), they say, because the subjects it addresses are socially important, and close attention to health care’s complexities yields more pertinent insights than does preoccupation with doctrinal categories or disciplinary methods.

There are thus, broadly speaking, three “takes” among lawyers on the field’s prospects and problems. One is rejectionist: the law of the horse does not merit separate study. Get the doctrine right, within each *legal* category, and the results will be good, or at least legitimate, for health care and all other endeavors. The second calls on lawyers to agree on a unifying account of what diverse legal and regulatory schemes should accomplish in the health care sphere. The third tells health lawyers not to fret about theory: get the policy right, case by case, by paying heed to law’s practical impact, and do not worry about coherence in the abstract, either within or across doctrinal realms.

I shall argue herein that health law has enormous potential to ameliorate our nation’s worsening crises of medical care access, cost, and quality, but that none of these approaches can fulfill this promise. Health law rejectionists, I will contend, ignore the urgency of legal coordination. Pursuit of rigor within doctrinal categories and regulatory regimes can create incoherence in the governance of health care provision. Legal tools that are well designed for some purposes yield dysfunctional results when they work poorly in concert. Proponents of grand theory promise to solve this coordination problem, but basing all of health care law on a single paradigm is not possible. The law of health care provision, like medicine

---

12. See Greely, *supra* note 9, at 406–07 (advising health law scholars not to fret about the absence of an agreed-on organizing paradigm and to instead get on with the work of analyzing health care law’s diverse problems). It is my impression (for which I do not claim proof) that health law scholars with left-of-center politics have been less inclined than have those toward the right to press for recognition of one or another overarching theory—and more inclined to press for particular legal changes without giving great weight to theory. Sara Rosenbaum, for example, has focused on expanding health care access and bringing civil rights law to bear on racial disparities in care. *See* Sara Rosenbaum & Joel Teitelbaum, *Addressing Racial Inequality in Health Care, in Policy Challenges in Modern Health Care* 135 (David Mechanic et al. eds., 2005). George Annas has emphasized the importance of safeguarding patient autonomy and, more recently, the protection of professional discretion from encroachment by powerful, market-driven institutions. *E.g.*, George J. Annas & Frances H. Miller, *The Empire of Death: How Culture and Economics Affect Informed Consent in the U.S., the U.K., and Japan*, 20 Am. J.L. & Med. 357, 369 (1994). Alex Capron has focused on insulating the physician-patient relationship from market pressures. *See, e.g.*, Alexander Morgan Capron, *At Law: Between Doctor and Patient*, Hastings Ctr. Rep., Sept.–Oct. 1996, at 23, 24. And Rand Rosenblatt has focused on resisting the stratification of health care quality based on ability to pay. *E.g.*, Rand E. Rosenblatt, *Rationing “Normal” Health Care: The Hidden Legal Issues*, 59 Tex. L. Rev. 1401, 1407–16 (1981).
itself, pursues diverse and conflicting aims. Organizing the legal governance of medicine around any one theory is bound to neglect some of these aims. Such neglect, I will contend, is incompatible with stable governance. Theory, nevertheless, is indispensable. Too often, health lawyers ignore the big picture, urging solutions to practical problems without heeding the connections between moving parts. Coherence matters, even if it can never be complete, owing to health law’s competing goals.

This will lead me to a sharply different conception of health care law. My central contention is that the law of health care provision and the health care system itself are best understood and acted on as emergent systems. This understanding comes to terms with health law’s seeming chaos—its emanation from disconnected regulatory and judicial decision makers, and from myriad, separate doctrinal spheres. As with all emergent systems, these many inputs interact in unpredictable ways, clashing with, reinforcing, and reacting to each other. No one actor is in position to sort out these influences. No one actor takes a grand overview. There is no center of command and control. The health care policy this system produces is the sum total of these inputs and of mutual adjustments by stakeholders and decisionmakers.

What legal scholars and practitioners who specialize in health care have to offer thus falls short of an ability to influence the law in top-down fashion. Yet their contributions can make a critical difference. By virtue of their disinterestedness, understanding of clinical practice and health systems, and grasp of relevant fields of law, they are best situated to see how the moving parts fit together. They can glimpse, albeit imperfectly, beyond contiguous interactions between colliding doctrines, rival stakeholders, and decision makers with overlapping authority. They are thereby able to counsel changes of course that take account of effects throughout the health care system, while giving weight to legal values such as due process and doctrinal coherence. They can amplify, dampen, or redirect the flow of policy influence through networks of legal and

---

13. They are, of course, not literally disinterested—they have preferences and passions (and perhaps even clients and consulting arrangements in the health care industry)—but they are not wholly committed to serving stakeholders’ interests, as are legal practitioners, legislative advocates, and hospital and health plan officials.

14. Scholars of health care law cannot be expected to have fine grain knowledge of medical practice, the organization and financing of care, or the myriad legal doctrines and regulatory frameworks that govern medical care provision and financing. Competent specialists in each of these areas will have richer “local” knowledge. Health law scholars are akin to general contractors: they should be sufficiently informed to see the connections and to tap specialized expertise when it can add substantial value.
regulatory decision makers, as well as health care industry actors. Health lawyers, in short, can shape the dynamics of emergence, guiding the law toward accommodations among its many aims.

I shall proceed as follows. Part II will weigh the three, above-described stances toward health care law: rejectionism, the quest for a unifying analytic framework, and the pursuit of solutions to practical problems with little regard for either legal coherence or connections between the health system’s moving parts. I will consider each stance in stylized form. In practice, the lines between them are blurry, and health law commentators often cross over. Using examples from diverse doctrinal realms, I will argue that each of these stances ignores critical aspects of health law’s role, and that none offer an adequate account of what health law’s decision makers should try to achieve. In Part III, I will make the case for considering the legal governance of health care as an emergent system, unguided by any one actor and thus not susceptible to any centrally imposed paradigm. Health care law’s contradictions, I will contend, make sense in bottom-up terms, as the product of competing perspectives and concerns that the law must accommodate. These contradictions give rise to feedback among legal decision makers, feedback that sculpts health law in self-organizing fashion as these decision makers react to each other.

In Part IV, I will urge a reform strategy that rests on an understanding of health care’s governance as an emergent system. I will argue for a reimagining of the role of law as an instrument of health reform—a shift from linear pursuit of specific policy objectives to a quest for evolutionary pathways toward reformers’ ultimate efficiency, equity, and other goals. Competing values and stakeholders, not grand designs, drive health law’s evolution. Reform-minded actors therefore should become opportunists. They should look for potential evolutionary pathways that launch from present-day institutional arrangements and incentives. And they should pursue legal and policy interventions that push our health system along these pathways, powered by stakeholders’ and legal decisionmakers’ interacting responses. The key here is to craft interventions that are “nonlinear” (in emergent systems argot)—interventions that achieve large, long-term impact through minimally disruptive short-term change. To illustrate this strategy, I will offer approaches to some of the most urgent challenges facing health care reformers.

II. THREE “TAKES” ON HEALTH CARE LAW

There is wide agreement that the law of health care provision, like our
medical care delivery system, is in disarray. Commentators who attempt overviews of the field reach this conclusion unfailingly, each discovering anew that chaos reigns and that the law sends incompatible, often incomprehensible messages to health care payers, providers, and consumers. Astonishingly complicated regulations cover such matters as Medicare fraud and abuse and the tax treatment of nonprofit hospitals and health plans. Frustratingly convoluted case law governs Employee Retirement Income Security Act (“ERISA”) preemption of state efforts to regulate health plans and expand medical coverage. Further confusion besets health care antitrust law, medical liability, and other regulatory realms.

Legal scholars bemoan this, since they are lovers of coherence. They

15. E.g., HALL ET AL., supra note 9, at xxxi; Bloche, supra note 11; Elhauge, supra note 9.


20. Several states, including Massachusetts, California, Connecticut, and Maryland, are considering (or, in Massachusetts’ case, implementing) plans that would expand coverage in part by requiring employers to choose between providing coverage themselves, or paying taxes or fees to support state-sponsored coverage. ERISA preemption jeopardizes these efforts. See, e.g., Retail Indus. Leaders Ass’n v. Fielder, 475 F.3d 180, 198 (4th Cir. 2007) (holding that ERISA preempts Maryland’s so-called Wal-Mart law, requiring firms with ten thousand or more employees to spend 8 percent or more of their payrolls on medical coverage for their workers); Retail Indus. Leaders Ass’n v. Suffolk County, 497 F. Supp. 2d 403, 416–18 (E.D.N.Y. 2007). But see Golden Gate Rest. Ass’n v. City & County of San Francisco, 512 F.3d 1112, 1127 (9th Cir. 2008) (concluding that a San Francisco mandate requiring employers either to provide medical coverage or pay into a city-administered health fund is likely to survive preemption); Golden Gate Rest. Ass’n v. City & County of S.F., 546 F.3d 639 (9th Cir. 2008) (concluding that ERISA does not preempt a San Francisco mandate requiring employers either to provide medical coverage or pay into a city-administered health fund).

ascribe the chaos variously to ignorant legislators, inept agency bureaucrats, clueless judges, and the power of interest groups to shape the law to their liking. Academics who write about health law also get some of the blame. It has become conventional wisdom within hiring and tenure committees at elite law schools that scholarship in this field is poor and that the supply of exciting prospects is thin by comparison with corporate law, antitrust, and other established subjects. Both health law rejectionism and advocacy of a cross-cutting paradigm are responses to the field’s disarray. Proponents of case-by-case pragmatism treat this disarray as beside the point—irrelevant to the work of making health care more available, effective, efficient, and fair.

A. REJECTIONISM: THE CASE AGAINST HEALTH LAW

The law-of-the-horse put-down works by connotation, not crystalline logic. The problem with horses is that they are passé. Other areas of law are no less of a doctrinal and statutory jumble, yet they are widely taught, and some have considerable scholarly cachet. Environmental law is an example. It would not have worked as witticism for Easterbrook. It has become a fixture of curricula at almost all law schools, including the U.S. News & World Report elite. Articles on environmental matters appear often in the toniest student-edited law reviews—health law articles do not—and the U.S. Supreme Court regularly hears high profile environmental cases. As Einer Elhauge points out, even some of the classics of the law school curriculum began as hodgepodes. Tort law dates back many centuries, but contract law (as an integrated field) does not: it is a mélange of once-separate subjects, such as suretyship, admiralty, and the law of

22. The Peter Hammer affair—due to the discovery process that followed his lawsuit against the University of Michigan for denial of tenure—became the occasion for rare public expression of this sentiment. See supra note 10. But I have heard it expressed frequently, in private, in conversations about faculty hiring with legal scholars at elite schools.


24. One could say equally of environmental law and the law of the horse that they are constituted by “property, torts, commercial transactions, and the like.” Easterbrook, supra note 6, at 208. Indeed, environmental law is much more of a hodgepodge than is the law of the horse, since myriad state and federal regulatory regimes contribute to it.

sales. So a field’s being a doctrinal admixture is no bar to its becoming an important focus for scholars and an established part of the curriculum.

Another factor, not the hodgepodge problem, drives health law rejectionism. Legal categories are malleable over time, as the case of contract law illustrates, but the categories that govern at any given moment carry great weight. In all human endeavors, categories frame perceptions and thereby shape decisions. But law’s categories are special. Young lawyers are taught to venerate them and to make arguments that treat them as givens. The practice of law is, in large measure, the translation of real-world occurrences into narratives that fit into particular legal categories—say, elements of a cause of action, prerequisites for a binding agreement, or triggers for regulatory intervention. Students, especially in their first year, are assessed and ranked based on their ability to perform these acts of translation with aplomb, on behalf of hypothetical clients or causes. Law’s categories anchor this enterprise, and disregard for them will not do.

This conservatism about categories is at the heart of law’s morality. It constrains legal decisionmakers’ discretion and thus limits what lawyers can plausibly argue on their clients’ behalf. It is central to what we mean by due process. Its powerful corollary is the importance of interpretive consistency and coherence both within and between legal categories. These are not merely ideals of craft, or further safeguards against arbitrariness; they are answers to a bounded-rationality problem. Legal categories invite endless bids for special exceptions, based on claims of unique circumstance. But lawyerly cognition is not up to the task of fully appreciating the fractal geometry of special circumstances. Legal decisionmakers who craft exceptions to rules and categories, especially those that govern complex fields of endeavor, are at high risk for getting things wrong. They also risk producing inconsistent results and thereby undermining confidence in rule-of-law values.

27. The extent to which law’s categories and procedures constrain discretion is, of course, much disputed—this large question has long been one of the central foci of legal scholarship for the past century. E.g., Frederick Shauer, The Limited Domain of the Law, 90 VA. L. REV. 1909, 1915–17 (2004).
29. The Supreme Court cited this concern in Pegram v. Herdrich, 530 U.S. 211 (2000), as a reason for rejecting a health plan subscriber’s bid to construe ERISA to bar some, but not all, financial rewards to physicians for withholding costly treatments. Holding that ERISA’s fiduciary duty provisions did not apply to a health plan’s attending physicians, the Court said it lacked the health policy expertise necessary to distinguish between acceptable and troublesome incentives to clinical caregivers to practice frugally, and thus would not apply ERISA fiduciary duty principles to the practice of medicine. Id. at 222, 231–33.
Skepticism toward health law reflects this conservatism about categories—and associated concerns about consistency and coherence. Claims that one or another aspect of medical care merits distinctive treatment under tort, contract, or antitrust law invite allegations of special pleading and anxiety about departure from the rule of law. The proposition that a unifying paradigm for the legal governance of health care ought to trump interpretive consistency within doctrinal spheres raises an even greater spectre of lawlessness. Health law’s low standing among academics is a byproduct of these misgivings.

As environmental law illustrates, such misgivings need not be decisive: a subject’s public import and social cachet can inspire legal decisionmakers (and scholars) to shift their professional focus toward policy coherence across doctrinal categories. But health law has not yet won such recognition. Courts and regulators have been reluctant to sculpt legal doctrines to accommodate health care’s peculiarities. To be sure, there are exceptions. In the late 1990s and early 2000s, judges bent the law of ERISA preemption to permit patients to sue health plans for medical negligence. Likewise, courts have from time to time applied antitrust law with a wink to let doctors and hospitals collaborate, purportedly on patients’ behalf. But judges have eschewed explicit reliance on any overarching governance model for health care. Instead, they have typically pursued doctrinal coherence in disparate realms of law, with little regard for the health policy consequences. They have, for example, sustained

30. This is not to say that environmental law (or any other “hodgepodge” field) achieves such coherence—sharp differences over such matters as the role of cost-benefit analysis stand in the way. It is merely to say that pursuit of such coherence across diverse doctrinal spheres and regulatory schemes is a widely recognized environmental law goal.

31. Section 514 of ERISA preempts state laws that “relate to” fringe benefit plans. 29 U.S.C. § 1144 (2006). To allow patients to sue HMOs in state courts for negligent care by staff physicians, some courts characterized HMOs as medical care providers rather than as components of employers’ fringe benefit plans. See Bloche, supra note 11, at 301; Korobkin, Reinterpreting ERISA Preemption, supra note 19, at 535. And to circumvent ERISA preemption of actions against employer-provided health plans for negligent refusal to authorize services, some courts characterized health plans’ utilization management decisions as medical rather than administrative. Korobkin, Reinterpreting ERISA Preemption, supra note 19, at 522. The former characterization has thus far survived; the latter was rejected by the Supreme Court in 2004. See Aetna Health Inc. v. Davila, 542 U.S. 200 (2004) (holding that ERISA preempts state actions against health plans for negligent denial of medical coverage).

32. See, e.g., Cal. Dental Ass’n v. FTC, 526 U.S. 756 771–73 (1999) (upholding a professional society’s restraints on advertising as procompetitive on the ground that they protected patients against misleading claims). Some market-oriented health law scholars have been sharply critical of courts’ willingness to soften their application of antitrust principles when confronted with claims from professionals that unmitigated competition might harm patients. See, e.g., Clark C. Havighurst, Health Care as a (Big) Business: The Antitrust Response, 26 J. HEALTH POL’Y & L. 939, 949–53 (2001).
medical malpractice law’s deference to extant clinical practice patterns, impeding efforts to make medical care more evidence based\(^\text{33}\) and cost sensitive.\(^\text{34}\) And they have, for the most part, enforced antitrust principles with vigor, in pursuit of a free-market vision for medicine that strains against tort law’s more egalitarian approach to specifying the range of allowable clinical alternatives.\(^\text{35}\)

Congress and the federal agencies with authority over medical care financing and provision have shown, if anything, less regard than the courts for the health policy impact of their decisions. The convolutions of Medicare fraud and abuse law, Medicare payment to hospitals and health plans, tax treatment of nonprofit hospitals, and rules governing health information privacy reflect the triumph of interest-group power and compromises among competing stakeholders. Additional regulatory convolutions play out at the state level. Constraints on potentially duplicative capital investment by hospitals dampen competition that antitrust law aims to encourage.\(^\text{36}\) Statutes requiring health insurers to cover particular services or provider types are products of interest group

---

\(^{33}\) A much publicized RAND Corporation study of clinical decisionmaking found that American patients receive only 54.9 percent of “recommended care” when measured against a set of more than four hundred evidence-based best-practice standards. Elizabeth A. McGlynn et al., The Quality of Health Care Delivered to Adults in the United States, 348 NEW ENG. J. MED. 2635, 2642 tbl.3 (2003). This is hardly a vote of confidence in extant practice patterns, or in the longstanding medical tort law policy of deference to these patterns, whether or not scientific evidence supports them.

\(^{34}\) Extant practice patterns have been forged largely by fee-for-service incentives, which discourage economizing, and by accompanying patient expectations of all possible beneficial care.

\(^{35}\) The free-market vision allows for multiple levels and standards of care tied to patients’ ability and willingness to pay. Havighurst, supra note 11, at 23–25. Tort law, by contrast, presumes a unitary standard of care, with only slight downward flexibility when health care providers can show they were operating under resource constraints. Since clinical practice patterns vary widely, CTR. FOR THE EVALUATIVE CLINICAL SCI., DARTMOUTH MED. SCH., THE QUALITY OF MEDICAL CARE IN THE UNITED STATES: A REPORT ON THE MEDICARE PROGRAM 91–104 (1999); John E. Wennberg & Philip G. Peters, Jr., Unwarranted Variations in the Quality of Health Care: Can the Law Help Medicine Provide a Remedy/Remedies?, 37 WAKE FOREST L. REV. 925, 937–41 & figs. 1–2 (2002), the idea of a unitary standard of care is mythic, but it is nevertheless an obstacle to formal legal recognition of multiple tiers of care.

\(^{36}\) As of mid-2008, thirty-six states require that a hospital obtain a Certificate of Need ("CON") in order to commence some capital projects, such as construction of a new wing or acquisition of new equipment with costs above some statutory threshold level. National Conference of State Legislatures, Certificate of Need: State Health Laws and Programs, http://www.ncsl.orgprograms/health/cert-need.htm (last visited Mar. 20, 2009); 41 C.J.S. Hospitals § 8 (2008). The premise behind CON regulation—that rivalries among hospitals tend to generate wasteful overcapacity—is at war with the antitrust law premise that competition honies efficiency. Though health law commentators have been making this point for a generation, see, e.g., Clark C. Havighurst, Regulation of Health Facilities and Services by "Certificate of Need," 59 VA. L. REV. 1143 (1973), robust CON regulation and antitrust enforcement persist, side by side.
competition, rather than an overarching understanding of what medical coverage should include. A comprehensive survey of health care law’s crosscurrents and eddies (and contradictory policy messages) is beyond my scope here. But one is not needed to underscore the point that pursuit of policy coherence across disconnected doctrinal categories and regulatory regimes has not yet become a driving force for health law decisionmakers.

Legal academia’s rejectionist stance toward health law both reflects and reinforces courts’ and regulators’ desultory approach to health care policy coherence. An entry-level scholar would be ill advised, from a careerist point of view, to plunge deeply into health care’s institutional and clinical peculiarities. It is better, or at least safer, to offer a new take on an oft-pondered doctrinal question or to develop an elegant economic model, whether or not its assumptions come close to capturing health care’s realities. Even if the model’s premises are profoundly mistaken, the professional risks to the modeler are low. This is because only a few scattered scholars of health law and policy are sufficiently knowledgeable and well positioned to assess the fit between the model’s premises and health care’s peculiarities, and to gain an audience for their criticisms. An early-career scholar can get things fundamentally wrong, from a health policy perspective, while making a stunningly positive impression on colleagues who are unfamiliar with health care.

These perverse professional incentives lock in health law rejectionism and reduce legal academia’s ability to contribute to the rationalization of health care’s regulatory governance. In view of the enormity of our health system’s problems, this desultory approach to its governance is a costly indulgence. Mark Hall and Elhauge have argued that health law deserves recognition as a “field” because medical care and its financing are distinctive, even unique, in ways that matter for the application of law. I

---

37. Interest groups at play in statehouses across the country include providers’ trade associations and patient advocacy groups, which tend to push for expansion of coverage for particular services, and insurers and employers, which resist new coverage mandates in order to control costs and maintain market flexibility.

38. Such an intellectual immersion is at high risk of yielding work that strikes legal scholars as of limited reach and therefore uninteresting.

39. See Plaintiff’s Brief, supra note 10 (asserting that an elite law school should give little weight to the opinions of health law scholars when assessing tenure candidates’ work).

40. Both state that health care’s distinctive features are so important to the analysis of legal issues that an industry-wide focus is preferable to treatment of health care as just another application of generic legal doctrines. HALL ET AL., supra note 9, at 361; Elhauge, supra, note 9, at 380. Elhauge distinguishes his argument from Hall’s by chiding Hall for failing to say why medicine’s unique features merit treatment of health law as a separate field. Elhauge, supra note 9, at 380–81. But Hall does point to particular features that he says might merit separate legal treatment: these include the
would press this further. Fixing America’s health care mess is a matter of national urgency, and an integrated approach to the development of health law will be essential to any solution.

The high stakes are familiar but worth underscoring. Continuation of the growth in medical spending that has persisted over the past several decades will ensure federal fiscal catastrophe. To support Medicare and Medicaid at this rate of growth, the percentage of GDP that goes to taxes would need to rise by nearly one-third by 2030 and more than one-half by 2040. By 2050, it would need to nearly double. Failure to keep pace with this schedule of shockingly large tax increases would lock in unsustainable budget deficits. Absent this Medicare and Medicaid growth, we would face no such nightmare scenario: tax revenues could remain stable, at 18.3 percent of GDP (the average rate in recent decades), without a long-term federal deficit. The sustained gap between rates of medical spending increase and growth throughout the rest of the economy also threatens the ability of businesses to compete in world markets while employing Americans. Germany and Canada, our closest health spending rivals, spend...
little more than half of what we do, per capita, on medical care, and no other country so burdens its business sector with direct responsibility for health care costs.\textsuperscript{44} Finally, our national failure to provide medical coverage to forty-seven million Americans\textsuperscript{45} is not merely cruel and indecent; it is a threat to social stability. In the two other industrialized nations that have eschewed universal coverage, the resulting suffering and indignity have fed large-scale civic unrest.\textsuperscript{46} We are hardly at the point of riots in the streets over health care; to the contrary, most Americans report satisfaction with their medical coverage. So far, this satisfaction has been an obstacle to health care reform: voters are disinclined to give up what they have in order to improve the lot of others. But the growing number of uninsured Americans could tip the balance suddenly from complacency.

\textsuperscript{44} The United States is alone in relying so heavily on employers to provide coverage to its nonelderly. Other industrialized countries (except for China, which does not provide universal coverage) spread this expense more broadly, through various public-financing schemes. Germany, with its system of employer-supported, quasi-public “sickness funds,” comes the closest to our workplace-based system. See Stephanie Stock, Marcus Redaelli & Karl Wilhelm Lauterbach, \textit{The Influence of the Labor Market on German Health Care Reforms}, 25 \textit{Health Aff.} 1143, 1144 (2006) (discussing German employers’ evolving role in financing that country’s Social Health Insurance system). But German employers’ contributions to sickness funds cover only 46 percent of the cost of care for workers and their families. \textit{Id.} at 1144. Employees pay an additional 54 percent. \textit{Id.} By comparison, American employers pay, on average, 84 percent of premiums for employee-only coverage and 73 percent of premiums for family coverage. \textit{Kaiser Family Found. & Health Research & Educ. Trust, Employer Health Benefits: 2008 Annual Survey} 68 (2008), \textit{available at} http://ehbs.kff.org/pdf/7790.pdf. Employees and their families pay the rest; public funding plays no role (unless one counts the tax expenditure represented by the deductibility of employer and employee contributions toward health insurance premiums). In the United States, employment-based insurance covers approximately 60 percent of individuals (workers and their dependents). Press Release, Ctr. on Budget & Policy Priorities, \textit{The Number of Uninsured Americans Is at an All-Time High} (Aug. 29, 2006), \textit{available at} http://www.cbpp.org/8-29-06health.pdf. In 2006, 27.6 million workers were uninsured because not all businesses offer health benefits, not all workers qualify for coverage, and not all employees can afford their share of health insurance premiums even when workplace-based coverage is available to them. \textit{DeNavas-Walt et al., supra note 2, at 23.}

\textsuperscript{45} See \textit{DeNavas-Walt et al., supra note 2, at 18.} Over the past two decades, the ranks of the uninsured have risen by about eight hundred thousand per year. \textit{Id.} at 58 tbl.C-1.

toward popular ire.47

Should this happen, law will be critical to the crafting of an affordable and effective approach to Americans’ health-related hopes and fears. Statutory drafters will need to consider how disconnected regulatory schemes work together, and against each other, to frame choices for the health system’s many actors. And the bounded rationality inherent in these drafting efforts will require courts and agencies to fill in the statutory interstices as unanticipated situations arise. To do so without a strategic eye toward the governance of our health system as a whole would be to sow chaos.

The same is true of efforts to gain control of medical costs. Neither public nor private health care spending can be contained in isolation: each influences the other by shaping research investment, product development, standards of care, and patients’ expectations. Cost control that persists will require trade-offs that Americans can tolerate. This will call for management of tensions between medicine’s therapeutic, caring, and other purposes, as well as mediation of conflicts among health care industry stakeholders.48 Striking balances between benefits, risks, and costs in the abstract will not do. As questions arise within the doctrinal and regulatory realms that bear on medical spending, legal decisionmakers will need to assess the impact of proposed answers on industry actors’ behavior. They will also need to think strategically about synergies and conflicts between disconnected legal frameworks. Fixation on doctrine and disregard for the health care context will lock in health policy disarray.

This is not to say that health care lawyers and health law decisionmakers should eschew doctrinal consistency or other rule-of-law values. To the contrary, these values are a vital part of the health law mix; the health sphere should not become lawless in pursuit of even the most urgent policy objectives. But where plausible interpretations of the law can accommodate important health care policy concerns, legal decisionmakers should not shy away from adopting such interpretations. And coordination among the doctrinal and regulatory schemes that shape health care policy should be a high priority when legal decisionmakers are called on to make

47. See supra note 45. Rising copayments, deductibles, and employee contributions toward premiums for employment-based coverage are likely to feed dissatisfaction even among the insured. These costs have not increased substantially as a proportion of total medical spending, but they have risen in relation to employee compensation. See KAIser FAMILY FOUND. & HEALTH RESEARCH & EDUC. TRUST, EMPLOYER HEALTH BENEFITS: 2006 ANNUAL SURVEY 6 (2006), available at http://www.kff.org/insurance/7527/upload/7527.pdf.
interpretive judgments in the health sphere.

These are hardly radical propositions. Nine years ago, the Supreme Court did both of these things when it ruled that health plans’ financial rewards to physicians for practicing frugally do not violate ERISA’s fiduciary duty provision.\(^49\) Writing for a unanimous Court, Justice Souter acknowledged ERISA’s ambiguities, pointed to health plans’ need to limit services to stay within budget, and concluded accordingly that the fiduciary requirement should not be read to bar rewards to doctors for rationing care.\(^50\) Rationing, he wrote, was necessary to control medical spending.\(^51\) Souter also underscored the need to resolve ERISA’s ambiguities in a manner consistent with the surrounding health law context.\(^52\) Construing ERISA to prohibit health plans from rewarding their doctors for saving money would have put ERISA at odds with the Health Maintenance Organization (“HMO”) Act of 1973,\(^53\) he said, since such incentives are essential to HMOs’ efforts to keep within their budgets. The 1973 Act awarded federal subsidies to HMOs and required employment-based health plans to offer an HMO option; this, Souter said, constituted congressional endorsement of HMOs’ rewards to doctors for practicing frugally.\(^54\) Souter also cited state law remedies for medical malpractice as reason not to create an ERISA cause of action for improper physician incentives.\(^55\) Such a cause of action, he wrote, would duplicate malpractice law, since proof of substandard care would be necessary to show that improper incentives

\(^{49}\) Pegram v. Herdrich, 530 U.S. 211, 236 (2000). But see infra text accompanying notes 95–99 (pointing out contradictions between the Court’s understanding of health care law in Pegram and in subsequent cases).

\(^{50}\) Pegram, 530 U.S. at 219, 225, 235–36. My own view is that Pegram was unwisely decided. The Justices took no account of the corrosive effect of payments to physicians for withholding care on professional trustworthiness and the doctor-patient relationship. It is indisputable that rationing is inevitable when a health plan undertakes to provide care within a limited budget, but it is hardly the case that physicians must play the lead role in doing the necessary rationing. See M. Gregg Bloche & Peter D. Jacobson, Commentary, The Supreme Court and Bedside Rationing, 284 JAMA 2776, 2777 (2000). Pegram nevertheless represents an effort to accommodate vital health policy concerns—in this case, the importance of cost containment—and to harmonize the operation of uncoordinated legal and regulatory schemes within the constraints of existing doctrine.

\(^{51}\) Pegram, 530 U.S. at 221.

\(^{52}\) Two articles by Russell Korobkin on ERISA’s treatment of employment-based health plans’ coverage determinations, Korobkin, Reinterpreting ERISA Preemption, supra note 19, and states’ efforts to extend coverage to the uninsured, Korobkin, Battle over Self-Insured Health Plans, supra note 19, represent, in my view, the finest effort by a legal scholar to resolve ERISA’s vagaries in a manner sensitive to both health policy concerns and the surrounding legal and regulatory context.


\(^{54}\) Pegram, 530 U.S. at 220–22.

\(^{55}\) Id. at 235–36.
resulted in harm.56

Integration of rule-of-law values with sensitivity to law’s impact in the health care sphere is central to the work of health lawyers. So is acceptance that their working conditions are hazardous. Health law practitioners, scholars, and decisionmakers stand on seismically active ground, cleaved by regulatory and common law schemes that strain against each other. Policymakers who are in a position to draft new statutes and regulations would seem to have it better. They can, in theory, formulate rules that take account of both the health system’s realities and the surrounding legal environment. But in practice, interest group power and unintended consequences often foil the best of intentions. Later in this Article, I will set out a strategy for legal practitioners, scholars, and decisionmakers that takes account of these distinctive challenges.57 That the challenges are sufficiently distinctive and urgent to treat health law as both a separate field and a high professional priority cannot, in my view, be seriously contested.

B. “BIG THEORY”: PURSUIT OF A UNIFYING PARADIGM

If the health law rejectionists are wrong—if the governance of our health care system is in dire need of integrated treatment, as I contend—where should we begin? The way forward, say some, is more and better “big theory”—greater effort by the brightest minds to develop a unified understanding of what the law of health care provision ought to accomplish. Several unifying models have been urged. One—health law as a scaffold for market competition—ranks well ahead of others in its hold on scholars who aspire toward coherence in health care law. Another—protection for professional authority—often plays the role of straw man in legal scholarship; yet it enjoys considerable support. A third is defense of patient autonomy, and a fourth is public determination (through politically accountable mechanisms) of medical spending priorities. These models are not mutually exclusive; indeed some commentators on health law call for a unified understanding that taps different models for varying governance purposes.58 For example, the law could support political (or market) determination of a health plan’s overall budget while deferring to doctors’ clinical judgments within this budget. Such a composite approach could also preserve some space for individual patient choice.

Proponents of each of these several models, and advocates of

56. Id. at 236.
57. See infra Part IV.
58. HALL ET AL., supra note 9, at 359–60; Elhauge, supra note 9, at 379–90.
composite approaches, hold that an overarching conception of health care’s governance should guide the law’s treatment of medicine. They make their cases for why one or another model is best, or why one or another composite is best matched to health law’s variegated governance tasks. But they do not say how we should choose from among them. Hall and Elhauge each contend that argument about which is best is an endeavor that health law scholars should undertake with zeal. But neither they nor others answer the question of how the makers of health law—the myriad courts, regulators, and legislators who shape it in piecemeal fashion—ought to settle this argument.

To give effect to a unified conception of health care governance, these disconnected decisionmakers would have to resolve such arguments in a tightly coordinated way, within disparate doctrinal and regulatory contexts. Coordination of this sort is unachievable. No single decisionmaker has the power to pull all (or even most) of the others into line. No networks, positive feedback loops, or mechanisms of viral spread are capable of the horizontal dissemination necessary to give effect to a single way of doing things. To the contrary, the clashing perspectives of multiple interest groups and levels and branches of government pose an insurmountable obstacle to broad agreement on a single understanding of health care governance.

An even larger obstacle is our irresolution, as individuals and as a society, over the purposes of medicine and, thus, the aims of health policy. It is often said that the purpose of medicine is the promotion and restoration of health, yet we could promote health in much more cost-effective fashion by doing more to create educational and economic opportunity. A large body of evidence supports the conclusion that income and wealth, education, social connectedness, and the quality of the built

59. HALL ET AL., supra note 9; Elhauge, supra note 9.
60. See HAYNES JOHNSON & DAVID S. BRODER, THE SYSTEM: THE AMERICAN WAY OF POLITICS AT THE BREAKING POINT 345–95 (1996) (analyzing the collapse of President Clinton’s health reform plan as the product of paralytic conflict between interest groups). Conceivably, a crisis of transcendent magnitude—say, an economic cataclysm equal to or worse than the Great Depression of the 1930s—could mobilize Congress and the president to act in the face of interest-group power to implement a unified understanding of health care governance as part of a plan for universal coverage and comprehensive health-system reform. But the failure of President Franklin Roosevelt’s Depression-era plan for universal coverage—a plan opposed by the American Medical Association and other interest groups—underscores the difficulty of doing so. See RICK MAYES, UNIVERSAL COVERAGE: THE ELUSIVE QUEST FOR NATIONAL HEALTH INSURANCE 19–20 (Univ. of Mich. Press 2004) (2001).
62. John T. Cacioppo & Louise C. Hawkley, Social Isolation and Health, with an Emphasis on
environment as more important than medical care as determinants of health. Some medical services make measurable contributions toward improving health at reasonable cost, but many others do not. It is easy to read this as proof that we are grossly overspending on medical care, but this begs the question of why. Self-serving, free-spending doctors may be part of the problem, but why are we so willing to go along? The answer is that we want something else beside utilitarian maximization of health—otherwise we would bring the wrecking ball to our intensive care units and reallocate this spending to pay for prenatal care or preschool. We want intangibles like hope (even when it is illusory), comfort, and reassurance. We are willing to pay for plausible explanations of our ailments: some tests that are pure waste from a treatment perspective allay anxiety by helping patients to better understand their circumstances. We want our doctors’ uncompromising loyalty at times of need: we appreciate the importance of cost control, but we would rather that they economize on the other guy. And we cling to the Saving Private Ryan perspective on rescue—whatever the cost—as affirmation of every person’s moral import and community membership: at dire moments, we believe, doctors should do all they can to save their patients.

We want all these things, but we would prefer not to pay. We elect...
politicians who promise tax cuts, and our shopping and dining choices keep the pressure on businesses to skimp on workers’ health care. We put the pressure on ourselves (and our doctors) as well, by choosing health plans with an eye toward price, then demanding tests, treatments, and referrals without regard for cost when we are ill and afraid. Some argue that there are right and wrong resolutions to our contradictory expectations of medicine—and of health law and policy. But even if this were true in the abstract, it is of little help in gaining agreement on the purposes to be served by health law and policy. As a practical matter, our irresolution is sure to persist, abetted by our resistance (as individuals and as a society) to acknowledging the contradictions within ourselves. Ongoing conflict over the aims of health law is therefore inevitable. Agreement on a unitary conception of health care governance, even one composed of a composite of the previously discussed models, is unachievable. The work of health care law, as I will argue later, must include management of fundamental differences tied to interest group viewpoints, politics and ideology, and our many cultural and psychological contradictions.

The impossibility of settling on a single conception of health care law is illustrated by the most prominent scholarly effort to purvey one. More than thirty-five years ago, Clark Havighurst began to challenge the then-prevailing assumption of deference to medical authority over health care resource allocation. Havighurst urged reliance on markets and criticized laws that allowed physicians to act collectively to fix prices and set standards of care. As the health planning paradigm gained influence in the early 1970s (culminating in legislation creating a national network of politically accountable planning bodies) he responded with a scathing

71. Norman Daniels, for example, holds that the moral purpose of health care is restoration and maintenance of health. Norman Daniels, Just Health Care 36–58 (1985). If so, hope, explanation, and affirmation of community solidarity are not grounds for additional medical spending. Clark Havighurst asserts that once a consumer signs up for a health plan, he or she should be bound by that plan’s economizing policies—and that courts have been too willing to defer to sick patients’ after-the-fact preferences for pricey care by forcing health plans to pay for services beyond the scope of plans’ contractual commitments. Havighurst, supra note 11, at 110–53, 157–221.

72. See infra text accompanying notes 138–58.

73. The fundamental nature of these differences distinguishes health care law from numerous other fields, especially those—antitrust, torts, and contracts, for example—that have become organized, more or less, around the paradigm of economic efficiency.


critique of this strategy’s coercive feature—its requirement that hospitals seeking to offer new services or to make major capital investments obtain a “Certificate of Need” from state regulatory authorities. Havighurst also rejected bioethics approaches that emphasized patient autonomy without regard for the need to set limits and to make cost-quality trade-offs. He thought of himself as a “radical,” and in the early 1970s he was, but he made shrewd use of prestigious and powerful institutions, including the Institute of Medicine and the American Enterprise Institute, to push his views into the mainstream. Over time, in conjunction with others, he formulated a comprehensive model of competition in markets for medical care and coverage. In the tradition of Milton Friedman, he emphasized personal freedom as much as efficiency. Today, his vision of health law as a catalyst for market allocation of clinical resources—driven by consumer preferences and specified through contracts among patients, doctors and hospitals, and health care payers—has come close to prevailing among legal scholars who focus on health care organization and financing. Within the upper echelons of the legal academy, it is the main alternative to health law rejectionism.

It has also had enormous real-world impact. In 1975, the U.S. Supreme Court discarded the “learned professions” exemption from application of the antitrust laws, opening the way for federal and private actions against anticompetitive practices in health care. Collective price setting and prohibitions against advertising—once praised by scholars, including a Nobel prize-winning economist, as essential to an anticommunal ethos that sustained patients’ trust in their doctors—were

77. Havighurst, supra note 36.
79. Havighurst was also a chief health policy advisor to Ronald Reagan during the 1980 presidential campaign and the early months of Reagan’s presidency.
80. Others who played leading roles in development of the market paradigm—and who at times collaborated with Havighurst—include Paul Ellwood (widely viewed as the father of the HMO concept), Alain Enthoven (who coined the term “managed competition”), James Blumstein (an early critic of deference to professional judgment and reliance on political mechanisms to allocate clinical resources), and Richard Epstein (an early advocate of contractual variation in clinical standards of care).
81. See generally Havighurst, supra note 11 (detailing his most comprehensive account of this model).
82. See supra note 10 (discussing elite legal academia’s skepticism toward health law).
83. What follows is a brief summary of the competition model’s transformative impact on health care law. I am not going so far as to assert that Havighurst’s work alone brought about this impact—the decisiveness of its influence would be exceedingly difficult to assess—but it is beyond question that Havighurst has been the preeminent voice for this model among health law scholars.
85. Kenneth J. Arrow, Uncertainty and the Welfare Economics of Medical Care, 53 AM. ECON.
suddenly illegal. By the end of the 1970s, the health planning paradigm had fallen into wide disfavor, and conservatives were gaining ground in their opposition to regulatory methods of cost containment. In 1980, Alain Enthoven’s call for cost control through competition between vertically integrated health systems seized policy makers’ attention. President Reagan’s budget director, David Stockman, lauded the proposal as a “counterrevolution in health care policy.” Insurers that once passively paid claims for whatever the doctor ordered began to say no to pricey, unproven treatments—and to create integrated systems like those that Enthoven (and Havighurst) envisioned. Courts empowered insurers to depart from doctors’ determinations of “medical necessity” (the almost-universal contractual standard for coverage, then and now) and to decline claims. Influenced by scholars sharply critical of laws protecting professional prerogative, judges whittled away at such doctrines as the ban on so-called corporate practice of medicine, which limited health plans’ and hospitals’ ability to exercise managerial control over physicians’ clinical judgment.

Most importantly, federal courts construed ERISA to preempt a wide range of state laws that would otherwise govern employer-sponsored health plans. This largely deregulated employment-based coverage, since ERISA neither mandates nor restricts employee benefits. Employer-sponsored plans were free to fashion packages of covered services without regard for professional beliefs about appropriate care—or for political action at the state level to set health care priorities. Plans, moreover, were

---

86. In 1979, a Democratic Congress rejected President Jimmy Carter’s proposed national scheme of hospital price controls. See Alain C. Enthoven, Consumer-Centered vs. Job-Centered Health Insurance, HARV. BUS. REV., Jan. 1979, at 141. Despite considerable evidence that hospital rate regulation constrains private sector health spending, it never again received serious federal consideration.

87. ALAIN C. ENTHOVEN, HEALTH PLAN (1980).

88. Id. (book jacket quotation).

89. E.g., Sarchett v. Blue Shield of Cal., 729 P.2d 267 (Cal. 1987). To be sure, in Sarchett and other similar cases, courts imposed stringent requirements of good faith and fair dealing. Judges also invoked the standard insurance law principle that ambiguity in coverage contracts must be construed against the insurer and in line with “the reasonable expectations of the insured.” Id. at 273. But even with these reservations, permitting insurers to say no represented a radical step away from blind deference to doctors’ determinations of medical necessity.


91. See supra notes 18–20.

immune from state medical malpractice suits for denial of coverage. This insulated them further from professional authority, since physician-set standards of care were (and still are) the touchstone of malpractice liability.

A measure of the market model’s real-world success is the fact that by 1992, cost containment through competition between health plans had become the centerpiece of the Democratic presidential nominee’s proposal for health reform.93 Since then, no serious candidate for the presidency has proposed health reform that did not rely mainly on markets to cover the uninsured and limit spending.

Yet, the market-oriented counterrevolution in health care law and policy never fully supplanted competing models. Efforts to shift medical malpractice liability from tort to contract94—and to thereby permit health care payers and providers to offer levels of care that diverged from professional standards—were almost uniformly rejected by the courts. Medical tort litigation remains a contest over whether defendants’ actions measure up to clinical practice norms set by physicians. Even in the antitrust setting, courts have displayed ambivalence about no-holds-barred medical markets. Most notably, a 1999 Supreme Court holding allowed California dentists to band together to set ethical limits on price advertising.95 The Justices said such limits were “procompetitive,” and thus permissible under the antitrust laws, because they helped to clarify consumers’ understanding of dentists’ price discounting practices. Market-oriented critics of the professional paradigm chided the Court for turning antitrust principles on their head by characterizing restraints on competition as “procompetitive.”96 The Justices, said Havighurst, had reverted to older thinking about the virtues of professional benevolence as a corrective for flawed markets.

In two more recent health care opinions, both authored by Justice Souter (who also wrote the opinion allowing dentists to restrict

93. To be sure, the Clinton plan (both during the 1992 campaign and through the 1993–94 legislative debate over health reform) also incorporated regulatory measures—for example, national budget ceilings for insured health spending—that the competition strategy’s proponents did not like. Enthoven participated in formulating the Clinton plan, then dropped out of the process, disillusioned. Havighurst contributed his views but sharply criticized the administration’s plan for being too regulatory. See Havighurst, supra note 78, at 123–27.


95. Cal. Dental Ass’n v. FTC, 526 U.S. 756, 771–73 (1999). The advertising restrictions at issue required dentists to reveal their standard, prediscount prices and to otherwise be transparent about the size of claimed discounts. Id. at 761.

96. Once again, Havighurst led the charge (among scholars, at least). Havighurst, supra note 32, at 949–53.
advertising), the Court showed its ambivalence about markets in a different doctrinal context—ERISA. Both cases involved the balancing of clinical benefits and costs when a physician provides care within a health plan’s budgetary constraints. In *Pegram v. Herdrich*,97 decided unanimously in 2000, the Justices embraced the market model wholeheartedly. The Court characterized clinical standards of care in economic terms as judgments about “acceptable . . . risk” and “optimum treatment levels” to be made by health plans and their physicians in response to market forces.98 But two years later in *Rush Prudential HMO, Inc. v. Moran*,99 the Court opted for the paradigm of deference to medical professionalism. Holding that ERISA does not preempt state laws requiring independent physician review of refusals by health plans to pay for tests, treatments, and referrals, a 5-4 majority characterized such review as akin to a doctor’s second opinion, not a legal remedy for contractual breach by a health plan.100 This maneuver enabled the majority to rescue state-mandated independent review from the black hole of ERISA preemption (since established jurisprudence holds that ERISA preempts state remedies for coverage denial), but it divorced independent review from health insurance contracts, and thus from the market. Under *Rush Prudential*, medical reviewers are free to make their own clinical judgments and to thereby require health plans to pay,101 without regard for the terms of the deal struck among employers, health plans, and subscribers. That Souter wrote both of these opinions, as well as the Court’s 1999 opinion on dentists’ advertising restrictions, underscores the Court’s irresolution when it comes to the market model.

For Havighurst and other market purists, irresolution is probably too polite a term. Havighurst condemns departures from the market paradigm as the product of “authoritarian/collectivist . . . leanings,”102 and he saves

---

98. *Id.* at 221–22. The Court treated ERISA as a statutory framework for such a market, but it allowed that Congress could intervene, if it chose, to set limits on these market-driven “judgments of social value.” *Id.*
100. See *id.* at 381–83 (rejecting characterization of independent medical review as an arbitral remedy for contractual breach).
101. Patients who prevail in medical review proceedings can then obtain judicial enforcement of the favorable result by pursuing their federal remedy under section 1132(a)(1)(B) of ERISA. *Id.* at 385.
102. Havighurst, *supra* note 78, at 110. Havighurst makes me into his example of “persons with authoritarian/collectivist, rather than pluralist, leanings” who oppose allowing “people [to] make consequential choices for themselves.” *Id.* He misconstrues my empirical account of the limitations of welfare economics as a tool for analyzing choice between health care’s competing purposes. “Bloche,” he says, cannot imagine “allow[ing] individuals . . . to make the consequential choices” and “is quite comfortable with having nonaccountable judges serve as the ultimate arbiters” of health care
special ire for those who would allow professional judgment to trump contractual limits on health spending. But Souter’s irresolution reflects our own, as a nation, about the purposes of health policy and thus the premises of medicine’s legal governance. No legal system can render clarity—certainly not clarity that lasts—out of pervasive conflict over core premises. Full commitment to any one paradigm requires sustained public disregard for passionately felt concerns that are embodied in others. We are nowhere near a settled view of the place of market mechanisms, public allocation, and professional judgment in the governance of medicine. We differ sharply, both between and within ourselves, over the relative import of equity, solidarity, rescue, relief of suffering, and the restoration and promotion of health. We differ, also, over the comparative weight we should accord to these purposes and to society’s other concerns; from education and the environment to criminal justice and national security. These differences make agreement on a unifying paradigm for health care law unattainable.

C. CASE-BY-CASE PRAGMATISM

Proponents of case-by-case pragmatism in health care law treat the quest for a unifying theory of legal governance as beside the point; a distraction from the work of making medical care more efficient, effective, equitable, and otherwise expressive of our values. As Henry Greely puts the point, “the existence or absence of a dominant paradigm has nothing to do with the value of academic health law” or with the quality of health care lawyers’ contributions. Whether one prefers a single paradigm or a “messy, sprawling, and loosely connected field” is a matter of personal style; neither “is right or wrong in the abstract.” Rather than fretting about the matter, health lawyers should just get on with it: “[t]here is work to be done.” Most law review articles on health care topics take this tack, as do lawyers’ contributions to the medical and health policy literature. Without reference to overarching theory, or lack thereof, this work addresses particular legal and policy problems, such as medical

choice. Id. at 110 n.5 (citing Bloche, supra note 11). And he misrepresents my acknowledgement that legal interpretation in the health care context requires normative judgment: this acknowledgement, he claims, constitutes a rejection of personal choice in medical matters. Id.

103. That the “medical necessity” standard for coverage (a staple of almost all health insurance contracts) constitutes contractual deference to professional judgment is a possibility Havighurst does not acknowledge.

104. Greely, supra note 9, at 408.

105. Id.

106. Id. at 409.
malpractice, racial disparities in care, and hospitals’ obligations to provide free care to the poor. It is influenced (overtly or otherwise) by underlying values, but its aim is practical guidance for courts and regulators, grounded in cross-disciplinary appreciation of the workings of health care and law.

This work has made important contributions to the solution of problems in health law. Sara Rosenbaum’s quest to bring civil rights law to bear on racial disparities has produced a blueprint for doing so and put pressure on providers and health plans to take equity more seriously. Jay Katz’s call for greater focus on sick people’s varying beliefs and fears has sensitized legal commentators, clinical caregivers, and some judges to the pitfalls of allowing informed consent to become a routinized, pro forma process. But these and many other efforts to address particular problems in health law pay too little attention to interactions among the medical care system’s moving parts—and to the contradictions and confusion embedded in the messages that health law sends.

For example, Rosenbaum’s advocacy for robust use of civil rights

107. Other topics that health law scholarship frequently addresses, in disconnected fashion, include tax treatment of nonprofit hospitals, Medicare fraud and abuse, regulation bearing on clinical quality and hospital rates, and myriad bioethics matters.


110. Hospitals and health plans have been critical of the civil rights approach, preferring to treat racial disparity in care as a quality issue better addressed by managerial methods that promote best practice for all. See Nicole Lurie & Tamara Dubowitz, Health Disparities and Access to Health, 297 JAMA 1118, 1120 (2007). But the possibility of civil rights litigation has pushed them to address the disparities question.

111. KATZ, supra note 108, at 151–64.
litigation to combat racial disparities in care disregards the potential impact of such litigation on efforts to improve the quality of medical services. Racial disparity is, at bottom, a quality-of-care matter. At issue are disparities in standards of care and in the compassion and respectfulness with which care is provided. 112 Strategies that bring quality of care (in these several senses) into line with agreed-on best practice will, in course, ameliorate racial (and other) disparities. Litigation is of doubtful value as a tool for achieving this, as abundant evidence from the study of the medical malpractice system shows. 113 Litigation prioritizes individual accountability over pursuit of systemic changes that have been shown to promote clinical excellence. These include promulgation of evidence-based practice protocols, candid discussion of clinical errors (with an eye toward “lessons learned”), collection of data on doctors’ and hospitals’ performance, and coordination of care in complex cases (involving multiple specialists). 114 Malpractice cases commonly turn on the opinions of partisan “experts” rather than science-based standards of practice, putting reduction of legal risk in conflict with pursuit of health care quality. 115 Individual blame, moreover, discourages open discussion of mistakes and of management strategies that might prevent them, 116 since

112. Not all differences in care constitute disparities. The Institute of Medicine has proposed a useful distinction between appropriate differences in the care patients receive (arising from differences in clinical circumstances and patient preferences) and inappropriate disparities (tied to race and ethnicity, absent clinical justification). Inst. of Med., Unequal Treatment 125–59 (Brian D. Smedley et al. eds., 2003).

113. See Comm. on Quality of Health Care in Am., Inst. of Med., supra note 4 (reviewing the large literature on mismatches between the messages sent by the medical tort system and the causes of medical errors).


115. The medical tort system, for the most part, continues to labor under the fiction that there is a single standard of appropriate care in each case to be determined by the trier of fact based on testimony from plaintiffs’ and defendants’ experts. Malpractice law typically accords partisan experts trump status over standards of care developed by academic and clinical leaders, based on scientific evidence. This makes malpractice litigation into something of a roulette wheel, since doctors’ practice styles vary greatly and often depart from evidence-based standards. Cf. Ctr. for the Evaluative Clinical Scis., Dartmouth Med. Sch., The Dartmouth Atlas of Health Care: 1998, at 53–80 (1998) (reviewing and analyzing local variations in medical and surgical responses to a broad range of illustrative clinical problems). Thus, at best, the malpractice system offers minimal reward for best, evidence-based practice. At worst, the system encourages doctors to depart from best practice when doing so might protect them from plaintiffs’ experts.

admission of errors can increase liability risk. Fear of liability, moreover, discourages collection of data on doctor and hospital performance—data essential to ongoing quality improvement. And pursuit of culpable individuals diverts attention from opportunities to improve quality by better coordinating care and otherwise promoting team effort.

This is hardly to say that civil rights law has no place in efforts to reduce health care disparities. Nor is it to deny the moral force of the argument that racial injustice must be named and blamed, even when it results from institutional insensitivities, rather than intentional design. But it is to caution that individual culpability operates on health care systems in paradoxical fashion, creating incentives that put quality improvement, and thus amelioration of racial disparity, at risk. Management of this risk requires attention to medical care’s moving parts—and to the mix of messages that the prospect of liability sends.

Similarly, calls by Jay Katz and others for informed-consent law to take richer account of individuals’ beliefs, hopes, and fears disregard competing health law and policy goals, including cost control and distributive fairness. Empowering patients to assert their subjective preferences puts pressure on doctors to accommodate them. This, of course, is the point of such empowerment. But to the degree that doctors accommodate by prescribing pricier, more intensive treatments to some, medical spending will rise, and health insurance will spread this burden to all of us.

117. Immunizing discussion of possible errors from discovery—or from admissibility—in litigation does not fully address this problem, since potential plaintiffs can use information from such discussion to pursue other evidence of alleged clinical errors (for example, by deposing participants in such discussions).

118. See Richard Delgado & Jean Stefancic, Critical Race Theory 16–22 (2001) (arguing for the importance of identifying and addressing the racial bias embedded in our institutions, social structures, and thought processes).

119. See generally M. Gregg Bloche, Race and Discretion in American Medicine, 1 Yale J. Health Pol’y L. & Ethics 95 (2001) (analyzing racial disparities in health care as the product of interaction between clinical uncertainty, institutional and economic incentives, bias and stereotypes, and historical discrimination).

120. Current informed-consent doctrine, as Katz points out, makes little space for individual patients’ varying preferences. Katz, supra note 108, at 82–84. In most states, physicians need only tell patients about risks and benefits that a reasonable physician would deem material to a patient’s decision. (The reasonable physician standard, moreover, is typically applied by reference to prevailing professional approaches to disclosure.) In other jurisdictions, doctors must disclose those risks and benefits that a reasonable patient would deem material. This rule is no more friendly to individual differences in patients’ beliefs, hopes, and fears. See id. at 81–82.

121. To be sure, “medical necessity” clauses in insurance contracts limit physicians’ ability to accommodate patients’ subjective preferences. Insurers employ these clauses to resist covering care that lies at or beyond the margins of accepted clinical practice. On the other hand, health insurance law
The changes that Katz and others urge, moreover, would turn informed-consent law into an instrument of inequity—and of racial, ethnic, and gender disparity, to the extent that patients’ preferences (and willingness to pursue them) vary with group membership.\textsuperscript{122} Tying clinical practice more closely to sick people’s subjective preferences would empower the self-assertive to obtain costly, “boutique” care—care not typically provided to the more retiring among us—at the insurance pool’s expense.\textsuperscript{123} Not only could this widen disparities in care, it would also make health insurance into a mechanism for cross-subsidies from the diffident to the demanding.\textsuperscript{124}

Neither Katz nor other proponents of greater legal deference to patients’ individualized preferences acknowledge, let alone address, these conflicts among autonomy, control of costs, and distributive fairness. Empowering patients to express their hopes and fears is a deeply appealing idea. But health care law serves other purposes, at odds with maximum responsiveness to sick people’s personalized preferences. Focus on informed consent, without regard for these other purposes or for the legal doctrines that pursue them, contributes to health law’s confusion.

“There is work to be done,” as Greely says, and health care law is indeed a “messy, sprawling” field.\textsuperscript{125} But this work includes the accommodation of health law’s cacophony of aims and the management of conflict among its myriad legal doctrines and regulatory regimes. No single paradigm can neatly accomplish this. Yet disregarding this challenge would

\textsuperscript{122} There is some evidence that male patients are more assertive than women in their care-seeking behavior and that whites, as a group, are similarly more assertive than African-Americans. \textit{Inst. of Med.}, \textit{supra} note 112, at 131–35.

\textsuperscript{123} Magnetic resonance imaging (“MRI”), which typically costs in excess of $800, is an illustration. Should savvy and assertive patients be referred for MRIs to rule out exceedingly unlikely illnesses simply because these patients verbalize their anxieties (and make demands of their doctors) with less reserve than do others? Turning informed-consent law into a cudgel against doctors who resist such entreaties would further empower the most privileged patients and thus widen socioeconomic and racial disparities in medical care.

\textsuperscript{124} Since, within any given insurance plan, all pay the same premium, more demanding patients would enjoy subsidies from those in the same clinical circumstances who ask for less.

\textsuperscript{125} See Greely, \textit{supra} note 9, at 408; \textit{supra} notes 105–08 and accompanying text.
guarantee chaos in the governance of our medical system. Law’s contribution to creating a more cost-effective, caring, and just health system will turn in large measure on how courts, regulators, and other legal decisionmakers pursue this task.

III. HEALTH CARE LAW AS AN EMERGENT SYSTEM

Can health care law rise to this challenge? No single legal actor can answer this question. No homunculus can command health law’s fragmented decisionmakers to adopt one or another way of doing things. The law of medical care provision and financing can be usefully understood as an emergent system. It arises from myriad “deciders”—and from the interactions between them and the health care system’s disconnected participants. Like other emergent systems, biological and social, the legal governance of health care exhibits an intelligence (often perverse) that materializes from below. Efforts to influence this intelligence for the better must take account of this. In this part and the next, I shall propose a strategy for doing so—a strategy that breaks sharply with the counsel that commentators on health law have, so far, offered legal decisionmakers.

126. My proposition is not that health care law “is” (in some absolute sense) an emergent system; my claim, rather, is that the emergent systems model has value as a tool for understanding and navigating the obstacles to health law reform.


128. See, e.g., ROBERT AXELrod & MICHAEL D. COHEN, HARNESSING COMPLEXITY (2000) (urging business leaders to think of their organizations as complex adaptive systems, empowered by variation, in both product lines and decisionmaking strategies, to adjust to changing market conditions); THOMAS C. SCHELLing, MICROMOTIVES AND MACROBEHAVIOR 13–14 (1978) (considering the connections between individual incentives and patterns of social behavior).

129. The logic of emergent systems is, from the perspective of the aims we seek, often perverse: common examples include the development and spread of cancer, epidemics, war, and economic bubbles and busts. See, e.g., ROBERT J. SHILLer, IRRATIONAL EXUBERANCE 15–17 (2d ed. 2005) (tracing breakdowns in market valuation that arise from interactions between individuals’ self-deceptions and misperceptions).

130. See generally JOHN H. HOLLAND, EMERGENCE: FROM CHAOS TO ORDER (1998) (laying out the idea of emergence); STUART KAUFFMAN, AT HOME IN THE UNIVERSE (1995) (offering accounts of how order in complex systems emerges from innumerable interactions among simpler elements).
A. BEYOND THE MYTH OF THE “DECIDER”

Commentary on health care law (and other legal fields) typically presumes the existence of key decisionmakers—and their top-down authority over the law within their domains. More often than not, in most fields of law, this presumption is a close-enough approximation to reality. The Supreme Court holds sway over federal constitutional law, and a variety of federal agencies set the rules within their regulatory realms, subject to judicial review and congressional oversight. Health care law does not function this way. No single authority sets the rules or is in position to implement the proposals and paradigms urged by commentators. Health law is the product of many, scattered deciders who act not in concert but in interdependent fashion. It exhibits the properties of an emergent system—a system with a design that arises from ongoing feedback among these scattered deciders. Its design—its intelligence—transcends these deciders. Indeed, it is a common feature of emergent systems that their component elements do their part absent awareness of their places in the larger scheme.

Ants, for example, “decide” to forage or to fight, or to follow paths and to ferry food from distant places, based on pheromone levels they detect. They neither take orders from superiors nor grasp their larger mission on the colony’s behalf. Researchers have shown this by exposing individual ants to different mixes of pheromones in laboratory settings. The ants then forage or follow as they would in the wild, behavior that seems perversely out of context beneath the laboratory’s bright lights. Neurons, similarly, sum up the electric signals they receive, then fire to activate or suppress follow-on cells that participate in networks tied to perceiving, understanding, and acting on the world. Neurons have no “sense” of their larger, networking mission. They simply follow the laws of chemistry and physics; the logic of our thoughts and behavior emerges from this.

131. Standard examples of agencies that function as the principal authorities within their realms of law and policy include the Securities and Exchange Commission, the Internal Revenue Service, and the Environmental Protection Agency.

132. The emergent properties of health care law (by comparison to other areas of law) are a matter of degree. All areas of law are influenced by multiple, interacting decisionmakers; thus all areas of law can be seen as emergent to some degree. My limited point here is that the law of health care provision and financing is more dependent on myriad, minimally coordinated decisionmakers—and less influenced in top-down fashion by centralized legal authority—than almost any other field of law.


134. See id. at 74.

135. See EDELMAN, supra note 127, at 115–18.
Likewise, the designs of cities, societies, and economies emerge from the motives and actions of individuals who think they know what they are doing but who are mostly unaware of their roles in fashioning and sustaining neighborhoods, subcultures, industries, or the other social forms that organize our collective lives. We are, of course, different from ants and neurons—we are more flexible (since our neural networks evolve in response to events), hierarchical, and, up to a point, self-aware. But what we have in common with our remote, six-legged relatives is that the intelligence of our social forms transcends our sense, as individuals, of our motives, judgments, and actions.

B. THE EMERGENT LOGIC OF HEALTH CARE LAW

The structure of health law is similarly emergent, for better and worse. Take, for example, the tension between malpractice law’s reliance on professional standards of care and the proposition that markets should permit consumers to pick from among different levels of care, an idea embedded in antitrust doctrine and, to some degree, judicial interpretation of health insurance contracts. Commentators on health law treat this tension as a failure of coherence. Market-oriented commentators complain that liability for breach of professional standards prevents health plans and providers from offering lower-cost care and coverage options. Liberals who object to tying medical care to ability to pay defend professional


137. Other legal scholars have invoked emergence, albeit toward ends that differ from mine. Commentators on environmental law have drawn an analogy between ecosystems (often analyzed by researchers as complex adaptive systems characterized by self-organization and nonlinear responses to changing conditions) and the legal regimes designed to protect them. They have argued that complexity (and the variation it generates) makes legal governance more robust—more responsive to changing circumstances—just as complexity and chaos (which engender variation and thus expand evolutionary options) make species and ecosystems better able to adapt to change. This line of reasoning has led them to favor such approaches as greater devolution of regulatory authority to the states and the vesting of federal regulatory authority in multiple, overlapping agencies. E.g., Donald T. Hornstein, Complexity Theory, Adaptation, and Administrative Law, 54 DUKE L.J. 913, 930–31 (2005); J.B. Ruhl, The Fitness of Law: Using Complexity Theory to Describe the Evolution of Law and Society and Its Practical Meaning for Democracy, 49 VAND. L. REV. 1407 (1996). These scholars appear to presume that law adapts by becoming more “fit” in response to selective pressures. I am skeptical about this proposition (certainly the present state of health law is profoundly maladaptive, if by “adaptive” we mean well-suited for the pursuit of agreed-on policy ends), given the power of interest groups, cascades of collective fear and belief, and other nonrational factors to shape legal outcomes. Cf. Mark J. Roe, Chaos and Evolution in Law and Economics, 109 HARV. L. REV. 641 (1996) (arguing that different approaches to corporate governance in the United States, Europe, and Japan are products of initial conditions and path dependence, not pure “evolution-toward-efficiency,” and that suboptimal governance schemes persist in the absence of rival approaches with large efficiency advantages).

138. E.g., Havighurst, supra note 11, at 115–17.
standards as a floor below which levels of care should not fall.  

Looking at health law as an emergent system yields a different understanding—one that treats this conflict as a mechanism of feedback among scattered deciders with differing perspectives. A deeply felt commitment to health equity, and to the ideal of life’s pricelessness, animates tort law’s deference to professional standards of care, as does sick people’s yearning to trust their doctors. Were the law to utterly abandon its reliance on professional standards, it would detach itself from these concerns. This would undermine people’s confidence in law’s responsiveness to their hopes and fears. Yet life is not priceless, resources are scarce, and Americans revere the market as the most efficient, least authoritarian way to manage scarcity. Antitrust and other doctrines that promote consumer choice in health care express this. The legal regimes that govern medical malpractice and restraints on competition thus embody different suites of concerns to which Americans are inextricably committed. From an emergent systems perspective, this is not a contradiction; it is an opportunity for mutual feedback among component systems that constitute health law. Antitrust lawyers who take Havighurst’s combative stance toward professional standards can stay true to their convictions, as can egalitarians who see health care allocation based on ability to pay as anathema. Both sides think they know what they are doing—campaigning to make health law more consistent (and to get it “right”) by cleansing it of the pernicious influence of the opposing view. Both sides, meanwhile, participate in a larger process of which they may be unaware—a process of feedback between legal schemes that sometimes sustains existing arrangements and that at other times pushes health care governance hard in one direction or another, as scattered deciders take

139. See, e.g., Sara Rosenbaum et al., Who Should Determine when Health Care Is Medically Necessary?, 340 NEW ENG. J. MED. 229, 229 (1999) (urging reliance on professional standards to determine levels of care and health insurance coverage).

140. See GUIDO CALABRESI & PHILIP BOBBITT, TRAGIC CHOICES 135 (1978) (reflecting on the tension between the ideal that life is priceless and the reality that we put lives at risk for economic gain).

141. Mark Hall has perceptively observed that people’s trust for their doctors increases with severity of illness—and the accompanying anxiety and fear. He cautions that trust deepens out of proportion to trustworthiness as patients become more needy. Mark A. Hall, Law, Medicine, and Trust, 55 STAN. L. REV. 463, 507–09 (2002).

142. I have oversimplified my depictions of these sets of concerns—the thinking behind both (that is, consumer-choice approaches and policies that put greater emphasis on equity and/or reliance on professional norms) is more nuanced and variegated. But my oversimplification will serve to support the larger point I am making here about the role of these suites of concern in health law’s emergence.

143. Since the late 1970s, health care law has shifted dramatically toward the market model, albeit not as wholeheartedly as some market enthusiasts would have preferred. See supra text accompanying
account of developments in neighboring suites of law.

There are many other examples of such feedback schemes in health care law. Some involve classic tensions in American public life, between national and local governance (the struggle over ERISA preemption of state efforts to expand coverage is a case in point), equity and autonomy (the debate over the extent to which informed-consent law should accommodate individuals’ varied preferences is illustrative), and public versus personal responsibility for finding shelter against life’s vicissitudes (the central theme of recurring battles over the scope of Medicaid, the State Children’s Health Insurance Program (“SCHIP”), and other health insurance initiatives for the disadvantaged). Others are more specific to medicine (for example, different views on the role of science versus clinical intuition in shaping medical practice).

Some feedback mechanisms drive change in health systems through public impression as much as law. During the late 1990s and early 2000s, the managed-care industry successfully fought off class action suits and Congressional proposals (so-called patients’ bills of rights) to hold it accountable for refusing to cover physician-prescribed care. But press coverage of lawsuits and legislative hearings made managed-care horror stories into the stuff of kitchen-table conversation. Consumers left highly restrictive health plans or pressed their employers to do so, and investors turned bearish toward the industry, motivated by consumer backlash and perceived legal risk. Health plans responded by abandoning the very practices (such as frequent coverage denials and monetary rewards to doctors for withholding care) they had fought in Congress and the courts to

notes 74–96.

144. See, e.g., Retail Indus. Leaders Ass’n v. Fielder, 475 F.3d 180 (4th Cir. 2007) (holding that ERISA preempts Maryland’s so-called Wal-Mart law, requiring firms with ten thousand or more employees to spend 8 percent or more of their payrolls on medical coverage for their workers). Efforts by multiple states, most notably Massachusetts and California, to expand coverage by requiring employers to contribute more toward medical costs, will likely lead to reprises of this struggle in the months and years ahead.

145. See supra text accompanying notes 120–24.

146. Although the Daubert principle, requiring that expert testimony on scientific and technical matters be grounded in “scientific knowledge,” Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 589–90 (1993), has been applied by state as well as federal courts in many legal contexts, it has not generally been applied to medical testimony concerning appropriate treatment in malpractice and insurance coverage cases. Courts’ peculiar reluctance to extend Daubert to these contexts probably reflects their regard for physicians’ clinical judgment—the proverbial “art of medicine”—when supporting scientific evidence is lacking.

defend.\textsuperscript{148} The industry prevailed in the legal arena, but the struggle carried a cost imposed on health plans by unhappy customers and investors.

Such feedback schemes enable the expression of values and concerns that are at odds with each other but deeply felt, to the point that health law cannot realistically discard them. Legal and regulatory actions that offend these values inspire responses—from the losing parties and from legal decisionmakers with different perspectives. Decisionmakers charged with implementing different legal regimes—tort and contract, ERISA, antitrust, and many others—send negative or positive feedback signals through their responses. Refusal by state judges, for example, to endorse contractual departure from professional standards of care in medical malpractice cases sends a dampening message to antitrust and other decisionmakers eager to advance the market model in the medical realm. On the other hand, state courts’ growing willingness since the 1970s to permit insurers to deny coverage for physician-prescribed services on contractual grounds\textsuperscript{149} signals that their support for professional authority has diminished.

The Supreme Court’s refusal to give full effect to the market model even in the antitrust context—for example, the Justices’ acceptance of professional restrictions on price advertising\textsuperscript{150}—may reflect its summing of these and other mixed signals, from many decisionmakers, about the comparative desirability of unfettered competition and deference to professional norms. Justice Souter’s seeming confusion about the sweep of markets—his characterization of clinical standards of care as the product of market-driven cost-benefit trade-offs in \textit{Pegram}, followed by his portrayal of medical standards as a matter of professional opinion, not contract, in \textit{Rush Prudential}\textsuperscript{151}—may merit criticism as lawyerly craftsmanship. But it is a sign of the Court’s role as a processor of mixed messages about the role of markets and professionalism in health care governance. The Justices participate in overlapping networks of feedback involving health law’s myriad decisionmakers.\textsuperscript{152} In response to the varied signals the Justices receive, they invoke competing models of medical governance, all of which have some legal force. So it is hardly surprising that the Court sends

\begin{itemize}
\item \textsuperscript{148} Id. at 37–38.
\item \textsuperscript{149} See supra text accompanying note 86–89.
\item \textsuperscript{150} See supra note 95 and accompanying text.
\item \textsuperscript{151} See supra text accompanying notes 95–101.
\item \textsuperscript{152} The Court is, to be sure, an outsized participant: its “signal” to these networks is decisive on federal law matters plainly covered by its precedents, and it is “loud,” due to its audibility, even on matters outside this scope. Yet the network metaphor still holds: by analogy to strategically placed cells in neural networks, the Justices have much influence, but they exercise it through constrained channels in response to other decisionmakers.
\end{itemize}
messages that do not cohere: consistency would require the Justices to discard large parts of health law, embodying values and concerns Americans are unwilling to abandon.

Within the networks of decisionmaking that constitute health care law, negative feedback tends to support the status quo, and positive feedback tends to promote change. Novel judicial, regulatory, and legislative gambits typically provoke suppressive responses, but they sometimes catch fire, propagating to broader networks of decisionmakers. The law’s embrace of the market paradigm is the highest profile example. Isolated initiatives in the 1970s—the Supreme Court’s abandonment of the learned-profession exemption from antitrust law and congressional passage of a law promoting HMOs—triggered positive responses, probably potentiated by rising skepticism toward professional authority. Other decisionmakers picked up, then amplified the signal. The Federal Trade Commission began antitrust enforcement against health care providers, state regulators backed away from limitations on hospitals’ capital investment, and courts, as mentioned earlier, allowed insurers to decline coverage for physician-prescribed care.

Preceding and parallel developments in neighboring legal spaces widened the possibilities for propagation. Those who urged more robust informed-consent requirements during the 1960s and 1970s did not mean to promote medical markets, but by winning broader legal recognition for patient autonomy, they primed courts’, regulators’, and the public’s receptivity to the competition paradigm. And for the Congress that enacted ERISA in 1974, in response to pension fund scandals that shattered

153. An example is the effort by some state and federal judges, beginning in the late 1990s, to chart a path around ERISA preemption of managed care liability for negligent coverage denial. See Bloche, supra note 11, at 301. To avert preemption under ERISA’s section 514 of state laws that “relate to” employment-based health plans, 29 U.S.C. § 1144(a) (2006), judges sought to characterize health plans’ coverage determinations as medical judgments (beyond the preemptive reach of section 514, based on established precedent) rather than plan administration (clearly within ERISA’s preemptive shield). See Bloche, supra note 11, at 301. Variants of this approach caught on in some jurisdictions, including several federal circuits, but the Supreme Court squelched the strategy in 2004, in Aetna Health Inc. v. Davila, 542 U.S. 200, 208–21 (2004), holding broadly that ERISA’s preemption provisions preclude such liability.


156. See M. Gregg Bloche, Medical Ethics in the Courts, in ETHICAL DIMENSIONS OF HEALTH POLICY 133, 135–40 (Marion Danis et al. eds., 2002) (considering the emergence of patient autonomy as a value in bioethics commentary and legal doctrine during the 1960s and 1970s).
American workers’ confidence, the potential implications for health insurance were an afterthought. But by preempting most state regulation of fringe benefits (and substituting no minimum requirements of its own), ERISA largely deregulated the market for medical coverage.

Out of many interwoven networks of deciders, health care law emerges. This process hardly guarantees a governance system that serves us well; by way of analogy, emergence in biological systems generates tumors, seizures, and other phenomena that careen out of control when the feedback mechanisms that maintain homeostasis fail. America’s worsening crises of cost and access, clinical mistakes that kill tens of thousands of patients per year, and the proliferation of treatments absent proof of their value strongly suggest that, in health care law, much has gone awry. How to intervene to make health law part of the solution is a question that calls for attention to the logic of emergence.

IV. TOWARD AN AGENDA FOR HEALTH CARE LAW

Commentators on health care law and policy urge courts, legislators, and sundry regulators to pursue elegantly designed approaches, rooted in one or another governance paradigm. Rarely is this advice taken. Instead, health law decisionmakers continue to churn out a hodgepodge of disconnected doctrines and policies. Academic disdain for this incoherence makes for edgy commentary, but it has done little to change health law. If the health law commentariat is to become more than marginally relevant, it will need to radically shift its focus, toward opportunities for influencing the dynamics of emergence. Seen through an emergent systems lens, health law’s contradictions express competing, deeply felt values and concerns that feed back on each other. If health law is to maintain its democratic legitimacy, these discordant values and concerns cannot be abandoned. Thus the challenge for health lawyers is not to efface the field’s contradictions. It is to glimpse or intuit the flows of influence through networks of scattered deciders, with an eye toward chances to amplify, dampen, or redirect the flow; and with a readiness to seize moments as they arise.

The most effective democratic leaders—and the greatest legal advocates—have preternatural understandings of their potential avenues of influence. They intuit how networks of decisionmakers might react to

157. In my view, David Hyman is by far the most engaging—and insightful—on this theme. See, e.g., DAVID A. HYMAN, MEDICARE MEETS MEPHISTOPHELES (2006).
158. President Franklin Roosevelt, a law school dropout, intuited open and closed pathways with
legal and policy changes—and thus how these changes might play out over the long haul. They grasp the potential for small changes to have large long-run impacts—that is, they intuit possible nonlinear relationships between legal interventions and social consequences. They do not invoke the emergent systems model or metaphor. Yet this model captures a critical aspect of their judgment: their ability to anticipate the possibilities and limits of their influence by intuiting other legal and political actors’ responses.

In the field of health care reform, such understanding has been in short supply. With disastrous results, the Clinton administration crafted an unwieldy reform scheme that took little account of likely sources of resistance. After the Clinton plan’s collapse, many observers wrote off the possibility of substantial reform, concluding that interest group opposition stands immovably in the way. This pessimism is misplaced. Opportunities for transformation abound, but they require attention to the dynamics of health law’s emergence. They also require reformers to acknowledge a corollary of the logic of emergence—that they can jumpstart change but cannot order up precise results, since exact outcomes cannot be known in advance.

I shall devote the rest of this Article to these opportunities for transformation. Though the obstacles are formidable, possibilities are plentiful on the health care policy fronts that are of most urgent concern: access to care, cost, and value. There are, of course, large differences of opinion as to what constitutes sufficient access to care, how much America should spend on health services, and how to assay their value. I have opined in detail on these questions elsewhere, and I will not do so here.


160. Emergent systems are self-organizing; that is, their order arises from the in calculable (quite literally) combination of simpler interactions at lower levels (for example, neurons that constitute a nervous system; businesses and individuals who comprise an economy). Because these countless, simpler interactions cannot be exhaustively predicted, their emergent results cannot be specified in advance. See supra Part III.A. Emergent software is illustrative: its repeat “plays” of a given, complex scenario (for example, a model for the spread of an epidemic, the propagation of a financial panic, or the evolution of traits by natural selection) yield different results. The predictive power of such software comes not from individual runs, or plays, but from large numbers of plays (made possible by enormous computing power) that, together, suggest the range of possible outcomes.

161. See M. GREGG BLOCHE, DO NO HARM (forthcoming 2009); Bloche, supra note 11.
But I note that my views about the goals of reform are influenced by my belief that making decent medical care available to all is a moral imperative, that current medical spending trends are unsustainable, and that the law should leave room for diverse understandings of health care’s value.

I note also that thinking about health care governance as an emergent system hardly predisposes the resulting analysis toward reform. To the contrary, the emergent systems model is descriptive—and open to use (or exploitation) by anyone who aims to advance or stymie reform. Indeed, as I will point out below, strategies that show awareness of emergent possibilities have, in the past, been employed most effectively by actors and interest groups intent on blocking health systems change. My aim in Part IV is to invite reformers to harness the power of emergent strategies on behalf of urgently needed change in health care provision and financing.

A. EXPANDING ACCESS TO CARE

Although a large majority of Americans support universal health insurance coverage,162 political and legal obstacles have repeatedly stymied efforts to achieve it.163 Contemporary barriers include ERISA preemption of state initiatives to expand coverage (many of these initiatives require employers to cover their workers or pay into public funds set up to subsidize insurance), ideological resistance to publicly supported coverage as incompatible with personal responsibility, and health care stakeholders’ concerns about disruptions in cash flows on which they have come to rely. Foremost among the likely disruptions is the shift from veiled cross-subsidies to visible means of financing care for the less well-off. Americans subsidize care for the medically indigent through a variety of mechanisms that few understand. These include extra payments from the


163. These failures date back to the administration of President Woodrow Wilson, whose nascent proposal for publicly sponsored coverage was undercut by wartime portrayals of public coverage as a German concept (German Chancellor Otto von Bismarck had pioneered the idea of universal publicly provided health insurance in the 1870s) incompatible with Americanism. See RONALD L. NUMBERS, ALMOST PERSUADED 75–78 (1978). Numbers observes: “As [World War I] progressed, Americans in increasing numbers began referring to compulsory health insurance as ‘un-American’ and predicting that it would lead to the ‘Prussianization of America.’” Id. at 77. In the 1930s, President Franklin Roosevelt’s administration developed a plan for public coverage (as a companion to Social Security), but Roosevelt backed off in the face of fierce resistance from the American Medical Association and others. Other presidents who unsuccessfully proposed universal coverage include Harry Truman, Richard Nixon, and, of course, Bill Clinton. See generally MAYES, supra note 60.
Medicare trust fund to hospitals with large numbers of uninsured patients, as well as private insurance premiums set high enough to contribute to the costs of indigent care.\textsuperscript{164} Publicly sponsored coverage for the less well-off would supplant these covert cross-subsidies with a high-profile tax,\textsuperscript{165} an inviting political target. The prospect of these cross-subsidies’ disappearance, moreover, alarms hospitals and clinics, who fear that public funding for broader coverage will not suffice to replace this “bird in hand.”\textsuperscript{166}

1. State Solutions?

States have seized the initiative on the health reform front, and creative, bipartisan ideas about how they might expand coverage have spread virally.\textsuperscript{167} From a conventional health reform perspective, the prospect of fifty different insurance schemes is anathema: a single, national system (whether market oriented or government administered) is essential to avoid Byzantine bureaucratic and legal complexity.\textsuperscript{168} But from an emergent systems vantage point—a perspective that focuses on evolutionary possibilities—the state-by-state route is worth encouraging. Ongoing ideological and interest group gridlock at the federal level has stymied reform at the national level. State-by-state progress could build momentum toward nationwide insistence on universal coverage, so long as high-visibility state initiatives are seen as successes worth propagating.\textsuperscript{169}

\textsuperscript{165} A tax with a distributive profile akin to that of the federal income tax would be more progressive than the current system of veiled cross-subsidies (from private insurance premiums and the Medicare trust fund) for uncompensated hospital care. Id. at 156–58. On the other hand, public coverage sufficient to provide access to comprehensive, mainstream care would cost more than the current, incomplete web of cross-subsidies for care in hospitals and community clinics.
\textsuperscript{166} Resistance to California governor Arnold Schwarzenegger’s failed health reform plan was illustrative. Schwarzenegger proposed in 2007 to pay for expanded medical coverage in part by pooling current cross-subsidy streams and rechanneling them from hospitals and clinics to support insurance premiums for the less well-off. GOVERNOR OF THE STATE OF CAL., GOVERNOR’S HEALTH CARE PROPOSAL 7 (2007), http://gov.ca.gov/pdf/press/Governor_HC_Proposal.pdf. Health care providers—the recipients of these cross-subsidies—have fretted about the prospect that they could lose these cross-subsidies and still face a substantial uncompensated care burden, absent the achievement of universal coverage.
\textsuperscript{168} Multistate employers, especially, dread the prospect of myriad state regimes, each with its own minimum coverage requirements and revenue-raising scheme.
\textsuperscript{169} There is no small risk here. The success or failure of Massachusetts’s pioneering plan for universal coverage will have a large impact on the future of state reform. The financial difficulties that endanger Maine’s Dirigo program, Pam Belluck, \textit{Maine Learns Expensive Lesson as Universal Health...
Similarities in design are likely to result from the propagation of successful state models along informal networks of influence;\textsuperscript{170} this would ease administrative burdens. But if large employers or health plans become concerned about the balkanization of legal and regulatory requirements, they could press Congress and the White House for federalization of the emerging universal coverage scheme. They might well succeed, demonstrating the power of feedback mechanisms to transform health policy and law in circuitous fashion\textsuperscript{171}—and locking in a national commitment to medical coverage for all.

Support for state initiatives thus constitutes a wise gamble from an emergent systems perspective. It carries no guarantee that the country will embrace any particular model for expanding coverage;\textsuperscript{172} states will decide, case by case, and more likely than not, one or a few prevailing models will emerge. Nor must it lead, in the end, to state governance of health insurance coverage. Congress and the White House could respond to state initiatives by imposing an overarching federal scheme. Were this to happen, state reforms would still have served a vital purpose as steps in the evolution of universal coverage.

This rationale favors legislative revision of ERISA to clear the way for state experimentation,\textsuperscript{173} and, in the meanwhile, this rationale supports judicial construction of ERISA to minimize preemption of state initiatives.\textsuperscript{174} There is ample doctrinal space for such a judicial reading.


\textsuperscript{170} Such networks include the National Governors Association, the National Conference of State Legislatures, the Council of State Governments, and numerous think tanks that function as forums for the sharing of state health reform experiences and ideas.

\textsuperscript{171} See supra text accompanying notes 153–55.

\textsuperscript{172} States are now weighing a variety of models, alone and in combination; these include expansions of Medicaid, employer obligations to provide coverage or contribute toward its cost, consumer-directed health care, premium support, and insurance market reforms. CTR. FOR BEST PRACTICES, NAT’L GOVERNORS ASS’N, LEADING THE WAY: STATE HEALTH REFORM INITIATIVES (2007), available at http://www.nga.org/Files/pdf/0707HEALTHREFORM.PDF.

\textsuperscript{173} Bipartisan support for revising ERISA will become increasingly likely as states enact coverage expansion initiatives and look to their congressional representatives for support. Former Massachusetts governor Michael Dukakis argues that California and other states considering such initiatives should ignore the ERISA preemption issue as they draft legislation, then ask Congress to either exempt them or to trim back the preemption for everyone. Personal Communication with Michael Dukakis, in L.A., Cal. (Feb. 2007).

\textsuperscript{174} The extent to which ERISA preempts state laws requiring employers to either provide coverage for their employees (up to some state-defined minimum level of benefits) or to contribute funds in some other fashion, toward coverage of the uninsured, will be the principal focus of such
The Supreme Court has said, in a case involving state regulation of hospital charges for the purpose of expanding coverage, that ERISA’s preemptive provisions are to be read narrowly when they infringe on traditional state power over health matters. To be sure, there is lower court precedent to the contrary, but the accretion of state reform initiatives would put pressure on judges not to stymie legislators’ wills when neither Supreme Court precedent nor the plain language of ERISA requires it.

2. Personal Responsibility

Objections to publicly supported coverage on the ground that it is incompatible with personal responsibility pose a larger challenge for efforts to expand health care access. Commentators, advocacy organizations, public officials, and others who favor government action to increase access have offered many countervailing arguments. This battle has been joined in American politics since Theodore Roosevelt urged national health insurance during his Bull-Moose run for the presidency in 1912. There have been incremental steps forward—Medicare and Medicaid in 1965, Medicaid expansion during the 1980s, and SCHIP in 1997. Yet portrayals of public coverage as a handout—a step toward socialism and away from self-reliance—have retained their resonance.

preemption litigation as state reform gathers steam. See supra note 20. State insurance market reforms, including new mechanisms for pooling risk among small employers, could also face preemption challenges under ERISA.


176. E.g., Retail Indus. Leaders Ass’n v. Fielder, 475 F.3d 180 (4th Cir. 2007).

177. The leading proponent of this view among legal scholars is Richard Epstein. See generally RICHARD A. EPSTEIN, MORTAL PERIL: OUR INALIENABLE RIGHT TO HEALTH CARE? (1997).


179. MAYES, supra note 60, at 1.

Universal coverage proponents have struggled to rebut this portrayal with more and better arguments. But the logic of emergence suggests another approach—one that takes advantage of the tension between people’s contradictory commitments to universal coverage and to self-reliance. Rather than ruling this contradiction, health policy progressives should harness its political energy by weaving individual responsibility and mutual obligation together into a new reciprocity of personal and public commitment to health. This new reciprocity might start with an “enhanced sense of individual obligation—to eat sensibly, exercise regularly, avoid smoking, and otherwise care for ourselves.”\(^{181}\) It could include an obligation to buy insurance. Our failure to do these things should carry consequences, such as premium surcharges and a measure of embarrassment over personal behavior that adds health risk without corresponding social benefit.\(^{182}\) The state, in exchange, should offer some protection when self-reliance falters. Americans who cannot afford coverage should be able to turn to their government for help in acquiring it. If the United States is to come close to universal coverage, personal responsibility will probably need to play a larger role than it did in the mid-twentieth century welfare state.\(^{183}\) But in return, we should be able to count on each other, through our government, to shield us from the degrading, life-endangering consequences of going without basic care because we cannot pay.

3. Taxes, Subsidies, and Settled Expectations

Health care stakeholders’ concerns about disruption of their revenue streams as a result of movement toward universal coverage need to be taken seriously. From a conventional policy wonk perspective, this disruption should not count. It is a mere transition problem. If one or


182. Such behaviors include substance abuse, reckless sex, and overeating. Here, conservatives have a point (in my view) when they chide some liberals for characterizing these behaviors as wholly the products of illness, compulsion, corporate marketing, or social injustice, rather than personal choice. Social norms that reward self-control and punish lapses have a role. See M. Gregg Bloche, *Obesity and the Struggle Within Ourselves*, 93 GEO. L.J. 1335, 1351–54 (2005). This is hardly to say that social conditions have no causal role in behaviors that put health at risk; to the contrary, poverty (and its tendency to keep people focused on their immediate needs), environmental disadvantages, the media’s messages, and other social circumstances are important factors. But a sense of individual responsibility can make a positive health difference, even when social unfairness renders the playing field uneven.

183. The health care reform ideas being taken seriously in state capitals and in the 2008 presidential campaign are notable for their emphasis on personal responsibility. Bloche, *supra* note 181, at 1174–75. Some (including the Massachusetts plan) include an individual mandate to buy insurance, and most make some reference to people’s responsibility to keep fit, stop smoking, and otherwise care for themselves.
another universal coverage scheme constitutes an improvement over today’s tangled web of cross-subsidies, it ought to be enacted—unless a competing scheme would improve things even more. But from an emergent systems perspective, transitions are crucial. They are not details to be worked out, bureaucratically and legally, after new policies are chosen; they are the terrain that must be negotiated to achieve policy ends. Obstacles thrown up by stakeholders, bureaucratic structures, and legal regimes must be anticipated. And public perceptions are crucial, as is illustrated by voters’ resistance to new taxes, even when these would supplant payroll deductions that cross-subsidize care for the poor.

Presidents Franklin Roosevelt and Lyndon Johnson understood this last point when they insisted on characterizing working Americans’ contributions toward Social Security and Medicare as insurance premiums, not taxes. Aspiring architects of expanded medical coverage today would do well to fashion schemes that separate collection of general tax revenues from public financing of care for people unable to meet their own needs. This is more than just rhetoric; both promising political pathways and insurmountable obstacles to reform emerge from the structure of people’s perceptions about the options they confront.184

Aspiring architects of reform should also avoid large, immediate disruption of current financial arrangements, even when the policy case for disruption is powerful. Sudden disruption of settled expectations invites fierce political and legal resistance from stakeholders—resistance that can put reform at risk.185 From an emergent systems perspective, getting reform right is more than a matter of preparing a blueprint for the best policy in the abstract; it requires charting a path through networks of political and legal influence. Policies that postpone the prospect of disruption—leaving open multiple, more gradual evolutionary possibilities—will tend to arouse less resistance.

There is, for example, a strong public policy case for ending tax exemption of nonprofit hospitals upon the advent of comprehensive, universal coverage.186 The prevailing rationale for property and income tax exemption of hospitals has long been their provision of care to people

184. See Drew Westen, The Political Brain 89–93 (2007) (drawing on neuroscience evidence to argue that people form policy positions by (unconsciously) organizing their perceptions of new circumstances into preconceived patterns, then reacting emotionally to these patterns).
unable to pay. Adoption of universal coverage would render this rationale obsolete. Elimination of these tax subsidies would make additional state and federal dollars available to support insurance for those unable to afford it. Redirecting public funds from subsidies for hospitals to coverage for the uninsured would both empower patients and better match public spending with clinical need. Yet the nonprofit hospital sector’s resistance to loss of its tax exemptions weighs heavily against trying to do so as part of a health reform plan. Exemption, even for hospitals that provide minimal “charity” care, has become a settled expectation, and enactment of universal coverage—at either the state or the federal level—without the nonprofit sector’s support is difficult to imagine. Thus the demise of this otherwise unjustifiable subsidy is not worth demanding.

The same is the case for other cross-subsidy schemes entangled within the disordered web of American health care financing. Extra Medicare payments to teaching hospitals for the training of residents, so-called disproportionate share subsidies from Medicare to hospitals that admit large numbers of poor patients, and myriad other flows of cash have their dug-in defenders. For some observers, such seepages of public funds constitute arguments against government action to expand coverage. But

187. This “quid pro quo” rationale is well-established in state property tax law, and until 1969 it was explicitly part of the IRS rationale for federal income tax exemption. Id. at 382–83. Other proposed justifications for tax exemption include Henry Hansmann’s argument that it compensates for nonprofit firms’ disadvantage in raising capital, owing to their inability to distribute profits to owners, and the nonprofit hospital sector’s claim that nonprofit status yields community benefits, beyond free care, deserving of public subsidy. Id. at 320–22.

188. Instead of being beneficiaries of hospital charity, the (formerly) uninsured would become consumers with purchasing power and choice of providers. Id. at 334.

189. Tax subsidies for hospitals support hospital-based care, rather than the full range of clinical services (including outpatient screening, chronic disease management, and preventive care) available to patients with adequate insurance. Tax subsidies are thus a poor substitute for insurance. Id. at 369.


191. Although tax exemption is, in my view, unjustifiable, see Bloche, supra note 186, from a policy analytic perspective, its persistence presents an opportunity. Rather than insisting on its elimination, one might (from an emergent systems perspective) seize on it opportunistically, as a fulcrum for policy leverage. This might be accomplished by taking nonprofit hospitals’ claims of community benefit, see Horowitz, supra note 190, very seriously, to the point of conditioning tax exemption upon hospitals’ achievement of benchmarks for health promotion, clinical quality, and as care for the needy. Transforming tax exemption into a type of pay-for-performance, in this fashion, is politically and legally more plausible than eliminating it altogether. M. Gregg Bloche, Tax Preferences for Nonprofits: From Per Se Exemption to Pay-for-Performance, 25 HEALTH AFF. W304 (2006), http://content.healthaffairs.org/cgi/content/abstract/25/4/W304.

192. See, e.g., Hyman, supra note 157, at 27–47.
for those who hold that failure to extend coverage to the nearly fifty million Americans without it is indecent, this leakiness is an acceptable cost. The emergent systems perspective counsels patience. Perhaps, once universal coverage becomes America’s baseline expectation, these embedded subsidies will be seen as giveaways, and courts and regulators will no longer countenance them. On the other hand, they could survive, like farm subsidies, despite popular scorn—protected by politically leveraged advocates.193

4. The Politics of Emergence: The Demise and Rebirth of Health Care Reform

Thus far, opponents of publicly sponsored universal coverage have displayed a deeper intuitive awareness of the power of emergence than have advocates of health insurance for all. A stunning example played out in 1993, as congressional Republicans scrambled to prepare for President Clinton’s anticipated health care reform juggernaut. The party’s Senate and House leaders eyed plausible compromises that might have achieved near-universal coverage with a reduced role for government.194 These compromises hewed to traditional Republican principles. They would have left open a wide playing field for competition between health plans,

193. This points to another role for health law and policy scholars—as participants in the process of emergence. Scholars of health care governance are uniquely positioned to detect embedded interest-group influence, to expose it, and to speak to public audiences about its pernicious policy and legal impact. They are especially well-situated to identify cases of government responsiveness to this influence and to call public officials to account when they service parochial interests. This has traditionally been the role of investigative journalists, but deeply probing reporting on public affairs is in decline. National news organizations are budgeting less for investigative reporting and in-depth analysis, and recent changes in the ownership and business objectives of leading newspapers (most visibly the sale of the Los Angeles Times and the Wall Street Journal by founding families deeply committed to these publications’ journalistic missions) could lead to further declines in penetrating reporting and analysis. The expertise necessary to track and interpret government action in such complicated realms as health makes it unlikely that the blogosphere will fill this gap. By incorporating this work into their professional role, and by seeking visible platforms for their findings and analyses, scholars of health law and policy can diminish the ability of embedded interests to shape health law and policy, unrestrained by the prospect of public revelation. A potent array of public platforms is available to scholars and researchers: these include op-ed pages, medical and health policy journals covered by national media (principally the New England Journal of Medicine, JAMA, and Health Affairs), symposia and briefings sponsored by high-profile think tanks, and blogs sponsored by some of these venues.

minimally restricted by federal regulators. But conservative strategist William Kristol looked beyond the policy logic of the possible deals and toward the longer-term implications of government-guaranteed coverage. For Republicans, he intuited, the implications were disastrous. Enactment of any publicly financed scheme to cover all would rekindle Roosevelt-era confidence in government as guarantor of personal security, undermining the broader Republican case for lower taxes and less government. Conversely, utter defeat for health care reform on President Clinton’s watch would deliver a lasting blow both to Americans’ belief in government’s ability to solve complex social problems and to confidence in the Democrats’ ability to deliver on their promises.

In a memo that quickly achieved iconic status among conservatives, Kristol urged Republicans to go all-out to kill health care reform. There should be no deals, no carefully nuanced compromises, Kristol argued. The Clinton plan should come to nothing, except disillusionment. Swayed by Kristol’s analysis, House and Senate Republican leaders abandoned compromise alternatives in favor of a scorched-earth stance toward health care reform. By the fall of 1994, the Clinton plan had succumbed. A few months later, disillusioned voters delivered both houses of Congress to the Republicans for the first time in forty years. Universal coverage disappeared from the national agenda for a decade, despite the ongoing increase in the numbers of the uninsured. More than that, Americans maintained their skepticism toward government’s ability to transform their

195. SKOCPOL, supra note 159, at 145–46 (quoting Memorandum from William Kristol, Chairman, Project for the Republican Future, to Republican Leaders (Dec. 2, 1993)). Calling the Clinton plan “a serious political threat to the Republican Party,” Kristol warned that passage of comprehensive reform would “revive the reputation . . . of Democrats as . . . the generous protector of middle-class interests” and “relegitimize middle-class dependence for ‘security’ on government spending and regulation.” Id. at 145.

196. Kristol wrote that rejection of the Clinton plan “by Congress and the public would be a monumental setback for the president, and an uncontestable piece of evidence that Democratic welfare-state liberalism remains firmly in retreat.” Id. at 146.

197. See id. at 145–46.

198. “The goal over the next several months,” Kristol urged, at the height of the battle over the Clinton plan, “should not be simply to wound the proposal, to nitpick the numbers or criticize some of the most onerous provisions, but to defeat the Clinton plan root and branch. . . . We want to use the health care debate as a model for routing contemporary liberalism and advancing an aggressive conservative activist agenda.” Adam Meyerson, Kristol Ball: William Kristol Looks at the Future of the GOP, POL’Y REV., Winter 1994, at 14, 15.

199. See SKOCPAL, supra note 159, at 146–47.

200. Neither Kristol nor congressional Republicans can claim full credit for defeating health reform. Potent opposition from health insurers and other interest groups had a large impact, as did the Clinton administration’s tactical missteps. See JOHNSON & BRODER, supra note 60, at 123–24, 137–207.
lives for the better through grand social policy schemes. Kristol had gotten it right. By focusing his party on the emergent consequences of the success or failure of health care reform, rather than on the policy pluses and minuses of particular compromises, he positioned Republicans to achieve their larger, longer-term objectives.

Proponents of robust government action to achieve universal coverage have been slower to seize on the promise of emergence. The architects of the Clinton plan intended for it to take effect as a finished product. To be sure, they envisioned a phase-in period, and they deferred to competition among health insurers to fill in the plan’s fine details. But they fashioned a detailed, top-down regulatory scheme to define the parameters of this competition, and they envisioned little change in the plan’s basic structure once it went into effect. Advocates of Canadian-style single-payer coverage likewise urge top-down imposition of their approach, with little regard for the enormous disruption it would entail. This disruption is the driving force behind opposition to the single-payer model. A sudden switch to single-payer would push the American health economy toward chaos by shattering current financial arrangements and dislocating millions of workers. Political resistance by those potentially affected makes this approach a nonstarter.

201. Kristol did not explicitly invoke emergent systems thinking, but he thought emergently. He strategized to create conditions more likely to give rise to feelings and beliefs conducive to longer-term Republican political and policy success.

202. The Clinton plan’s regulatory mechanisms addressed myriad matters in top-down fashion, including specification of minimum benefits to be provided by competing health plans, establishment of cross-subsidies among insurers to compensate for risk selection and adverse selection, and requirements that employers assume financial and administrative responsibility for employee coverage.


204. Adoption of single-payer coverage would put an end to cash flows in the hundreds of billions of dollars per year from private health care payers to hospitals, doctors, drug and device makers, and others. Cash flows from the public payer (or payers, if a system of regional payers were adopted) would commence in lieu of private payments, but there would surely be substantial changes in coverage policies and amounts paid, with profound financial implications for health care providers. Moreover, many of the millions of Americans who administer our decentralized system of private coverage and payment could find themselves out of work. There would be ripple effects as well, on labor markets (as millions, or at least hundreds of thousands, found themselves out of work), businesses that look to insurance companies for investment capital, and economic sectors that depend, in turn, on these businesses’ buying power and on the purchasing power of insurance company employees.

205. I take no position here on the policy question of whether a single-payer model would be better as an end state, in the abstract, than other universal coverage schemes. For a powerful argument that the single-payer model is superior, see THEODORE R. MARMOR, UNDERSTANDING HEALTH CARE
There is, nevertheless, cause for optimism about health care reform. A new generation of proposals harnesses the power of emergence in ways that enhance the likelihood of extending coverage to all, or at least to many. During the 2008 presidential campaign, leading candidates from both parties urged legal changes that would free states to pursue promising initiatives—initiatives now jeopardized by ERISA preemption and by limits on states’ ability to make creative use of their Medicaid and SCHIP funds to expand coverage. Some supporters of universal coverage dismiss state initiatives as mere incrementalism—a diversion from the quest for universal coverage. This criticism ignores the emergent possibilities of state-by-state action—it’s potential to propagate “me-too” optimism (and feasible compromises), as well as the prospect that state-by-state success (and ensuing worries about regulatory balkanization) could prompt Congress to enact nationwide reform.

Likewise, proposals advanced by both Republicans and Democrats during and after the 2008 campaign would leave private, employment-based coverage intact while opening up evolutionary pathways toward large-scale change. President Bush and the principal Republican contenders to succeed him urged an end to tax preferences for employer-provided health plans. Americans, they argued, should be able to spend pretax dollars on coverage and care, up to a limit, whether or not they acquire or tap workplace-based insurance. By leaving employment-based

REFORM 215–33 (1994). My limited point is that top-down imposition of a single-payer model by legislative enactment would be so disruptive as to preclude its happening.

206. See supra notes 173–74 (discussing possible ERISA preemption of state laws requiring employers to contribute toward their workers’ health benefits or toward funds established to subsidize coverage for the uninsured).

207. Mitt Romney, Rudolph Giuliani, and Barack Obama were among the candidates who made greater deference to state initiatives part of their campaign messages on health care. However, they did not specify the legal changes they would pursue in order to accomplish this. See Robin Toner, 2008 Candidates Vow to Overhaul U.S. Health Care, N.Y. TIMES, July 6, 2007, at A1.

208. See supra Part IV.A.1.


210. Under current law, employees’ and employers’ contributions toward workplace-based medical coverage are not treated as taxable income. I.R.C. § 105 (2006). Likewise, employee contributions toward health savings accounts are nontaxable (up to an annual limit). Id. § 223. Employers can also make nontaxable contributions to workers’ health savings accounts (up to an annual limit) when employers offer and workers choose high-deductible insurance plans. Id. By contrast, Americans who do not subscribe to employment-based health plans must spend post-tax dollars on care and coverage (up to very high annual limits, above which medical expenses become deductible). Id. § 213.

211. See Katherine Baicker, William H. Dow & Jonathan Wolfson, Lowering the Barriers to Consumer-Directed Health Care: Responding to Concerns, 26 HEALTH AFF. 1328 (2007) (article by former Bush administration Council of Economic Advisors member and staffers, making the case for
coverage in place, this approach averts sudden, large-scale disruption of settled arrangements and expectations. But by removing a powerful disincentive to the purchase of care and coverage outside the employment relationship, this strategy opens the way to the emergence of new ways of pooling risk—and to new health plan designs. Over time, as innovative pooling mechanisms appear, workers with employment-based coverage could migrate to them. Meanwhile, Americans without workplace-based insurance options could pay for care and coverage on their own, using pretax dollars. This level playing field could reduce the ranks of the uninsured, especially if combined with public subsidies for the least well-off.212 On the other hand, this new generation of Republican proposals calls for greater out-of-pocket (albeit tax-subsidized) spending on care213 and a reduced role for insurance, relative to traditional health plans (including HMOs and preferred provider organizations). Over time, this approach would probably lead to steeper tiering of levels of care, based on wealth.214

Democratic proposals hold out a different range of emergent possibilities. The leading Democratic presidential candidates prioritized near-universal coverage (their Republican rivals did not), but sought to minimize disruption of established arrangements and settled expectations.215 To this end, the Democrats’ proposals would leave

treating employment-based and independently purchased health plans in tax-neutral fashion).

212. Id.

213. President Bush has called for tax-deductibility of contributions to health savings accounts (his principal proposed vehicle for out-of-pocket medical spending)—a regressive tax subsidy since those most in need pay the lowest marginal tax rates. Other proponents of this approach (so-called consumer-directed health care, accompanied by high-deductible insurance) urge that the least well-off be given tax credits toward their contributions to health savings accounts—a more progressive approach. Id.

214. M. Gregg Bloche, Consumer-Directed Health Care and the Disadvantaged, 26 HEALTH AFF. 1315, 1316–22 (2007). By “levels of care,” I refer to levels of personal attention, convenience, and technological intensity—aspects of health care that are attractive to many patients but that do not necessarily correlate with clinical outcomes.

employment-based coverage in place. They pursue universal coverage by expanding Medicaid and SCHIP to reach lower-income Americans not now eligible for these programs and by subsidizing middle-income Americans’ purchase of private insurance. They avoid extending Medicaid and SCHIP to people at income levels that are within the marketing sights of private insurers (doing so would arouse strong insurance industry opposition216), and the subsidies they promise for the purchase of private coverage are a multibillion dollar benefit for insurers.217 The only likely near-term losers are employers who do not now provide coverage: they would have to choose between offering insurance or paying a tax (or “fee”) to support the public subsidies.218 Thus, these plans would pursue universal coverage by leveraging some existing arrangements and minimizing disruption to others.

On the other hand, they open pathways toward more fundamental, long-term change. By establishing insurance exchanges to pool risk (and thereby reduce premiums) for individual insurance purchasers and small employer groups,219 they create an economically viable alternative to workplace-based coverage. Over time, this alternative purchasing mechanism could eclipse the workplace as America’s main source for private insurance. The ability of insurance exchanges to attract large numbers of purchasers220 and to offer many coverage choices will give

216. The battle over state and federal efforts to expand SCHIP to cover children from families with higher incomes illustrates the likelihood of such opposition. New York, for example, attempted in 2007 to make SCHIP available to children in families with annual incomes as high as $80,000. After the Bush administration announced that it would construe the SCHIP statutory scheme to disallow this, the state indicated it would challenge the administration in court. Sarah Kershaw, Eight States to Press Bush on Insurance Coverage of Children, N.Y. TIMES, Oct. 2, 2007, at B1.

Meanwhile, in the last months of 2007, President Bush vetoed two Congressional efforts to expand SCHIP funding and eligibility to income levels unacceptable to the administration. Robert Pear & Carl Hulse, Congress Set for Veto Fight on Child Health Measure, N.Y. TIMES, Sept. 25, 2007, at A28. The 2008 election resolved this conflict: within a month of President Obama’s inauguration, Congress passed yet another SCHIP expansion bill, which the president promptly signed. John K. Iglehart, Expanding Coverage for Children—The Democrats’ Power and SCHIP Reauthorization, 360 NEW ENG. J. MED. 855 (2009).

217. Employers that provide insurance to low-wage workers will also benefit from these subsidies (and, possibly, from expansion of Medicaid and SCHIP).

218. They would be losers to a lesser degree than they would have been under the 1993 Clinton plan, since Democrats contemplate raising most of the revenues needed to support the public subsidies by allowing President Bush’s term-limited income tax cuts to expire at the end of 2010 for the wealthiest Americans. See Laura Meckler, $318 Billion Tax Hit Proposed, WALL ST. J., Feb. 26, 2009, at A1.

219. The large risk premiums that insurers charge for individuals and small groups mean that the prices they pay for a given level of coverage are much higher than the prices for larger groups (which incur more predictable aggregate medical costs).

220. Larger numbers of purchasers translate into lower premiums for health plans listed on an
them formidable advantages over employment-based plans. Vast purchasing pools could turn these exchanges into the “Amazon.com’s” of medical coverage, able to outperform all but the largest employers on price. Things could play out this way, but, then again, they may not. The plans leave the future of employment-based coverage open. Its persistence, or demise, would be determined by millions of Americans, acting as best they can to protect their families and themselves, with minimal attention to the policy impact of their choices.

A more provocative possibility is the emergence of single-payer coverage from these plans. The proposals call for creation of a public plan, to be listed on health insurance exchanges as an alternative to the private options. If the public plan fared better than its rivals in the competition for subscribers—whether because of lower administrative costs, better deals with doctors and hospitals, or other reasons—it could eventually come to overshadow them. This growth could feed back on itself in positive fashion by empowering the plan to obtain lower prices from providers, thereby crowding out private competitors. Absent congressional intervention to limit the public plan’s monopsony power over providers or to otherwise restrain its growth, it could evolve into single-payer coverage. This long-run outcome—ideal in the eyes of some and nightmarish to others—is hardly foreordained. American antipathy toward government bureaucrats and one-size-fits-all solutions could limit the public plan’s appeal. But the leading Democratic plans leave this possibility open, to be decided in emergent fashion by future health plan subscribers.

exchange, thanks to larger risk pools and higher numbers of “covered lives.”

221. Hillary Clinton’s proposal called for “a public plan option . . . modeled on the traditional Medicare program.” Press Release, Hillary For President, supra note 215. The Barack Obama and John Edwards proposals contained similar language.


223. See Gerard F. Anderson et al., It’s The Prices, Stupid: Why the United States Is So Different From Other Countries, HEALTH AFF., May–June 2003, at 89, 101–03 (reporting that prices for health services are lower in nations with monopsonistic public plans (or multiple plans that bargain collectively) than they are in the United States, where health care purchasing power is fragmented, and explaining these price differences as a function of international differences in payers’ ability to exercise monopsony power).

224. Private plans might remain in the market, offering high-end, boutique coverage options for wealthy subscribers.
B. CONTROLLING COSTS AND PURSUING VALUE

We know, in general terms, what needs to be done to control health care spending. In theory, we need simply say no to care that exceeds budget limits we set, whether for individuals, institutions, or society. But this of course begs many questions. Who should set these limits, and at what level of governance—from the individual patient to hospitals, health plans, or the nation as a whole? And how should resources be dispensed within these limits? We could, in theory, just say no once annual budgets are exceeded (or on a random basis) without regard for the comparative value of different kinds of care. Virtually all agree that this would be a preposterous approach: limit setting should be tied, somehow, to the expected value of diagnostic and therapeutic measures. But how do we figure these expected values, trade them off against each other (and against the expected value of nonmedical spending options), and decide what health plans should pay for within their economic constraints?

1. Obstacles to Progress

Despite countless, carefully thought-out efforts by scholars to resolve these questions, we have not progressed as a society toward answers. America has been loath to embrace total health care spending limits at the national or regional level, and consumers have proven hostile to tight constraints on health plan budgets. They have also been reluctant to

---

225. Were it possible to achieve consensus on how to figure the expected values of diagnostic and therapeutic measures—say, in quality-adjusted life years or some other metric that achieves commensurability—trading them off against each other (and against the expected values of alternative, nonmedical use of the resources at issue) would be a matter of simple arithmetic. But we are far from agreement on a commensurable measure—or on how to cope with the incommensurability of expected results from different clinical interventions for different illnesses. Bloche, supra note 11, at 275–77; Einer Elhauge, Allocating Health Care Morally, 82 CAL. L. REV. 1449, 1493–1524 (1994).

226. People able and willing to pay will have access to extant treatments regardless of the limit-setting treatments that health plans make, but “thumbs-down” judgments by health plans could reduce wealthy people’s demand for some treatments by stamping them as low-value.

227. Early versions of President Clinton’s health plan included global budgets—national and regional—to be implemented as a backup cost-control strategy if managed competition failed. In the face of strong resistance from health care interest groups (and charges from Republicans that the Clinton plan would ration care), the Clinton plan’s drafters transfigured their global budgets into a comprehensive scheme of caps on health plan rates—and, therefore, health plan spending. Continued characterizations of this aspect of the plan as health care rationing played a substantial role in the Clinton plan’s declining popularity and eventual defeat. See JOHNSTON & BRODER, supra note 60, at 85–86, 161–63; SKOCPOL, supra note 159, at 39–47.

228. Americans’ resistance to health plan budget limits played out in different forms during the several years after the Clinton plan’s collapse, as employers shifted vast numbers of workers into HMOs and other restrictive health plans. Beginning in the late 1990s, restrictions on choice of provider and access to costly treatments triggered intense popular backlash (expressed through political, legal,
appoint themselves as limit setters by signing up for lower-cost coverage that kicks in only after they and their families spend thousands of dollars on care out-of-pocket.\footnote{229} Moreover, we are nowhere near to agreement on an approach to working out the expected value of clinical interventions, then making the requisite trade-offs, within whatever budget limits are established.

a. Assessing the Benefits and Hazards of Medical Interventions

There are myriad obstacles to the making of these trade-offs—obstacles that pose large challenges for health law. We lack data concerning the effectiveness of most medical interventions,\footnote{230} and political resistance from doctors, hospitals, and drug and device makers has blocked large-scale, publicly funded research to fill this void.\footnote{231} Private insurers lack the requisite incentives to step into the breach. Research into the comparative efficacy of tests and treatments is a classic public good, supplied at socially suboptimal levels by private health plans because they cannot capture all of its social benefits. Savings from published research that results in the demise of low-value therapies redound to the benefit of

and market mechanisms, see supra text accompanying notes 145–48), forcing health plans to abandon these restrictions and allow costs to float upward. More worrisome is our country’s resistance to limits on Medicare spending, though Medicare’s long-term threat to American fiscal stability dwarfs that posed by Social Security, military spending, or any other federal program. Aaron, supra note 41. On the other hand, Americans have proven quite tolerant of budget limits on health plans for the poor and near-poor. Under the pressure of competing priorities and frugal taxpayers, states have capped their Medicaid benefits at levels unthinkable for Medicare and private health plans, to the consternation of advocates for the disadvantaged. See, e.g., Hurley, supra note 169 (interviewing an advocate of Tennessee’s Medicaid program).

\footnote{229} So-called consumer-directed health plans, which combine very high deductible insurance with cash contributions to health spending accounts (vehicles for pretax, out-of-pocket medical spending), enrolled only 5 percent of the 158 million Americans who received medical coverage through the workplace in 2007 (up one percentage point from 2006). Only 10 percent of employers offered such plans in 2007. \textit{Gary Claxton et al., Health Benefits in 2007: Premium Increases Fall to an Eight-Year Low, While Offer Rates and Enrollment Remain Stable, 26 Health Aff. 1407, 1411–13} (2007). The economist Rashi Fein has argued that people choose more comprehensive medical coverage (when they can afford it) in part because they dislike the experience of having to trade off money against health when they or their loved ones are ill; low deductibles that do not otherwise make economic sense (since they raise premiums substantially) are attractive to health plan subscribers as a safeguard against this unpleasant, sometimes anguishing experience. \textit{Rashi Fein, Medical Care, Medical Costs} 147 (1986).

\footnote{230} \textit{Bloche, supra note 11, at 266–70.}

all health plans, not just those that pay for the research. Likewise, benefits from treatments found to be of high value accrue across the medical marketplace, not just to the plans (and subscribers) that fund the studies. To be sure, pharmaceutical firms and medical device makers finance a great deal of research, but these studies are fashioned with regulatory hurdles in mind. They are aimed at identifying chemical candidates for intellectual property protection and Food and Drug Administration ("FDA") approval, neither of which require showings of comparative therapeutic value. Safety and efficacy, not cost effectiveness (by any measure) are all that the FDA regulatory scheme requires for approval.

Even if the federal government (or the private sector) were to commit to a large-scale program of comparative research into the outcomes of diagnostic and therapeutic interventions, serious obstacles to evidence-based, cost-sensitive practice (and payment policies) would remain. Selection of outcome measures for such studies is fraught with normative questions that lack agreed-on answers. A classic example is the comparison of coronary revascularization (angioplasty and coronary artery bypass surgery) and drug therapy for atherosclerotic heart disease. What roles should prolongation of life, reduction of pain, and improvement of physical endurance have in assessment of these therapies? Such measures sometimes correlate, but often, they diverge. Preferences will vary from patient to patient, and for some patients, they will fluctuate over time.

Variation of this sort opens the way for competing interest groups—say,

---

232. In theory, a health plan could conduct clinical effectiveness research on a proprietary basis, then use the research results to formulate coverage policies that yield competitive benefits through cost savings that accrue uniquely to the plan. In practice, this scenario is implausible, since coverage policies that deviate from industry practice would spark hostile reactions (including appeals to state-mandated independent reviewers and to the courts) from doctors and patients. To defend these policies, the plan would have to explain them, by going public with its research design and results—and thereby transforming its proprietary information into a public good.

233. The Pharmaceutical Research and Manufacturers of America ("PhRMA") reports that its members spent $44.5 billion on drug research and development in 2007, and that such spending for the pharmaceutical industry as a whole was $58.8 billion. PhRMA, About PhRMA: Who We Are, http://www.phrma.org/about_phrma/ (last visited Mar. 20, 2009). Skeptics contend that a great deal of this purported investment in research is in fact disguised advertising and other promotional spending. E.g., JERRY AVORN, POWERFUL MEDICINES 198–216 (2004).

234. The FDA has taken the position that its enabling statute does not permit it to consider a candidate drug's cost-effectiveness or comparative value. The relevant statutory language requires only that drugs be safe and effective; it thereby supports this position. JOHN R. THOMAS, PHARMACEUTICAL PATENT LAW (2005). The pharmaceutical industry opposes Congressional revision of the FDA's enabling statute to empower the agency to consider comparative efficacy, value, or cost.

235. Elhauge, supra note 225, at 1496.
heart surgeons, invasive cardiologists,236 medication-prescribing internists, and cost-conscious insurers—to reject research results (by criticizing the outcome measures chosen) when studies do not go their way.

The design of comparative clinical trials is bedeviled by another problem that constrains their real-world applicability. Participants in clinical trials typically represent a homogeneous subset of the population with the disease or symptoms being studied. This reduces the risk that confounding influences—such as age, genetic and lifestyle factors, and the coexistence of other illnesses—will interfere with comparison of the tests or treatments being studied. But this prerequisite for good science means that a study’s findings often apply to a small fraction of the patient population for which the tests or treatments are potentially relevant.237 That is, most real-world patients would not have qualified for inclusion in the study, rendering application of its findings a dubious proposition for them.238 The enormous cost of large-scale clinical trials, which can run to the tens of millions of dollars, makes this a large obstacle to construction of an evidence base for most of medical practice, even if outcome measures can be agreed on.

There is, moreover, a fractal geometry of medical decisionmaking that complicates the fashioning of clinical practice protocols even when their drafters have abundant data at their disposal. Any protocol applied to a group of patients is open to the criticism that it constitutes a one-size-fits-all approach to sick people who vary in relevant ways—genetically, behaviorally, or otherwise. The astonishing complexity of human biology virtually guarantees the plausibility of this criticism. The more we discover about our biology, the richer the diversity that we can envision. We have, for example, just begun to explore human genomic variation, its implications for the individualized expression of disease, and the resulting possibilities for personalized treatment.239 It will be increasingly possible to

236. Heart surgeons perform bypass surgery; angioplasty is typically performed by cardiologists (internists who have done fellowships in cardiology).
237. See Bloche, supra note 11, at 276 (discussing this problem as an instance of bounded rationality in health care policy).
238. For example, anticipated differences in the effectiveness of coronary angioplasty—depending on the anatomy of a patient’s coronary vasculature, the extent and distribution of atherosclerotic disease across this vasculature, differences in lipid chemistry (for example, levels of high and low density lipoproteins, known to be mediators of cardiovascular risk), behavioral and lifestyle factors, genetic markers, and age—might lead clinical investigators to narrow the inclusion criteria for an angioplasty trial on such grounds. But by so doing, the investigators narrow the real-world clinical relevance of their findings to the subset of cardiovascular disease patients who meet these inclusion criteria.
239. See, e.g., Thomas J. Lynch et al., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib, 350 NEW ENG. J.
object to practice or payment protocols by claiming that some patients to
whom a protocol applies will benefit greatly from a disallowed treatment,
or visa versa. In practice, the former claim will be more frequent. Doctors,
drug makers, and others who stand to gain from a disallowed treatment will
have strong incentives to stake this claim—and to seek evidence to support
it by reanalyzing data and performing new studies. Clinical protocols
that group patients for the purpose of guiding practice are a probabilistic
exercise. They reflect average, expected outcomes, when, in fact, outcomes
vary depending on characteristics that group members do not share.
Research that elucidates such characteristics, thereby opening the way to
more precise predictions for subgroups, will lead clinical protocols to
unravel.

b. Balancing Benefits and Costs: Preferences, Principles, and Political
Taboo

A further obstacle to use of clinical protocols, once cost concerns are
allowed to count, is our inability as a society to come close to agreement
on how to value the benefits of care, even when we have good enough data
to quantitate these benefits. Scholars and researchers have proposed
myriad formulations, aimed at making assessments of benefits commensurable for the purpose of weighing them against each other and

\[ \text{MED. 2129 (2004) (reporting on genetic variations that dramatically increase one particular type of}
\]
\[ \text{tumor’s responsiveness to a chemotherapy agent previously found to be only minimally effective for}
\]
\[ \text{patients with this tumor type).}
\]

240. Patients who vest hope in the disallowed therapy represent additional leverage for health care
providers and drug and device makers intent on challenging clinical protocols. The lobbying efforts of
the so-called Center for Patient Advocacy are a high profile example. The Center was founded by a
back surgeon opposed to a federal agency’s 1993 practice protocol that came out against spinal fusion
and discectomy surgery for low back pain. Brownlee, supra note 231, at 28. Not only did it advocate
successfully against broad adoption of this protocol by health care payers, but it also lobbied
successfully—in conjunction with other provider groups, as well as drug and medical device
manufacturers—for federal legislation that downsized the offending agency and forbade it from issuing
additional practice protocols. Id. On this and other issues, the Center has leveraged people’s trust in
their doctors, as well as their worries about insurers’ skimping on care. Links—accompanied by
favorable references to the Center as a resource for patients—from such websites as those of the Kaiser
Family Foundation and the Public Broadcasting System program Frontline today bring people to the
Center’s website without informing them about the Center’s origins and ongoing advocacy role for
ref_links/ reflinks_advocacy.cfm (last visited Mar. 20, 2009); Public Broadcasting Service, Frontline:
(last visited Mar. 20, 2009).

241. Explicit cost consciousness has not, thus far, been incorporated into protocols developed by
federal agencies, professional societies, or medical academics. Cost sensitivity has played a role in
proprietary payment protocols employed by health plans, but there have been no reports of plans
weighing costs against benefits in systematic fashion; rather, consideration of costs has been ad hoc.

against costs. These approaches range from lives or life-years saved to all manner of methods for calculating quality-adjusted life years. But none of these approaches have caught on, and none seem about to; it is thus implausible that any of these formulations could become a stable solution, in the foreseeable future, to the problem of valuing medical care’s benefits.

For this reason, some argue, individuals should decide for themselves by choosing from among explicitly stated clinical rationing policies when they subscribe to health plans. This solution is morally appealing but unlikely to work well in practice. As I have argued elsewhere, coexistence of multiple clinical allocation policies would impose too great an information-processing demand on doctors called on to implement them at the bedside. An engineer can adjust a levee’s design to withstand a ten-year flood, or a hundred- or thousand-year tempest, but a doctor cannot adhere simultaneously to multiple cost-benefit trade-off schemes for differently insured patients. Physicians, like soldiers, learn to react, as much as to reason, as clinical circumstances unfold. Medical training entails perception and recognition of patterns—patterns that prompt doctors to make clinical decisions in rapid sequence, typically without engaging in

243. For an excellent review of these formulations and their shortcomings, see Elhauge, supra note 225, at 1493–1526.
244. Havighurst envisions a medical marketplace made up of differently priced private health plans, offering multiple tiers of quality and different cost-benefit trade-off policies. Consumers would choose from among these plans based on both their ex ante preferences concerning cost-benefit trade-off policies and their willingness and ability to pay. HAVIGHURST, supra note 11, at 22–24. Elhauge, by contrast, envisions a marketplace of equally priced private health plans, offering benefits of equivalent actuarial value. Elhauge, supra note 225, at 1524–26, 1529–30, 1538–44. Public financing (constrained by a politically determined global health care budget) would cover the cost of enrollment. The plans would offer a variety of clinical resource allocation policies readily comprehensible to consumers, who could then choose from among competing plans based on their ex ante resource allocation preferences. Id. at 1524–26. Patients could purchase additional care out-of-pocket (if able to afford it), but there would be no Havighurst-style tiering of health plans by ability and willingness to pay. Id. at 1524–26.

As Elhauge points out, the ex ante perspective is essential here. Id. at 1507. Allowing patients to choose cost-benefit trade-off policies (at the insurance pool’s expense) ex post the onset of illness reintroduces the moral hazard problem that choice between allocation policies from behind the “veil of ignorance” (about future medical problems) is meant to avoid. Also, as Elhauge notes, the validity of ex ante consent to an allocation policy is contingent upon the judgment that the conditions under which consent was given are morally acceptable. Id. at 1536. The public subsidies that Elhauge envisions, which would ensure universal coverage sufficient to purchase health care at levels now affordable to the middle class, suffice (in my view) to render the conditions of ex ante consent morally acceptable under Elhauge’s scheme.
245. The principal moral concern that many share—that this approach legitimizes multiple tiers of coverage and care, tied to ability to pay (an objectionable development if one views health care as a “merit good”)—dissolves if the less well off are given public subsidies sufficient to enable them to afford the levels of coverage and care that middle-class Americans now receive. See Elhauge, supra note 225, at 1491 & n.124.
conscious, probabilistic reasoning. Human cognitive capacity is limited to a degree that precludes application of such reasoning to more than a small fraction of the decisions doctors make each day. It is beyond this cognitive capacity for a single physician to adopt multiple clinical practice styles, each tied to different resource allocation principles.

One might finesse this problem by placing each physician within only one health plan; then each physician could follow his or her plan’s allocative principles and policies without fretting about multiple resource allocation schemes and practice styles. This might work, in theory, in heavily populated areas with health care markets big enough to support multiple plans, each with their own in-house specialty services. Market forces, though, have not played out this way. Most medical specialists and

247. This is an instance of the more general truth, increasingly recognized by cognitive scientists, that people engage in conscious reasoning for only a small fraction of the many quick-fire judgments they make each day. See Gerd Gigerenzer, Peter M. Todd & ABC Research Group, Simple Heuristics That Make Us Smart 141–67 (1999) (employing medical and other examples to argue that people make most decisions by employing “fast and frugal” heuristics, not conscious, systematic reasoning).

248. See generally Bounded Rationality (G. Gigerenzer & R. Selten eds., 2002) (reviewing a variety of psychological adaptations to human cognitive limitations, including cultural norms, imitation, and emotional responses, as well as unconscious heuristics).

249. Physicians’ past responses to heterogeneous incentives from different payers reflect this limitation. When, in 1983, Medicare radically changed the way it paid for acute inpatient care—shifting from fee-for-service to lump-sum payment based on diagnosis—hospitals reduced their average lengths of stay for all populations of insured patients—private, fee-for-service as well as Medicare. Judith Feder, Jack Hadley & Stephen Zuckerman, How Did Medicare’s Prospective Payment System Affect Hospitals?, 317 NEW ENG. J. MED. 867, 870 & tbl.2 (1987).

This reduction was an expected response to the new Medicare reimbursement scheme, which rewarded frugality through the lump-sum method. But its spillover into the fee-for-service market was surprising, since this spillover reduced hospitals’ revenues from private, fee-for-service patients. It is difficult to explain this spillover except as an expression of physicians’ bounded rationality—their inability to change their approach to Medicare patients without also changing their approach to fee-for-service inpatients. More recently, studies of physicians who see patients covered under multiple private plans with differing incentives—for example, fee-for-service, capitation, and other schemes that reward doctors for doing less—have found that doctors do not vary their practice styles for patients in differing plans. See, e.g., Laurence C. Baker, Association of Managed Care Market Share and Health Expenditures for Fee-for-Service Medicare Patients, 281 JAMA 432, 434–36 (1999); Uwe E. Reinhardt, The Economist’s Model of Physician Behavior, 281 JAMA 462, 462–64 (1999).

250. The Kaiser-Permanente system (comprised of an HMO and a set of medical practice groups that treat only subscribers to the Kaiser HMO) is the most prominent example of a plan organized in this fashion. See Fast Facts About Kaiser Permanente, http://xnet.kp.org/newscenter/aboutkp/fastfacts.html (last visited Mar. 20, 2009).

251. Outside of such areas, there probably is not sufficient demand to support multiple lineups of specialty care providers, each dedicated to a single health plan. See, e.g., Rebecca T. Slifkin, Thomas C. Ricketts III & Hilda A. Howard, Potential Effects of Managed Competition in Rural Areas, HEALTH CARE FINANCING REV., Summer 1996, at 143 (discussing difficulties that confront efforts to engender competition between multiple health plans, with their own doctors and hospitals, in rural environments).
virtually all elite tertiary care centers have maintained their independence from health plans. They treat patients from many plans, and they possess the bargaining power to resist plans’ efforts to influence their practice styles. Restructuring specialty care as an in-house component of private health plans would require aggressive government intervention, at odds with the prevailing preference for market-driven organization of medical care.

In addition to these obstacles to assessing the benefits of care, efforts to limit medical spending must confront a larger challenge. Americans remain, for the most part, unwilling to acknowledge that long-term cost-containment will require the withholding of beneficial care. The “R-Word”—rationing—remains taboo in public discussion of policy responses to rising costs, except as an epithet employed by politicians to cast aspersions on health reform proposals they oppose. We are not absolutists in practice: unarticulated trade-offs between benefits and costs are embedded in clinical judgment. But our public morality permits no discussion of this, at least by elected officials, health plan marketers, and

252. One can interpret this in Coasean, theory-of-the-firm terms. See R.H. Coase, The Nature of the Firm, 4 ECONOMICA 386 (1937). The higher transaction costs associated with the independence of specialty physicians (and tertiary care hospitals) are counterbalanced by the benefits (for both health plans and providers of specialized services) of the flexibility that comes from annual contracting in a quickly changing marketplace, as compared with the rigidities and sunk costs of vertical integration. See James C. Robinson, The Future of Managed Care Organization, HEALTH AFF., Mar./Apr. 1999, at 7, 8–9, 12–14, 17–23.

253. For a blunt discussion of the need to ration beneficial care in order to hold medical spending to manageable levels, see AARON & SCHWARTZ, supra note 66, at 6–8.


255. The charge that President Clinton’s health reform plan (which envisioned competition among HMOs and other prepaid managed health plans) countenanced the rationing of care was one of the missives hurled by the plan’s Republican critics in 1993 and 1994. A few years later, when House Republicans proposed that Medicare beneficiaries be enrolled in HMOs, Democrats returned the favor, claiming that Republicans were planning to ration senior citizens’ care. See Robert Pear, Familiar Ring to the G.O.P Medicare Plan? It’s What Clinton Talked About, N.Y. TIMES, Sept. 26, 1995, at A20. Both accusations were accurate. A unanimous Supreme Court said as much in Pegram v. Herdrich, 530 U.S. 211, 221 (2000), when it noted that “inducement to ration care goes to the very point of any HMO scheme.”


257. The Hippocratic ethic of undivided loyalty to patients, operating in conjunction with insurance coverage for most medical expenditures, obliges treating physicians to take little or no account of costs, reinforcing the taboo against rationing. Some contend that the necessity of rationing justifies permitting doctors to depart from this ethic by withholding care with comparatively low expected benefits even though insurance contracts do not explicitly countenance this and patients expect their doctors to do all they can (so long as expected benefits outweigh expected harm). See, e.g., Hall, supra note 141, at 497. I have cautioned that this puts patient trust at too great a risk, with worrisome
others concerned about popular opinion. Health plans do not promote competing rationing formulae on their websites, television ads, or billboards on the sides of buses. And insurance contracts persist in promising all medically necessary care, without any reference to the weighing of benefits against costs for the purpose of determining what is necessary. Likewise, medical malpractice law continues to defer to extant professional standards of care, which are, for the most part, only minimally sensitive to cost. For now, at least, efforts to control medical spending will have to proceed within the confines of our country’s refusal to openly countenance the calculus of cost and benefit.

c. Putting Policy into Practice: Our Fragmented Health Care System

A final difficulty needs to be faced. Were it possible to surmount all of the obstacles just discussed, the fragmentation of our health care system would still present a formidable barrier to implementation of more evidence-based, cost-sensitive practice protocols. In the 1980s, many commentators on health policy predicted that consumers’ concerns about value would drive the consolidation of hospitals, doctors, and insurers into vertically integrated health plans with internal systems of cost and quality control. This vision has not panned out. Medical care remains a radically decentralized endeavor. Private physicians, for the most part, continue to practice alone or in small groups, organizationally separate from implications for medicine’s effectiveness and ability to contribute to people’s sense of security and solidarity. M. Gregg Bloche, Trust and Betrayal in the Medical Marketplace, 55 Stan. L. Rev. 919, 941 (2002).

258. As Elhauge points out, many academics, as well, take the absolutist view, refusing to countenance either health-health trade-offs or the weighing of clinical benefits against costs on the ground that we should shift public resources from other programs (for example, the military) to medicine and health. Elhauge, supra note 225, at 1460–61.

259. This reference to the balancing of benefits against costs is meant to include health-health trade-offs (that is, choices from among alternative uses of health care resources) within a limited budget, as well as decisions as to whether the expected benefits of a test or treatment justify spending additional dollars to cover it.

260. The Supreme Court’s conceptualization of independent review of coverage denials as akin to a second medical opinion, not a matter of contract interpretation, see Rush Prudential HMO, Inc. v. Moran, 536 U.S. 355, 381–83 (2002), is an additional bulwark against efforts to construe the medically necessary standard to permit cost-conscious coverage decisionmaking.

261. See supra note 34 and accompanying text.

262. See James C. Robinson, The Corporate Practice of Medicine 35–62 (1999) (discussing the reasons why a system of competing, vertically integrated health plans did not arise, and describing the decentralized, rapidly shifting contractual relationships among hospitals, doctors, and plans that developed in its stead).

263. There are exceptions—large multispecialty group practices have gained substantial market shares in California, New Jersey, North Carolina, and elsewhere, id. at 8, but medical practice remains a cottage industry in most locales.
hospitals and health plans. Hospitals have consolidated horizontally, to some degree, but they exercise minimal managerial control over medical practice, and they remain institutionally independent from health plans. Health plans bargain with doctors and hospitals for discounted rates, but they do not actually manage care. Physicians make clinical decisions on their own, influenced by personal values, peers and mentors, financial incentives, drug company marketing, and myriad other factors that contribute to wide variation in practice styles. Coordination of care often gets short shrift, since this fragmented system does not support team approaches to patients with multiple medical problems.

Alternative models of medical care exist. Leading hospitals and multispecialty group practices have adopted quality-improvement programs that promote evidence-based practice and collaborative decisionmaking. Medicine’s academic leaders have coalesced around an agenda for transformation that stresses the building of systems—systems that share information, reward cooperation, apply state-of-the-art clinical science, discover and learn from mistakes, and adjust to individual patients’ varying needs.


265. There are exceptions to this institutional independence: the Kaiser-Permanente HMO in California is the outstanding example—the Kaiser HMO owns its hospitals, which treat only Kaiser-Permanente subscribers. See Fast Facts About Kaiser Permanente, supra note 250.

266. “Managed care” has always been a misnomer. Even during the height of the managed care era, through the mid-1990s, health plans did not “manage” doctors, if by “manage,” one means rigorous oversight and direction of their performance with an eye toward standardizing their approaches to diagnosis and treatment. At most, health plans declined to cover some tests and treatments, refused to authorize some referrals, and profiled doctors’ clinical spending patterns with an eye toward selecting more frugal providers for their networks. Plans made minimal proactive efforts: they neither promulgated their own comprehensive, evidence-based clinical practice guidelines nor pressed their participating physicians to follow guidelines developed by academic or professional leaders.


270. See AVORN, supra note 233, at 292–312.

271. Failures of coordination can have both life-threatening and wasteful consequences: examples include prescribing medicines without regard for dangerous drug interactions, duplication of risky and costly tests, and incomplete diagnostic assessment of clinical signs and symptoms that “fall between the cracks” of multiple specialties.

needs. But neither market forces nor health law have nudged a critical mass of doctors and hospitals toward realization of this agenda.

Our system’s poor performance, measured by current understandings of best practice, reflects these failings. A much-publicized study of how American medicine fares nationwide on more than four hundred broadly accepted, evidence-based measures of appropriate care found that doctors make the “right” decisions only 50 to 60 percent of the time. There are stunning geographical variations in the care Americans receive and in the costs they incur—variations that lack scientific justification. Indeed, studies of state-by-state variation in Medicare costs have found correlations between higher-than-average per capita spending and lower-than-average performance on quality-of-care measures. These quality measures reflect standards of care supported by current financial incentives. They thus do not incorporate cost sensitivity to the degree necessary for long-term control of medical spending. But our health system’s weak performance on these measures bodes poorly for our future ability to put agreed-on standards of quality and value into effect.

2. Emergent Possibilities

These daunting obstacles to control of costs and pursuit of value in health care cannot be overcome by some grand stroke of legal design. No policy-wonk D-Day assault on the problem of medical spending can prevail over health care’s entrenched complexities, interest groups, and conflicts of value. Thinking about health care’s governance in emergent-systems terms supports a more modest approach. The emergent-systems model channels our attention toward opportunities to set change in motion—to navigate around some of the obstacles and to allow others to become less formidable needs.

273. See generally COMM. ON QUALITY OF HEALTH CARE IN AM., supra note 114 (setting out an agenda for health care reform and establishing six aims for improvement).


275. McGlynn et al., supra note 33, at 2642 tbl.3 (finding that patients receive 54.9 percent of recommended care).

276. See Wennberg et al., supra note 67.


278. Katherine Baicker & Amitabh Chandra, Medicare Spending, the Physician Workforce, and Beneficiaries’ Quality of Care, 23 HEALTH AFF. W4-184, W4-187 to -189, http://content.healthaffairs.org.libproxy.usc.edu/cgi/reprint/hlthaff.w4.184v1 (finding that states with higher Medicare spending have lower-quality care).
as time passes. It emphasizes opportunism over elegant, system-wide solutions that have minimal chance of being fully implemented.

a. Toward Evidence-Based Practice and Value-Based Protocols

What might a reform strategy sensitive to potential evolutionary pathways look like in the cost control realm? I shall point to some possibilities. For starters, such a strategy should aim to finesse (1) interest group resistance to comparative evaluation of therapies and (2) Americans’ aversion to the balancing of health benefits against economic costs. An encouraging sign is the recent surge in bipartisan support for a ramped-up program of comparative clinical outcomes research. Large federal deficits and ominous warnings about the consequences of failure to contain Medicare and other entitlement spending are pushing Congress toward action despite antipathy from those who profit from tests and treatments that might not pan out. Congress took a first step in February 2009 by appropriating $1.1 billion for comparative effectiveness research. Still needed is a mechanism to insulate this research from the bare-fisted politics of the annual appropriations process—and from the distorting influence of health care providers, pharmaceutical firms, and medical-device makers. Possible approaches include allocation of a fixed fraction of annual Medicare spending (to shield outcomes research funding from the politics


280. Aaron, supra note 41.


282. Such attacks crippled earlier federal efforts to conduct medical outcomes research and develop evidence-based clinical practice protocols. See Brownlee, supra note 231; Gray et al., supra note 231, at W3-295 to -298.
of the annual appropriations process and creation of an autonomous, Federal Reserve-style agency to perform this research (or to award research grants on a competitive basis, as does the National Institutes of Health). Research partnerships between the federal government and private insurers have also been urged to broaden both political and financial support for outcomes research.

Ideally, this agency or program should do more than just research: it should employ available data to assess and compare the value of clinical interventions, so as to guide doctors, hospitals, and health care payers. But doctors, drug makers, and others dependent on revenues from tests and treatments that could fare poorly in such evaluations have the legislative clout to defeat proposals that would empower government to perform them. From a traditional policy-design perspective, creation of an

---

283. Committing a fixed proportion of Medicare spending—say 1 or 2 percentage points—to outcomes research would give it status as an entitlement program, immunizing it from efforts by affected interest groups to cut it during the course of the annual budgetary appropriations process.

284. Possible mechanisms for maintaining such an agency’s independence include keeping it entirely separate from the Department of Health and Human Services (and thus from the direct influence of the president and his or her appointees), governance by a bipartisan commission appointed to staggered terms, and delegation of the task of appointing commission members to a nonpolitical entity (perhaps the Institute of Medicine of the National Academies of Sciences). The Federal Reserve model has been endorsed most prominently by former Senate Majority Leader Tom Daschle—President Obama’s first nominee for Secretary of Health & Human Services—who has urged that decisionmaking about health care policy more generally (including the comparative value of tests and treatments) be vested in an appointed “Federal Health Board.” Tom Daschle with Scott S. Greenberger & Jeanne M. Lambrew, Critical: What We Can Do About the Health-Care Crisis 139–80 (2008).

285. Wilensky, supra note 279, at w580–82.

286. Such partnerships could help to protect an outcomes research program from political attack by positioning insurers as a counterweight to interests that profit from treatments of uncertain value.

287. A possible model for such a program is Great Britain’s National Institute for Health and Clinical Excellence, which performs and publishes assessments of tests and treatments, then issues recommended guidelines for clinical care. See generally Welcome to the National Institute for Health and Clinical Excellence, http://www.nice.org.uk (last visited Mar. 20, 2009).

288. It would also be helpful for this agency or program to develop alternative analytic frameworks, or models, for: (1) the balancing of benefits against costs and (2) the weighing of health benefits against each other (more relevant for health plans and providers that must make do within fixed budgets). Private and public insurers (and providers) could then try out these models as tools for making allocative decisions in candid, accountable fashion. See Beyond Learned Helplessness, supra note 41. Insurers and providers might or might not experiment along these lines, and such experiments might or might not catch on. Whether or not medical resource allocation evolves to embrace such models would be decided in emergent fashion. But development and dissemination of these models would widen this potential evolutionary pathway.

289. Physicians, pharmaceutical firms, and medical device manufacturers have done so in the past. See Brownlee, supra note 231; Gray et al., supra note 231, at W3-295 to -297. Those involved in Congressional efforts to ramp up federal support for clinical outcomes research tend toward the view that including statutory language empowering government to perform comparative evaluations of
agency that sponsors clinical outcomes research but does not assess the results—or offer guidance to providers and payers—is problematic. Why do this research without using it to improve health care quality and value? However, from an emergent systems perspective, even this limited mandate holds great promise. Such a program would generate a flood of outcomes data, enabling others to compare therapies and develop evidence-based practice protocols. To be sure, these protocols would be quicker in coming were a federal agency to sponsor them on a large scale. But a series of high-profile studies that found oft-used therapies to be harmful or ineffective could inspire doctors and patients to demand more vigorous efforts to compare treatments and to develop evidence-based guidelines. Rising medical spending, moreover, will put growing pressure on guideline authors to take costs into account. From an expanding base of data on therapeutic outcomes, evidence-based, cost-conscious protocols for payment and practice could emerge despite strong resistance from affected stakeholders.

medical interventions and to develop clinical practice protocols would doom legislation to increase funding for outcomes research. Interview with Anonymous Congressional Staff Involved in Developing Outcomes Research Legislation (Dec. 2006). And indeed the $1.1 billion appropriated for comparative effectiveness research in February 2009, see supra note 281, was conditioned on the requirement that the interagency council responsible for coordinating this research not “mandate coverage, reimbursement, or other policies for any public or private payer” or issue “mandates or clinical guidelines for payment, coverage, or treatment.” American Recovery and Reinvestment Act of 2009 §804(g), Pub. L. No. 111-5, 123 Stat. 115, 188. The potential for backlash from stakeholders concerned about adverse assessments of the value of tests and treatments was underscored by angry denunciations of the interagency council—and the $1.1 billion appropriation—as a ploy to ration health care. See, e.g., Kevin Freking, Obama Team Sees Stimulus Advancing Health Reform, SEATTLE TIMES, Feb. 14, 2009, http://seattletimes.nwsource.com/html/politics/2008744217_apstimulushealthobama.html?syndication=rss.

290. By “traditional policy design perspective,” I refer here to approaches that envision a desired end state and call for reforms meant to bring about this state, rather than to create conditions for the future evolution of policy solutions. See supra text accompanying notes 202–03.

291. Among the actors that might make use of a surge in outcomes data to compare treatments and craft protocols are medical academics, health plans, and insurers. The risk of bias in the development of protocols is omnipresent (as it would be were these same actors to participate in the formulation of government-sponsored protocols). The important subject of the management of conflicts of interest (for example, medical academics’ relationships with drug companies, as well as their income from providing questionable treatments) is beyond my scope here.

292. Within the last few years, clinical outcomes studies have made headlines by finding that commonly prescribed treatments increase risks to life. Examples include estrogen replacement therapy for menopausal women, see Garnet L. Anderson et al., Effects of Estrogen Plus Progesterin on Gynecologic Cancers and Associated Diagnostic Procedures: The Women’s Health Initiative Randomized Trial, 290 JAMA 1739, 1745–47 (2003), and Vioxx and other new-generation nonsteroidal anti-inflammatory medications, see Claire Bombardier et al., Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis, 343 NEW ENG. J. MED. 1520, 1520 (2000).
Winning widespread compliance with such protocols will require an approach to our health care system’s fragmentation.\textsuperscript{293} Here also, there are emergent possibilities. Medicare is in a position to lead by adopting evidence-based performance standards and rewarding doctors and hospitals that comply. Congress recently authorized Medicare to make extra payments to hospitals that meet Medicare’s performance standards\textsuperscript{294} and to initiate small-scale trials of pay-for-performance incentives for physicians.\textsuperscript{295} Medicare’s nearly 40 percent share of acute care hospital spending\textsuperscript{296} and substantial contribution to physicians’ incomes\textsuperscript{297} give it enormous influence: past changes in Medicare’s financial incentives to providers have produced large changes in the providers’ treatment of both privately insured and Medicare patients.\textsuperscript{298} Thus far, Medicare has declined to explicitly count costs when issuing coverage rules\textsuperscript{299} or adopting performance standards. Its enabling statute arguably allows it to do so.\textsuperscript{300}

\textsuperscript{293}. \textit{See supra} text accompanying notes 262–71.


\textsuperscript{298}. \textit{See supra} note 249.

\textsuperscript{299}. The most recent guidance document on coverage policy from CMS, the agency that administers Medicare, states: “Cost effectiveness is not a factor CMS considers in making NCDs. In other words, the cost of a particular technology is not relevant in the determination of whether the technology improves health outcomes or should be covered for the Medicare population through an NCD.” CTRS. FOR MEDICARE & MEDICAID SERVS., DEP’T OF HEALTH & HUMAN SERVS., GUIDANCE FOR THE PUBLIC, INDUSTRY, AND CMS STAFF: FACTORS CMS CONSIDERS IN OPENING A NATIONAL COVERAGE DETERMINATION (2006), \textit{available at} www.cms.hhs.gov/med/ncp_view_document.asp?id=6. For an excellent review of the controversy over the potential role of cost in Medicare coverage decisionmaking, see generally Jacqueline Fox, \textit{Medicare Should, but Cannot, Consider Cost: Legal Impediments to a Sound Policy}, 53 BUFF. L. REV. 577 (2005).

\textsuperscript{300}. Section 1862(a)(1)(A) of the Social Security Act states: “Notwithstanding any other
but the usual alliance of doctors, hospitals, and drug and device companies has been firmly opposed. Still, there is reason for optimism. For the first time, Medicare is linking payment to compliance with clinical standards, thereby creating an incentive scheme that might someday be used to encourage cost awareness across our fragmented system. Private payers are following suit, joining with each other—and with hospitals and medical groups—to seek common ground on quality measures and practice protocols.  

So far, they have been no more willing than Medicare to openly count costs, but they are forging collaborative arrangements that could someday be employed to give effect to cost-conscious provision of [law], no payment may be made . . . for items or services . . . not reasonable and necessary for the diagnosis or treatment of illness or injury.” 42 U.S.C. § 1395y(a)(1)(A) (2000). The term “reasonable” has been construed by some commentators to permit consideration of cost; others have read this provision more restrictively. E.g., Fox, supra note 299, at 584–95. Because Medicare has never explicitly balanced costs against benefits when promulgating national coverage rules, its authority to do so has not been litigated.

301. America’s Health Insurance Plans, the principal trade association representing private health plans, is combining clinical data from multiple plans—and from Medicare—to make it possible to assess the performance of hospitals and physicians nationwide on agreed-on measures of health care quality. This aggregation of data will surmount a major obstacle to measurement of provider performance: the fact that providers report clinical data (for billing purposes) to multiple health plans, none of which, therefore, can assemble a complete picture of how well providers fare on quality measures. A consortium of health care industry stakeholders (including insurers, hospitals, group medical practices, and professional and trade associations) known as the National Quality Forum will formulate quality measures, including standards of care for common medical problems, that will then be applied to the aggregated data to assess health care providers’ performance. The results of these assessments will be widely disseminated with three related purposes in mind: encouraging doctors and hospitals to do better, enabling health plans to reward providers based on performance, and allowing consumers to select providers based on quality. Press Release, Robert Wood Johnson Found., National Effort to Measure and Report on Quality and Cost-Effectiveness of Health Care Unveiled (Oct. 3, 2007), available at http://www.rwjf.org/newsroom/product.jsp?id=22371.

302. Private health plans are beginning to collaborate with doctors and hospitals to develop standardized methods for tracking and comparing different providers’ costs for tests and treatments. Id. The avowed aim of this collaboration among stakeholders is to support patients’ (and payers’) efforts to shop for the least expensive (that is, most cost-effective) way to achieve a given therapeutic result. Id. But the collaborators in this endeavor, so far, have refrained from explicitly balancing benefits against costs when formulating quality-of-care benchmarks.

303. Interlocking consortia of private health plans, hospitals, medical specialty societies, and other health care industry stakeholders have formed over the past several years for the avowed purpose of reaching industry-wide agreement on the adoption and uses of quality-of-care benchmarks. These include the AQA alliance (focusing on physician care), the Hospital Quality Alliance (“HQA”) (focusing on hospital care), and the Quality Alliance Steering Committee (meant to coordinate the efforts of the AQA alliance and HQA). See Press Release, AQA, Health Care Quality Leaders Join Forces (July 21, 2006), available at http://www.aqaalliance.org/HCQLeadersJoinForces072106.htm. See also generally AQA-HQA Collaboration—Quality Alliance Steering Committee, http://www.aqaalliance.org/qaahqacollaboration.htm (last visited Mar. 20, 2009). The Department of Health and Human Services has participated in these consortia and indicated its intention to coordinate Medicare and private sector quality improvement efforts.
protocols.  

b. The Emergent Potential of Current Law

Awareness of these potential evolutionary pathways can and should play a role in development of several areas of law that bear on cost and quality: these include antitrust and privacy doctrine, medical malpractice, and the law governing disputes over insurance coverage. Comprehensive discussion of the cost and quality implications of each of these areas of law is beyond my scope here, but I will offer a brief roadmap of potential problems and opportunities from an emergent systems perspective.

i. Antitrust- and Privacy-Law Barriers to Information Sharing?

Antitrust-law barriers to clinical data sharing among doctors, hospitals, and health plans for outcomes-research purposes should be minimized, if indeed there are any. Privacy-law protections should be construed with an eye toward the social importance of this research. The

304. Health care reform proposals urged by President Bush and by Republican and Democratic candidates for the presidency in 2008 presented additional emergent possibilities. The consumer-directed model, see supra notes 213–14, 229, advanced by the Bush administration and by Republican presidential candidates Rudolph Giuliani and Mitt Romney, would make insured patients more sensitive both to cost in general and to insurance contract provisions designed to encourage patients to seek care from providers who score high on performance measures. For example, a consumer-directed health plan might require a patient to pay much more out-of-pocket for diabetes or heart disease care from a doctor who scores below some threshold on relevant quality-of-care measures. If and when quality measures come to incorporate cost-benefit trade-offs, this tiering of insurance coverage, tied to provider performance, would strengthen doctors’ and patients’ incentives to accept these trade-offs.

Analogously, the insurance exchanges proposed by President Obama and by candidates Hillary Clinton and John Edwards, see text accompanying notes 215–18, would require health plans to report their performance on quality-of-care benchmarks in order to sell coverage on these exchanges. If and when cost-benefit trade-offs are built into these quality measures, this prerequisite for market access would become a powerful lever for adoption of cost-conscious treatment protocols.

305. Whether such barriers are real or merely perceived is unclear. Leaders in academic medicine’s efforts to improve health care quality believe that antitrust law stands in the way. Mongan et al., supra note 272, at 3–5. Collaborative setting of standards for purposes of collecting and sharing data has raised antitrust issues in other industries, but antitrust law has been open to arguments about the pro-competitive impact of network economics. Medical antitrust law scholars who have considered this question tend toward the view that current antitrust doctrine poses no obstacles to industry collaboration on outcomes research. See, e.g., David A. Hyman, Five Reasons Why Health Care Quality Research Hasn’t Affected Competition Law and Policy, 4 INT’L J. HEALTH CARE FIN. & ECON. 159 (2004) (part of a special issue devoted to competition and health care quality); William M. Sage, David A. Hyman & Warren Greenberg, Why Competition Law Matters to Health Care Quality, HEALTH AFF., Mar.–Apr. 2003, at 31, 36–40.

306. See Lawrence O. Gostin & James G. Hodge, Jr., Personal Privacy and Common Goods: A Framework for Balancing Under the National Health Information Privacy Rule, 86 MINN. L. REV. 1439, 1440 (2002) (arguing that “[s]haring data may be necessary to achieve important health purposes” such as health research and public health, and urging that “health information privacy laws . . . carefully balance the need for individual privacy with the benefits of using health data for the common good”).
question of antitrust obstacles to collaboration for the purpose of agreeing on quality measures and clinical practice protocols is more complex. There is an obvious tension between antitrust principles, which promote competition on quality as well as price, and collaborative setting of quality benchmarks. Yet current antitrust doctrine leaves room for the argument that collaborative standard setting can facilitate competition on quality by making it easier for consumers to comparison shop.307 A comprehensive set of quality benchmarks, accompanied by comparative performance data, would empower patients to choose wisely from among competing doctors, hospitals, and health plans. This in turn would put market pressure on plans and providers to deliver greater value to consumers—the end result sought by antitrust law. There is a snarl of doctrinal and economic issues here, in need of disentangling by antitrust scholars familiar with health care.308 But antitrust law can play a constructive role in the development of national standards of quality and value.309 Antitrust law should aim to distinguish (that is, without information that could be used to trace the data back to individual patients) prior to its aggregation, should provide high levels of privacy protection. But elimination of all risks to privacy is not a realistic goal, particularly in view of the proliferation of high-powered data-mining methods and the possibilities for illicit use of these and other techniques. Sharona Hoffman & Andy Podgurski, In Sickness, Health, and Cyberspace: Protecting the Security of Electronic Private Health Information, 48 B.C. L. Rev. 331, 366 (2007).


308. Among the entangled issues are how to keep collaborative standard setting from slowing the pace of therapeutic innovation, how to prevent anticompetitive abuse of standard-setting mechanisms (to exclude competing treatments and providers without scientific grounds for so doing), and the extent to which antitrust enforcement agencies and the courts should delve into the details of medical science and economics in order to make such judgments. Alternative legal approaches include looking to procedural fairness as a surrogate for inquiry into whether standard setting is anticompetitive as a substantive matter and, in the extreme, outright rejection of industry-wide clinical practice protocols and other quality standards as anticompetitive.

309. Some market-oriented commentators hold a sharply different view. They question such standard setting, arguing that industry-wide adoption of medical practice protocols and other quality norms is contrary to the letter and spirit of antitrust law because it prevents competing providers and health plans from marketing multiple tiers of quality. See Clark C. Havighurst, Applying Antitrust Law to Collaboration in the Production of Information: The Case of Medical Technology Assessment, LAW & CONTEMP. PROBS., Spring 1988, at 341, 352–55 (arguing that agreements among professional bodies to develop consistent positions on the value of tests and treatments deny consumers the welfare-enhancing benefits of competition). Consumer choice is enhanced, in this view, by allowing multiple levels of care, HAVIGHURST, supra note 11, at 7, and in the digital age, there is no lack of market-generated information available to consumers to help them to comparison shop for care. See James C. Robinson, The End of Asymmetric Information, 26 J. HEALTH POL’LY & L. 1045, 1051 (2001). A rejoinder to this view, grounded in an analysis of antitrust doctrine, is beyond my brief here. But it would likely incorporate the near impossibility of comparison shopping (in the face of a cacophony of claims about quality) without broadly accepted benchmarks, as well as the near impossibility of...
between collaborative standard setting that spurs competition to deliver clinical value and collusive efforts that exclude rivals and suppress evidence-based therapeutic innovation. By so doing, antitrust law can promote the evolution of cost-sensitive clinical practice norms and their dissemination through our fragmented health care system.

ii. Tort Liability

Medical tort law’s approach to health care quality and value is a relic of past, disproven premises about the practice of medicine. It is thus an obstacle to the emergence of more evidence-based, cost-sensitive clinical care. The malpractice system’s greatest failing, from a quality and value perspective, is its reliance on clinical practitioners to specify standards of care. This deference to doctors is a departure from negligence law’s general requirement of reasonable conduct, a requirement typically understood in utilitarian terms as a duty to take precautions so long as maintaining multiple tiers of medical care when the same providers participate in many different health plans. See supra text accompanying notes 246–52. More controversially, it might suggest that enabling providers and plans to offer multiple economic tiers of care should count for less, from an antitrust perspective, than does preservation of most other forms of consumer choice, since medical care is widely seen as a merit good—that is, something society distributes (or ought to distribute) based on criteria other than ability or willingness to pay. See Richard A. Musgrave, *Merit Goods, in 3 THE NEW PALGRAVE: A DICTIONARY OF ECONOMICS* 452 (John Eatwell et al. eds., 1987) (setting out a definition of “merit good” and including health care as an example). Possible grounds for treating health care as a merit good, to be distributed (like education and fire protection) more equitably than most products and services, include: (1) the moral belief that all people should have access to high-quality care as a matter of right or human dignity and (2) the paternalistic concern that people will undervalue some forms of medical coverage and care—for example, preventive services and long-term management of silent but eventually devastating illnesses like diabetes and hypertension.

310. See supra note 308.

311. The medical tort system’s many failings have been widely discussed elsewhere. These failings include its lack of sensitivity and specificity as a tool for detecting negligence (studies that compared results from medical chart reviews of hospitalizations with the subsequent incidence of malpractice suits, settlements, and judgments arising from these hospitalizations have found little overlap between episodes of negligence discerned by chart reviewers and lawsuits brought, settled, or won), its limited deterrent impact on substandard practitioners, and its failure to compensate the vast majority of victims of negligence. Michelle M. Mello & David M. Studdert, *The Medical Malpractice System: Structure and Performance*, in *MEDICAL MALPRACTICE AND THE U.S. HEALTH CARE SYSTEM* 11 (William M. Sage & Rogan Kersh eds., 2006). Moreover, malpractice liability costs, combined with insurance market dysfunctions, have at times pushed liability insurance premiums high enough to measurably reduce patients’ access to physicians in high-risk specialties like obstetrics and neurosurgery. *Office of the Ass’t Secretary for Planning & Evaluation, U.S. Dep’t of Health & Human Servs., Addressing the New Health Care Crisis: Reforming the Medical Litigation System to Improve the Quality of Health Care* 3–6 (2003), available at http://aspe.hhs.gov/daltcp/reports/melilab.pdf. But see U.S. Gen. Accounting Office, *Medical Malpractice: Implications of Rising Premiums on Access to Health Care* 5–7 (2003), available at http://www.gao.gov/new.items/d03836.pdf (finding insufficient evidence to support claims that high malpractice insurance premiums are causing physicians in some specialties to withdraw from practice and thus reducing patients’ access to care).
benefits outweigh risks and costs.\textsuperscript{312} Negligence law, to be sure, often looks to common practice within an industry as the measure of reasonableness. But the justification for doing so is that the market works well as a cost-benefit\textsuperscript{313} balancing device—well enough to treat industry custom as the standard of care.\textsuperscript{314}

For medical care, this justification has broken down, if indeed it were ever valid.\textsuperscript{315} It is now widely recognized that physicians know little about the efficacy of most tests and treatments,\textsuperscript{316} that they often do not follow evidence-based clinical protocols even when such guidance exists,\textsuperscript{317} and that insurance encourages provision of care with few benefits relative to cost.\textsuperscript{318} Medical custom is thus a poor guide to socially optimal standards of care.

Malpractice law’s reliance on custom locks in extant clinical practice norms that are products of these market failures. This does not benefit practitioners, since absent evidence-based answers to most clinical questions, different doctors treat the same medical problems in different ways.\textsuperscript{319} The result is Russian roulette in the courtroom when things go

\textsuperscript{312} See, e.g., RESTATMENT (SECOND) OF TORTS § 283 (1965) (defining negligence law’s standard of conduct as “that of a reasonable man under like circumstances”); \textit{id.} §§ 291–93 (defining reasonableness in terms of the balance between the risk and the utility of an actor’s conduct). \textit{But see} Heidi Li Feldman, \textit{Prudence, Benevolence, and Negligence: Virtue Ethics and Tort Law}, 74 CHI.-KENT L. REV. 1431 (2000) (arguing that negligence law in fact recognizes nonutilitarian concerns such as prudence and care); Heidi M. Hurd, \textit{The Deontology of Negligence}, 76 B.U. L. REV. 249 (1996) (arguing that negligence law can be consistent with non-risk-based deontological theories).

\textsuperscript{313} I use “cost” here as shorthand for both risk and cost.

\textsuperscript{314} See James A. Henderson, Jr. & John A. Siliciano, \textit{Universal Health Care and the Continued Reliance on Custom in Determining Medical Malpractice}, 79 CORNELL L. REV. 1382, 1388–89 (1994) (arguing that courts should look to industry custom to determine negligence when networks of contractual bargaining suffice to take all affected interests into account).

\textsuperscript{315} It probably never was. Through the mid-twentieth century, most commentators on health care law and policy believed that doctors’ scientific knowledge and patient-centered ethics ensured that (barring negligence) they would exercise medical judgment to which society, including the legal system, should defer. Kenneth Arrow captured this set of assumptions in his oft-cited 1963 article contending that physicians promise patient-centeredness to the public in order to win trust—and business—in the face of patients’ inability to evaluate the effectiveness of medical care. Arrow assumed—with undue optimism, it turned out—that physicians \textit{did} know how well their tests and treatments worked, and that they largely delivered on their promise to abjure economic incentives to act contrary to the interests of their patients. Arrow, \textit{supra} note 85, at 965–66.

\textsuperscript{316} See \textit{supra} text accompanying notes 230–40.

\textsuperscript{317} See \textit{supra} text accompanying notes 33–35.

\textsuperscript{318} Commentators have borrowed the term “moral hazard” from the casualty insurance context to convey the impact of insurance on medical spending. I have elsewhere questioned the analogy between increased risk taking by people with fire or auto insurance and increased health spending by people with medical insurance, Bloche, \textit{supra} note 11, at 260–66, but it is plain that medical insurance promotes overspending on health services, relative to people’s other wants and needs.

\textsuperscript{319} CTR. FOR THE EVALUATIVE CLINICAL SCI., \textit{supra} note 115, at 2–5.
wrong and patients sue. If there are multiple therapeutic options and the one chosen turns out badly, the plaintiff can find a physician-expert witness who would have opted for one of the other options. Malpractice law lets such testimony in, so long as the witness qualifies based on his or her credentials. The law puts testimony about the appropriate standard of care to the test of professional acceptance, but it does not subject such testimony to Daubert-style scrutiny of its scientific foundations. And in many jurisdictions, malpractice law bars the admission of evidence-based practice protocols (by treating them as hearsay) unless an expert witness testifies as to their content. When evidence-based protocols find their way into court, they are usually given no more weight than other medical testimony, however flimsy the science base on which this testimony

320. If a treatment yields a bad result because it was administered ineptly—say, the proverbial sponge left in the surgical patient or an overdose of a dangerous drug—negligence is open-and-shut, not a matter of Russian roulette (unless the alleged ineptitude requires a borderline call). Such cases matter because it is important to deter ineptitude and to adequately compensate its victims, but they are not my focus in the above discussion because their health care policy import is comparatively small. These cases involve errors of execution, not larger conflicts over how health care resources should be spent.

321. Expert testimony is required in all jurisdictions unless “only common knowledge and experience” are required to judge the conduct. See H.H. Henry, Annotation, Necessity of Expert Evidence to Support an Action for Malpractice Against a Physician or Surgeon, 81 A.L.R. 2d 597, 608 (1962).

322. Legal tests for professional acceptance vary by jurisdiction: formulations in wide use include the requirement that a standard of care be upheld by a “consensus of opinion” among physicians, that it be adhered to by the “ordinary practitioner,” that it be followed by at least a “respectable minority” of physicians, and that it be what a “reasonable and prudent” doctor would undertake under similar circumstances. See Jackson v. Burnham, 39 P. 577, 580 (Colo. 1895) (“[W]hen a particular mode of treatment is upheld by a consensus of opinion among the members of the profession, it should be followed by the ordinary practitioner; and if a physician sees fit to experiment with some other mode, he should do so at his peril.”); Boyanton v. Reif, 798 P.2d 603, 604–05 (Okla. 1990) (“The question in professional malpractice suits is not whether a physician has made a mistake, but whether he has used ‘ordinary care’—that which is ordinarily exercised by his peers.”); Jones v. Chidester, 610 A.2d 964, 969 (Pa. 1992) (stating that the correct standard for avoiding malpractice liability is that the physician “followed a course of treatment advocated by a considerable number of recognized and respected professionals in his given area of expertise”); Harris v. Robert C. Groth, M.D., Inc., P.S., 663 P.2d 113, 116 (Wash. 1983) (“[T]he plaintiff in an action for professional negligence must show that the defendant health care provider ‘failed to exercise that degree of care, skill, and learning expected of a reasonably prudent health care provider in the profession or class to which he belongs.’”); 61 AM. JUR. 2D Physicians, Surgeons, Etc. § 189 (2002); Theresa K. Porter, Cause of Action Against Physician or Surgeon for Breach of the Duty of Attention and Care, in 21 CAUSES OF ACTION 1, 9–11 (1990).

323. See supra note 146.


Thus, doctors who follow these protocols are as vulnerable to the liability roulette wheel as are those who adhere to practice norms that lack a scientific basis. The opposing side need only produce an expert prepared to claim that an alternative therapy is widely employed and would have yielded a better outcome. Then jurors get to choose one side (unless the judge does so for them\textsuperscript{326}) based on professional acceptance, not scientific rigor. The unfortunate consequence for health policy is that early adopters of an evidence-based protocol face enhanced liability risk if the protocol departs from common practice. Prevailing malpractice doctrine is thus at odds with its supposed justification—the utility of medical custom as a measure of reasonable care.

From an emergent systems perspective, there is thus a strong case for privileging evidence-based practice protocols over professional custom. Opportunism knocks: health care providers have taken an interest in practice protocols as a way to ward off lawsuits,\textsuperscript{327} making providers potential supporters of greater legal deference to such protocols. This strategy may or may not shield doctors and hospitals from suits,\textsuperscript{328} but provider support for it could leverage reformers’ efforts to incorporate science-backed protocols into legal standards of care.

In the near term, doing so is unlikely to restrain rising costs, except insofar as compliance with such protocols averts adverse clinical outcomes that are expensive to treat. Today’s practice protocols rarely take cost into account, at least explicitly. But if and when practice protocols evolve toward greater cost sensitivity, their integration into legal standards of care would ease the way toward wide acceptance of clinical cost-benefit trade-offs—in medical malpractice law and in society more generally. There is no guarantee of such acceptance; there could just as well be popular backlash against the courts for countenancing rationing. But incorporating cost-sensitive, science-based protocols into malpractice doctrine will be necessary to keep this body of law from emerging as a formidable obstacle.

\footnotesize
\textsuperscript{326} A trial judge can do so, of course, by determining that one or the other side’s expert has stated the correct standard of care as a matter of law (that is, no reasonable juror could conclude otherwise).


\textsuperscript{328} Although considerable research has addressed the impact of damage caps, shortened statutes of limitations, and other much-debated reforms on the incidence of malpractice suits and the size and frequency of settlements and awards, no study has decisively addressed the influence of clinical practice protocols on these variables.
to the balancing of health care’s therapeutic benefits and economic burdens.

Detailed consideration of how evidence-based, cost-sensitive protocols might be incorporated into malpractice law is beyond my scope here. Three principles, though, should guide efforts to nudge malpractice doctrine in this direction—if malpractice law is to abet progress toward cost-benefit trade-offs that Americans can tolerate. First, protocols should be science based. By this, I do not mean that they should be put to the steep tests required by the research community to treat hypotheses as established. The fractal complexity of clinical outcomes research precludes gathering enough data to rest most medical decisions firmly on publishable science. A more realistic requirement is that protocols rest on clinical premises accepted by researchers as more probable than not, based on the best available data.

Second, the cost-benefit (and health-health) trade-offs embedded in a protocol should be both explicit and broadly accepted by society. Covert rationing is not sustainable. It is inexorably exposed by America’s entrepreneurs of revelation—plaintiffs’ lawyers, journalists, congressional investigators, and others who reap rewards by minding the gaps between what those in authority say and do. To win widespread, sustained acceptance for cost-benefit trade-offs, authors and adopters of practice protocols will need to state their premises about the value of life and various states of disability.

329. For a review of the possibilities, see Mello, supra note 327.
330. Strictly speaking, scientists can never say that their hypotheses are proven by experiments; they can only judge that a hypothesis has not been disproven. KARL POPPER, THE LOGIC OF SCIENTIFIC DISCOVERY 10 (Routledge 2d ed. 2002) (1935). In practice, though, researchers treat a hypothesis as established when a sufficient number and variety of experiments (sufficiency here is a normative judgment) yield data consistent with that hypothesis.
331. See supra text accompanying notes 237–40.
332. Use of a more-probable-than-not standard here reflects the reality that a clinician must decide, one way or the other. Since a decision must be made, any guidance with more than a 50 percent prospect of being “right” is useful. Judicial assessment of whether the factual premises undergirding a protocol are more probable than not will call for inquiry into both the reasoning behind them and the extent to which they are accepted by the research community. This is a demanding endeavor, but no more so than is the assessment required when courts engage in evidentiary gatekeeping under Daubert.
333. Bloche, supra note 257, at 946–47. Popular backlash in the late 1990s against covert rationing by aggressively managed health plans is illustrative. Id. at 925.
334. Government agencies have, on occasion, been forthright about these premises without unleashing popular backlash. The Federal Aviation Administration’s (“FAA”) basing of its aviation safety rulemaking on dollar values for lives lost and degrees of injury inflicted is illustrative. See GRA INC., ECONOMIC VALUES FOR FAA INVESTMENT AND REGULATORY DECISIONS: A GUIDE § 2-2 (2004),
Doing so will not guarantee public acceptance. Americans will first have to come to terms with the need to say no to some of medicine’s benefits—a need most of us are not willing to acknowledge. But if and when growing cost pressures bring about broad acknowledgment of the need to set limits, protocol development processes that engage a wide range of participants will stand the best chance of yielding trade-offs that endure. Industry-wide collaboration along these lines—involving doctors, hospitals, and health plans—is already underway. So far, this collaboration has focused on the setting of quality-of-care standards without regard for cost. But, like brain circuits that take on new behavioral tasks as evolution progresses, the organizations that oversee this collaboration could become venues for the weighing of benefits and costs.

Still to develop are mechanisms for incorporating the values and preferences of health care consumers. For reasons I set forth earlier, the favored mechanism of most market-oriented health law commentators—consumer choice from among health plans with multiple cost-benefit trade-off tiers—faces formidable cognitive obstacles and moral objections. These cognitive and moral factors favor maintenance of a single cost-benefit trade-off tier for liability purposes. This trade-off policy is likely to be a fuzzy compromise between two starkly different consumer perspectives: that of health plan purchasers who economize from behind a “veil of ignorance” concerning their future medical needs, and that of sick people who want all the beneficial care they can get. Arguably,

335. See supra text accompanying notes 253–61.
336. See supra notes 301–03.
337. See supra note 302.
338. See supra text accompanying notes 303–04.
339. Many such mechanisms have been proposed, including public opinion surveys, focus groups, presentation of hypothetical decisionmaking scenarios to research subjects, and elegant formulae that take account of data derived from these sources. So far, none of these approaches has gained institutional purchase, a reality that reflects our national unwillingness to acknowledge cost-benefit and health-health trade-offs in medical care.
340. See supra note 308.
341. This veil, in truth, is translucent, not opaque. Chronic disease, genetic and behavioral risk factors, and other health information known to consumers when they purchase medical coverage reduce their inclinations to economize on some kinds of care—the care they anticipate needing.
342. From an Olympian social welfare perspective, such a fuzzy compromise is unsatisfactory: the perspective of the consumer who economizes from behind the medical veil of ignorance is preferable. But as a practical matter, the perspective of the sick person in need will always have countervailing power: our hard-wired empathy (and the politics of social solidarity) will have a great deal of influence.
industry-wide collaboration that balances the perspectives of providers and health plans can serve as a crude stand-in for formalized consumer input. Since health plans profit by paying for less, while doctors and hospitals have incentives to do more, their competing interests approximate the divergent perspectives of consumers before and after the onset of illness.

Third, malpractice law should not incorporate practice protocols inflexibly as irrebuttable presumptions. Medicine’s irreducible variability—the fractal complexity of clinical situations—ensures that even protocols with solid research behind them will merit exceptions. Clinical outcomes research is necessarily population based, making it inevitable that some patients will be outliers. Malpractice law can accommodate this by treating protocols as rebuttable presumptions to be overridden upon an evidence-based showing that a different approach made sense in a particular case.343

Tort law can make another contribution to health care quality and value by incorporating state-of-the-art, systems approaches to the management of medical services. This will require moving beyond blame for individuals and toward shared duties to disseminate and adopt evidence-based protocols, coordinate diagnosis and treatment in complex cases, employ information systems that avert mistakes, and report and learn from errors.344 For example, a doctor’s failure to prescribe beta blockers or aspirin to a heart attack patient upon discharge from the hospital should be treated not just as negligence on her part, but as breach of duty by the hospital—if the hospital has not made these medications part of its post-heart-attack protocol and adopted monitoring practices to minimize the risk of their omission. And a nurse’s misunderstanding of a doctor’s hard-to-read handwritten order, resulting in a fatal overdose, should be understood not merely as the nurse’s (or the doctor’s) negligence, but as the hospital’s breach of its duty to employ reasonably safe information systems.

Rechanneling medical liability along these lines would help to

---

343. By “evidence-based” here, I do not mean scientific proof that measures up to Daubert standards of admissibility (an unrealistically high prerequisite, since comparative-effectiveness research cannot anticipate and keep pace with every potential exception to established protocols). A more pragmatic approach would be to require evidence sufficient to show that a prudent physician would, more probably than not, have departed from the protocol under the circumstances. Sharpening this test is a task beyond the scope of this Article. Doing so will be complicated by the tension between aspirations to make medical care more science based and more responsive to individual differences.

344. See supra text accompanying notes 114, 273–74.
promote the emergence of a better-coordinated, more efficient health care system. Some have urged enterprise liability as a means of improving health care quality. Were our medical system more vertically integrated, the case for this approach would be powerful. But our fragmented system presents high barriers to the transmission of enterprise liability’s deterrence signals from defendants (health plans or hospitals) to individual caregivers. And since malpractice settlements and judgments constitute less than 1 percent of U.S. health care spending, enterprise liability’s incentives would not suffice to bring about the vertical integration of American health care. More realistic—and more doctrinally modest, and thus more suitable for judges to do—would be to extend traditional joint

345. There are numerous open questions within the interstices of this proposition. These include whether health plans (which typically contract with many hospitals and physicians but do not exercise managerial control over them) should share in such liability, whether hospitals should ever share responsibility for their staff physicians’ negligent treatment of outpatients (courts have thus far said no), and how liability should be distributed among clinical caregivers and institutions (especially hospitals) with system-wide responsibility. Developing rich responses to these questions is beyond the scope of this Article.


348. In theory (from a Coasean perspective), the degree of fragmentation should make no difference: industry actors should bargain toward allocations of liability to the lowest-cost risk avoiders, regardless of starting point (or default) liability rules. In practice, this classic story breaks down in the health care industry for many reasons. These include the transaction costs involved in such bargaining (among vast numbers of actors), the difficulty of pinpointing lowest-cost risk avoiders when risk is the product of collective efforts by independent industry actors (for example, multiple specialists in separate practices who treat the same patient), and cultural factors (for example, doctors’ reluctance to forgo professional autonomy by acceding to hospitals’ or health plans’ supervisory authority in exchange for avoidance of the threat of liability).

Thus the choice of default liability rules matters greatly in health care. And in our fragmented system, hospitals and health plans generally lack the supervisory authority or bargaining leverage necessary to respond to enterprise liability’s incentives by obliging physicians to adopt state-of-the-art systems approaches to medical care. See supra text accompanying notes 264–73.

349. Gerard F. Anderson et al., Health Spending in the United States and the Rest of the Industrialized World, 24 Health Aff. 903, 910 (2005) (“The cost of defending U.S. malpractice claims, including awards, legal costs, and underwriting costs, was an estimated $6.5 billion in 2001—0.46 percent of total health spending.”).

350. Moreover, as a practical matter, doctors, hospitals, and health plans strongly oppose enterprise liability. Doctors equate giving up the “right to be sued,” as one put it, with surrendering their authority and autonomy to insurance or hospital bureaucrats, while hospitals and health plans fear that jurors will see them as “deep pocket[s].” Randall R. Bovbjerg & Robert Berenson, Enterprise Liability in the Twenty-First Century, in Medical Malpractice and the U.S. Health Care System, supra note 311, at 219, 230–31.
and several liability to encompass a duty to adopt proven systems approaches to improvement of quality and avoidance of error.\textsuperscript{351} The provider’s personal fault would remain part of the picture, but the failure of health care organizations to adopt information systems, management strategies, and other quality improvement methods that might have averted error\textsuperscript{352} would subject them to liability. This would complicate litigation and settlement to some degree, but mounting evidence of the risk avoidance achievable through state-of-the-art systems approaches\textsuperscript{353} weighs in favor of accepting this cost.\textsuperscript{354}

iii. Health Insurance Contracts and “Medical Necessity”

The law governing disputes over medical coverage is more consequence than cause of American society’s reluctance to accept limits on beneficial care.\textsuperscript{355} Nearly all health insurance contracts employ the term medical necessity as their standard for coverage, and Americans continue to see this term as a promise to pay for care whenever its expected benefits outweigh the clinical risks.\textsuperscript{356} Courts no longer defer blindly to treating-

\textsuperscript{351} The legal foundations for such a duty are already in place. Since the mid-1960s, courts have held that hospitals have duties to take reasonable care in reviewing the credentials of staff physicians (including those who are independent contractors rather than employees) and monitoring doctors’ and nurses’ ongoing performance. Lee J. Dunn, Jr., Hospital Corporate Liability: The Trend Continues, MEDICOLEGAL NEWS, Oct. 1980, at 16, 16. Updating this duty to encompass adoption of systems approaches to quality improvement would be a small doctrinal step.

\textsuperscript{352} Organizations subject to this duty would include health plans, hospitals, group medical practices, and all others in position to reduce the risk of error by adopting systems approaches.

\textsuperscript{353} See \textit{Comm. on Quality of Health Care in Am.}, Inst. of Med., supra note 4, at 61–62.

\textsuperscript{354} Any such extension of institutional liability should be accompanied by empirical study of both its costs and its impact on the incidence of error.

\textsuperscript{355} Some advocates of minimally regulated medical markets assert otherwise, contending that courts’ lack of deference to insurers’ coverage denials is a large obstacle to health care cost containment. See, e.g., Havighurst, \textit{supra} note 11, at 115. They are right about judges’ lack of deference, but in my view, judges’ attitudes toward nay-saying by health plans reflect our society’s unwillingness to tolerate the withholding of beneficial care. See \textit{supra} note 308.

\textsuperscript{356} To be sure, health insurance contracts also contain a wide array of specific exclusions and limitations; for example, no coverage for cosmetic surgical procedures and limited numbers of psychotherapy sessions per year. Legal disputes over these exclusions and limitations are much less common than are disputes over “medical necessity.” One type of exclusion, though, does occasion considerable conflict—noncoverage for “investigational” or “experimental” treatments. See, e.g., Elsroth v. Consol. Edison Co., 10 F. Supp. 2d 427, 440 (S.D.N.Y. 1998) (denying the insured’s motion for a preliminary injunction requiring the defendant-insurer to precertify high-dose chemotherapy treatment because it was deemed experimental); Watts v. Mass. Mut. Life Ins. Co., 892 F. Supp. 737, 746 (W.D.N.C. 1995) (denying the insured’s motion for a temporary restraining order and/or preliminary injunction preventing the insurer from declining to cover autologous bone-marrow transplant with high-dose chemotherapy (“ABMT-HDC”) because the treatment was experimental); Kekis v. Blue Cross & Blue Shield of Utica-Watertown, Inc. 815 F. Supp. 571, 578 (N.D.N.Y. 1993) (granting the insured a preliminary injunction and ordering the insurer to provide coverage of ABMT-HDC); Rollo v. Blue Cross/Blue Shield, Civ. A. No. 90-597, 1990 WL 312647 (D.N.J. Mar. 22, 1990)
doctors’ determinations of medical need, but the law still looks to professional norms to give content to this formless term. In forty states, independent medical review schemes rely on physician panels to rule on medical necessity, based on professional practice. Extant clinical practice is likewise the touchstone when courts confront medical necessity disputes, whether as breach-of-contract or tort claims. As the 1990s backlash against managed care underscores, Americans are not ready to recognize medical necessity as warrant for withholding care, so long as expected benefits outweigh clinical risks. But the law governing coverage disputes could support the emergence of cost-sensitive, evidence-based clinical protocols by permitting insurers to adopt them in lieu of traditional medical-necessity clauses. A cautious approach is in order: courts should not accede to contractual departures from long-standing consumer expectations absent clear explanation of the terms of coverage. Contract language allowing health plans to weigh therapeutic benefits against costs should explain trade-off principles in plain language.

357. See supra note 89 and accompanying text.
358. See supra 99–101, 121 and accompanying text.
359. These disputes present as breach-of-contract cases when patients (or providers) sue insurers to obtain payment after care has been provided or to secure preauthorization of payment in order to proceed with treatment. They present as tort cases when refusal to preauthorize care has led to denial of care, resulting (allegedly) in injury. ERISA preempts these state law claims when employers provide coverage. But patients with employment-based coverage can obtain payment for care under ERISA after prevailing in state-level independent medical review proceedings. Rush Prudential HMO, Inc. v. Moran, 536 U.S. 355, 359 (2002).
360. This deference to long-standing expectations reflects: (1) appreciation of the fact that people buy medical coverage (and other kinds of insurance) in large part for the sense of security that it offers and (2) acknowledgment that most insurance subscribers have no role in the drafting or negotiation of the specific provisions of insurance policies. This accords with insurance law’s special regard for “the reasonable expectations of the insured.” See generally Kenneth S. Abraham, Judge-Made Law and Judge-Made Insurance: Honoring the Reasonable Expectations of the Insured, 67 VA. L. REV. 1151 (1981) (discussing the justifications for the “expectations principle”).
361. Clarity about health plan terms that depart from consumer expectations requires more than the use of language readily accessible to the average person: plan marketing procedures should ensure that such terms are communicated to potential subscribers in vivid, high-visibility fashion. Coverage exclusions, in particular, should be conveyed in concrete language, perhaps accompanied by examples of tests and treatments covered or excluded under common circumstances. Bloche, supra note 11, at 316.
362. Id. The FAA’s explicit valuation of life—and of several levels of injury and disability—in dollar terms, GRA INC., supra note 334, offers one model for such clarity. As with other limits on medical coverage that depart from consumer expectations, see supra note 361, such valuations—and how they are to be incorporated into clinical protocols—should be presented clearly, in vivid, high-visibility fashion, in health plan marketing materials, not merely in the “small print” of insurance contracts.

Health plans should also be clear in their contracts about how the protocols they adopt treat scientific uncertainty concerning the efficacy of tests and treatments. Do they, for example, rely on best
Clinical protocols need not be written into the contract; it should suffice to incorporate them by reference. But the cost-benefit trade-offs that underlie each protocol should somewhere be made explicit, and they should be consistent with the trade-off principles set out in the contract.

One might imagine hybrid contracts, containing traditional medical-necessity clauses modified by language incorporating some evidence-based protocols—for example, all protocols adopted by one or another of the industry-wide collaborations I discussed earlier. Given the incompleteness of the science base for medical practice, total replacement of medical necessity (and thus, deference to customary practice) by clinical protocols is impracticable, and will remain so for the foreseeable future. Insurers might or might not offer these cost-sensitive contractual formulations, and consumers might or might not accept them in exchange for lower premiums. But if such plans emerge, the law should enable them, rather than stifling them by subjecting coverage denials to review based on customary practice when denials rest on evidence-based, cost-sensitive protocols.

c. Expectations, Incentives, and the Evolution of Medical Technology

The above-discussed adjustments to current law have large potential to speed the development of cost-sensitive clinical practice if and when Americans accept the need to limit beneficial care for the common good. But so long as society rejects such limits, law cannot impose them. Health plans will not set them, and providers will not abide by them. Still, there are measures that government can take to slow the escalation of estimates of efficacy by protocol drafters (including leading researchers in a specialty), or do they reject tests and treatments outright when these have not yet been shown scientifically to work? If plans take the latter, more aggressive course, they should advise consumers in plain language that many therapies in wide use lack scientific proof of efficacy and thus will not be covered. Bloche, supra note 11, at 316. An in-between course that plans could take is to cover widely used clinical measures based on best estimates of efficacy by protocol drafters, but to insist on scientific evidence of efficacy for new clinical interventions.

363. To require that they be set out in full in health insurance contracts could turn these contracts into multivolume medical treatises—hardly a way to make them understandable to subscribers.

364. It should suffice for protocol developers to state the cost-benefit trade-off rules on which protocols rely. The industry-wide protocol development collaborations now getting underway, see supra notes 301, 303, offer an opportunity in this regard: each collaboration could adopt a common cost-benefit trade-off standard for the protocols it adopts. This would enable health plans to adopt packages of protocols that rest on compatible trade-offs—trade-offs that are also consistent with the resource allocation principles articulated in plans' contracts with subscribers.

365. See supra notes 301, 303.

366. Market forces will drive health plans and providers to eschew such limits, as the late 1990s backlash against managed-care organizations’ rationing methods illustrates. See supra text accompanying notes 227–29.
technology-intensive medical spending. Attentiveness to emergent possibilities suggests an evolutionary strategy anchored in people’s different expectations about treatments that are technically feasible now and those that might arise as medicine advances. Put simply, most of us bristle at the prospect of being denied the benefits of today’s health care on account of cost, but we are not made livid by our lack of access to the technologies of the future.\textsuperscript{367} We hope for cures to diseases that terrify us, and some of us feel rage or despair over the blind cruelty of illnesses that wreck the lives of loved ones or end them prematurely. Yet we do not rail against health plans, providers, and public officials because they do not deliver, say, the magically effective care Dr. McCoy gives his \textit{Star Trek} shipmates.

This expectations gap constitutes a cost-control opportunity that does not depend on widespread willingness to ration contemporary medicine’s benefits. By reining in the development of ever more expensive technologies, we can restrain future spending growth without saying no now to beneficial care for identified patients. An obvious worry about this strategy is the risk of retarding clinical breakthroughs—advances that yield high value, relative to cost, and that are thus worth paying for.\textsuperscript{368} But there is a fortuitous answer to this problem. Major breakthroughs tend to result from leaps in \textit{biological} understanding of disease—advances in biochemistry and physiology that open the way for elegant, decisive interventions. Penicillin, which destroys bacterial cell walls, is perhaps the best-known example. A more recent illustration is the revolution in our understanding of lipid metabolism,\textsuperscript{369} which opened the way for development of the statin drugs that tens of millions of Americans take to slow the growth of artery-clogging atherosclerotic plaque.\textsuperscript{370} Therapies that target mechanisms of disease in such elegant fashion tend to be relatively inexpensive to provide, once the basic science that supports them has been

\begin{footnotesize}
\textsuperscript{367}. Put differently, our anchoring heuristic for the health care we expect is the medical technology currently available. People alive at the dawn of the twentieth century did not take umbrage at the unavailability of antibiotics (which did not appear until the 1930s). Similarly, we do not bristle today because the gene therapies of the future are not yet on pharmacists’ shelves.

\textsuperscript{368}. \textit{See generally} \textsc{CUTLER}, \textit{supra} note 65 (reviewing health services research that has identified tests and treatments worth paying for).

\textsuperscript{369}. \textit{See Nicole Kresge, Robert D. Simoni & Robert L. Hill, 30 Years of Cholesterol Metabolism: The Work of Michael Brown and Joseph Goldstein}, 281 J. \textsc{Biological Chemistry} e25 (2006).

\textsuperscript{370}. The statin medications work by inhibiting an enzyme that catalyzes one of the steps in cholesterol synthesis. This reduces the level of low-density lipoproteins (so-called bad cholesterol) in the blood, which, in turn, slows, stops, and under some conditions reverses the formation of atherosclerotic plaque. \textsc{Dominic S. Ng, The Role of Statins in Oxidative Stress and Cardiovascular Disease}, 5 \textsc{Cardiovascular & Haematological Disorders—Drug Targets} 165 (2005).
\end{footnotesize}
paid for.

By contrast, our most costly treatments—those that Lewis Thomas famously termed “half way technologies”371—tend to rest on comparatively crude understandings of the biology of disease. They are, paradoxically, marvels of engineering, electronics, and materials science, and of modest, often minimal medical benefit.372 Examples include drug-coated stents designed to keep atherosclerotic arteries open,373 high-technology life support,374 and last-ditch radiation and chemotherapy regimens meant mainly to sustain hope. Such treatments account for much of the outpouring of medical spending that occurs in the last months of life, in surgical suites, intensive care units, and elsewhere. They are expensive because they are both technology intensive and clinically indecisive. They employ costly, complex equipment and highly trained, well-paid personnel. And their inability, in most cases, to make more than a modest therapeutic difference leads, perversely, to their intensive and sustained (rather than one-shot) use. In medicine, as in warfare, decisive victory is cheaper than drawn-out struggle.

A rational incentive scheme for therapeutic advance would reserve the greatest rewards for those technologies most likely to add clinical value. But the American health care system rewards the adoption of new technologies with little regard for value. Physician time spent performing invasive, technology-intensive procedures is much better compensated than is time spent counseling patients, consulting medical journals, or ordering and overseeing minimally invasive measures.375 Doctors thus have

372. When I characterize their benefits as modest, I mean modest in the aggregate, relative to cost. Such technologies do, in some cases, add years to people’s lives and diminish suffering and disability. Examples include angioplasty during the first twelve hours after a heart attack, Albert Schömig et al., Mechanical Reperfusion in Patients with Acute Myocardial Infarction Presenting More than 12 Hours from Symptom Onset, 293 JAMA 2865, 2869–71 (2005) (finding that angioplasty within twelve to forty-eight hours from symptom onset can positively affect long-term outcomes), and replacement of severely arthritic hips and knees with artificial joints, NIH Consensus Dev. Panel on Total Hip Replacement, Total Hip Replacement, 273 JAMA 1950, 1950 (1995) (“Total hip replacement is an option for nearly all patients with diseases of the hip that cause chronic discomfort and significant functional impairment. Most patients have an excellent prognosis for long-term improvement in symptoms and physical function.”).
374. This can include computer-controlled ventilators and cardiac-assist devices, electronic monitoring of intracardiac pressures as well as peripheral blood pressure and heart rate, total parenteral nutrition (intravenous feeding), and pressor support for patients unable to sustain viable blood pressure.
375. William C. Hsaio et al., Results and Policy Implications of the Resource-Based Relative-Value Study, 319 NEW ENGL. J. MED. 881 (1988) (finding that despite the fact that both consume the same resource inputs, invasive procedures tend to be compensated at more than double the rate of
powerful incentives to adopt new halfway technologies, and, in turn, biotechnology firms (and investors) have strong incentives to develop them. By contrast, clinical advances that build on biological breakthroughs to treat disease in decisive fashion typically yield fewer financial rewards for doctors, since these therapies tend to be less invasive and technology intensive. This reward scheme is a recipe for rapid growth of spending on those technologies that are least likely to yield high clinical benefits relative to cost.

To the extent possible, given market and political constraints, the compensation gap between physician time spent performing technology-intensive procedures and talking with patients (or providing noninvasive care) should be closed. Market pressures rule out an immediate push by private insurers in this direction, since large cuts in a health plan’s payments for such procedures are likely to prompt specialists to drop out of that plan. But Medicare’s large market share—it accounts for almost one-fourth of physician payment—positions it to lead by initiating such reductions. Medicare should go as far as is politically feasible toward closing the chasm between payment for high-tech procedures and other uses of physician time. As evidence accrues concerning the comparative effectiveness of clinical approaches, Medicare should adjust its valuations of physician time accordingly.

Stakeholder opposition, mainly from medical specialists, will limit Medicare’s ability to do these things. Yet any progress that Medicare can

---

376. Hospitals can also profit handsomely from these technologies, which due to economies of scale and close proximity of complementary inpatient services, are often hospital based. But doctors’ incentives have a much greater influence on their rate of adoption, since doctors are the key decisionmakers.

377. An example is the prescription of statins—based on advances in our understanding of cholesterol metabolism, see supra note 370—to treat or prevent buildup of atherosclerotic plaque in blood vessels. Pharmaceutical firms, of course, can benefit greatly from the sale of drugs, so long as they remain patent protected, but they cannot ethically or legally share these revenue streams with prescribing doctors. The cardiologist who evaluates a patient, then prescribes a statin along with, perhaps, a few other medications might be able to bill a few or several hundred dollars. The cardiologist who spends the same time performing an angioplasty with placement of a stent might be able to collect a few or several thousand dollars.

378. In most regions, individual health plans lack sufficient market share to impose such cutbacks without losing large numbers of specialists and thereby diminishing their ability to compete. Antitrust law, of course, keeps plans from colluding to dictate such cuts.

379. See supra note 297.

380. See supra text accompanying notes 279–86.

381. Firms that develop and manufacture halfway technologies are likely to join in this opposition.

382. New legislation—sure to be resisted by specialty societies—would be necessary to empower CMS, the federal agency that runs Medicare, to do so. CMS is currently required by statute to set fees.
make on these fronts would nudge the future trajectory of health spending downward, especially if (as has happened with past Medicare payment reforms) private health plans follow Medicare’s lead. Such progress would diminish doctors’ incentives to adopt new halfway technologies and thus reduce investment in efforts to develop them. This, in turn, would slow their introduction into clinical practice, moderating their contribution to rising costs. Unidentified future patients would forgo some therapeutic benefits—probably low, in the aggregate, relative to the costs saved. But popular objections to denial of beneficial care would not come into play, since the tests and treatments “withheld” would not be available to anyone in the here-and-now.

This approach can be applied more generally, in ways that differentiate between technologies that are more and less likely to add high value relative to their costs. Pharmaceutical and medical device firms could be rewarded for new products with intellectual property protection for varying periods, based on how much a product improves therapeutic outcomes. This might nudge research and development decisions, over time, toward larger therapeutic advances by reducing these firms’ opportunities to reap windfalls from exclusive marketing of modest improvements. Alternatively, government could reward firms directly for medical innovation (through prizes or other payments) while requiring all such innovations to pass into the public domain. Such rewards could be tied to favorable comparative-efficacy research results, or to sales levels if evidence-based clinical practice protocols come to play a large role in the adoption of medical innovations.

Potentially intractable complications cast doubt on the viability of these ideas. Settling on metrics of therapeutic improvement would prove

---


383. See Steven Shavell & Tanguy van Ypersele, Rewards Versus Intellectual Property Rights, 44 J.L. & ECON. 525, 525–26 (2001) (arguing that giving innovators a choice between intellectual property rights and a reward system under which innovations would immediately enter the public domain is superior to merely conferring intellectual property rights).

384. Id. at 526.
difficult at both the statutory and administrative law levels. Political and legal conflict between stakeholders over the selection of benchmarks could paralyze implementation of any sliding scale reward scheme. And firms that benefit from full-fledged intellectual property protection for halfway technologies are likely to oppose enactment of any sliding scale scheme. I raise these ideas not because I am sure they would work, but because they suggest the broader potential of an evolutionary strategy—one that slows spending growth without awakening Americans’ passionate objections to the withholding of beneficial care.

This strategy seizes the opportunity presented by people’s different expectations concerning access to the beneficial care that is technically possible today and that might become feasible in the future. The strategy is emergence oriented in two ways: it exploits an opening for comparatively modest change in current law, and it anticipates industry actors’ adaptations to changed incentives (and to others’ adaptations). It finesses a premise embedded in our culture and politics—the notion that doctors should provide care, whatever the cost, whenever expected benefits outweigh risks—by slowing the development of high-cost technologies. By itself, however, this finesse could not suffice to keep health care from absorbing an ever-rising share of our national wealth. So long as we continue to reject clinical limit setting on account of cost, therapies of great technical virtuosity and modest benefit will proliferate at the ragged edges of biological understanding, pushing medical spending upward.

V. CONCLUSION

The American way of paying for and providing health care cannot

385. The possibilities for conflict are much enhanced by the subjectivity inherent in selection of medical outcome measures. As is the case for selection of outcome measures by comparative-effective researchers, see supra text accompanying notes 235–36, and adoption of quality-of-care benchmarks for the purpose of comparing provider performance, see supra text accompanying notes 300–02, different personal preferences and values are best captured by different measures. There will thus always be room to object to designated metrics of therapeutic advance on the ground that they privilege some patients’ concerns while giving short shrift to those of others.

386. They merit further exploration by scholars of intellectual property who are familiar with the dynamics of technological change in health care. That exploration is beyond the scope of this Article, as is consideration of whether likely opposition from drug and device makers renders these ideas politically implausible.

387. The term “ragged edges” is Daniel Callahan’s, meant to capture the truth that however far our biological understandings of disease advance, and however quickly we devise effective therapies based on these understandings, there will always be a frontier zone of biological ignorance and minimally effective tests and treatments. DANIEL CALLAHAN, WHAT KIND OF LIFE: THE LIMITS OF MEDICAL PROGRESS 63–65 (1990).
long survive. Since the early 1990s, a million people per year have lost or foregone medical coverage, a figure that masks countless stories of anguish—of loved ones dying too soon, life savings lost, and needless suffering and disability. Health spending, meanwhile, has become the fiscal equivalent of global warming. Current rates of increase are unsustainable without federal deficits or tax increases of astonishing size. American enterprise faces a parallel threat from the soaring cost of employee coverage.

Can law help to divert our country from this path? I have argued here that the law has enormous potential to do so, but that this potential remains unfulfilled. To take advantage of the possibilities, we must begin to treat health law as more than a jumble of diverse doctrinal parts. Legal schemes that are well designed for some purposes often work poorly in concert, yielding chaos instead of coherent governance in the health sphere. On the other hand, no single, unifying paradigm can capture all that we expect from the legal governance of health care provision. Like medicine itself, health law pursues diverse and conflicting aims. Organizing the governance of medicine around any one theory is bound to neglect some of these aims. Theory, nevertheless, is indispensable. Too often, health lawyers disregard the big picture, urging answers to discrete questions without heeding the connections between moving parts. Coherence matters, even if it can never be complete, owing to health law’s competing goals.

With an eye toward coherence, where possible, and toward opportunities to turn health care policy away from its current path toward ruin, this Article offers a new conception of health law. My core proposition is that health law’s disconnected doctrinal spheres and myriad decisionmakers are usefully understood as an emergent system. The same is the case for the American way of medical care financing and provision. This understanding comes to terms with health law’s contradictions, confusion, and resistance to wholesale change. It also explains our health care system’s multiple dysfunctions as regards access, cost, and value. These contradictions and dysfunctions are not the fault of some failed master designer. No one actor has a grand overview or the power to impose a unifying vision. Countless market actors, public planners, and legal and regulatory decisionmakers interact in oft-chaotic ways, clashing with, reinforcing, and adjusting to each other. Out of these interactions, a larger regulatory system emerges—one that incorporates the health sphere’s competing interests and values. Change in this system, for worse and for

388. See supra text accompanying notes 41–44.
better, arises from the interplay between its myriad actors.

By quitting the quest for a single, master design, we can better focus our efforts on real-world possibilities for legal and policy change. We can and should continuously survey the landscape of stakeholders and expectations with an eye toward potential launching points for evolutionary processes—processes that leverage current institutions and incentives. What we cannot do is to plan or predict these evolutionary pathways in precise detail—the complexity of interactions among market and government actors precludes fine-grained foresight of this sort. But we can determine the general direction of needed change, identify seemingly intractable obstacles, and envision ways to diminish or finesse them over time. Dysfunctional legal doctrines, interest group expectations, consumers’ anxieties, and embedded institutional and cultural barriers can all be dealt with in this way, in iterative fashion.

In this Article, I have set out a strategy for doing so. To illustrate this strategy, I have proposed a package of approaches to the most urgent questions we face in health care policy and law. I have urged approaches to universal coverage that build on possibilities immanent in existing legal and institutional arrangements, draw energy from cultural currents (for example, rising emphasis on personal responsibility), and minimize disruption of settled expectations. And I have counseled cost-control stratagems that work around obstacles to scientific assessment of tests and treatments, resistance from purveyors of profitable care, and the popular belief that we are entitled to all beneficial care, regardless of cost. The indirectness and incompleteness of these approaches is bound to dismay scholars and activists who prefer one or another elegant, sweeping solution to our crises of health care access, cost, and value. But we are not about to adopt any single, all-encompassing answer. The clashing values and perspectives of the health sphere’s disconnected legal and regulatory decisionmakers make doing so impossible.

There are early signs that reform strategies sensitive to emergent possibilities are catching on. Pending state-level reform plans, as well as proposals developed during the last presidential campaign, are open ended in their approaches to the health system’s future design. In contrast to President Clinton’s failed plan, which scripted the workings of the system it envisioned in great detail, this new generation of reform ideas leaves central questions unresolved. The principal Democratic presidential candidates’ plans built on employment-based coverage but opened the way to multiple evolutionary possibilities; these ranged from purchase of private insurance by individuals to single-payer coverage. Republican proposals
foreclosed the single-payer option but, like Democrats’, deferred to markets to decide between employment-based and individually acquired insurance. Both Democrats and Republicans also left space for states to seize the initiative by enacting their own reform schemes.

The emergent systems perspective makes sense of the seeming chaos that besets American health law and policy. It invites health reformers to develop pragmatic agendas for change by looking for evolutionary possibilities immanent in current law, institutions, politics, and culture. I have pointed to some of these possibilities and proposed legal and policy changes to exploit them. It is my hope that this Article will inspire other efforts to do so. Health law’s fragmentation and incoherence are large obstacles to urgently needed change. But they reflect the ongoing collision of values and interests that shape the health sphere’s legal governance. Whether we can avert health care’s threat to our nation’s solvency while extending twenty-first century medicine’s benefits equitably, to all, will turn on our ability to seize the opportunities this collision engenders.

The potential of emergent systems thinking as a way to understand fragmented schemes of legal governance is relevant beyond the health realm. Increasingly, governance problems—within and beyond America’s borders—cut across many areas of legal and regulatory authority. Disconnected decisionmakers in both the public and private domains shape policy concerning cyberspace, capital flows, and the built and natural environment. Prescriptions for new, hierarchical institutions to meet policy challenges in these areas are, more often than not, political nonstarters. They threaten powerful interests, and they infringe on fiercely guarded realms of authority. Proliferation of hierarchical mechanisms, moreover, would create new coordination problems, since inevitably, large issues will arise that cut across their domains. Efforts to understand fragmented governance in terms of self-organizing networks of decisionmakers have potential to guide law and policy in diverse fields. Adept use of emergent strategies to cope with our worsening crises of health care access and cost could become a model for the governance of other endeavors that sprawl across doctrinal and jurisdictional realms.